<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00095147</url>
  </required_header>
  <id_info>
    <org_study_id>IM101-043</org_study_id>
    <nct_id>NCT00095147</nct_id>
  </id_info>
  <brief_title>Abatacept and Infliximab in Combination With Methotrexate in Subjects With Rheumatoid Arthritis</brief_title>
  <official_title>A Phase IIIB, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Comparative Study of Abatacept or Infliximab in Combination With Methotrexate in Controlling Disease Activity in Subjects With Rheumatoid Arthritis Having an Inadequate Clinical Response to Methotrexate</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bristol-Myers Squibb</source>
  <brief_summary>
    <textblock>
      The purpose of this clinical research study is to learn if Abatacept or Infliximab in
      combination with Methotrexate demonstrate a greater reduction in disease activity over
      placebo.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2005</start_date>
  <completion_date type="Actual">July 2009</completion_date>
  <primary_completion_date type="Actual">July 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>DB; Adjusted Mean Change From Baseline to Day 197 in Disease Activity Score (DAS) 28 Score (Erythrocyte Sedimentation Rate [ESR]) For ABA Versus PLA (Last Observation Carried Forward [LOCF] Analysis)</measure>
    <time_frame>Baseline (Day 1), 6 months (Day 197)</time_frame>
    <description>The DAS28 is a continuous disease measure which is a composite of 4 variables: the 28 tender joint count, the 28 swollen joint count, ESR or C-reactive protein (CRP), and participant assessment of disease activity measure on a visual analogue scale. The DAS28 has numeric thresholds that define high disease activity (&gt; 5.1), low disease activity (&lt; 3.2) and remission (&lt; 2.6). A clinically significant response is a decrease in DAS28 score of &gt;1.2 from baseline.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>OL; Number of Participants With Death, Serious Adverse Events (SAEs), Related SAEs, SAEs Leading to Discontinuation, Adverse Events (AEs), Related AEs, and AEs Leading to Discontinuation</measure>
    <time_frame>From beginning of OL (Day 366) through end of OL (range from 1.9 months to 42.3 months)</time_frame>
    <description>AE=any new untoward medical occurrence or worsening of a pre-existing medical condition which does not necessarily have a causal relationship with this treatment. SAE=any untoward medical occurrence that at any dose: results in death, is life-threatening, requires inpatient hospitalization or causes prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, results in development of drug dependency or drug abuse, is an important medical event.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>OL; Number of Participants With AEs of Special Interest</measure>
    <time_frame>From beginning of OL (Day 366) through end of OL (range from 1.9 months to 42.3 months)</time_frame>
    <description>AE=any new untoward medical occurrence or worsening of a pre-existing medical condition which does not necessarily have a causal relationship with this treatment. AEs of special interest are those AEs that may be associated with the use of immunomodulatory drugs, including all infections, serious infections, autoimmune disorders; malignancies; and acute infusional AEs (pre-specified AEs occurring within 1 hour of start of infusion).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>OL; Number of Participants With Select Hematologic Laboratory Abnormalities</measure>
    <time_frame>From Day 366 through end of OL (range from 1.9 months to 42.3 months)</time_frame>
    <description>High=greater than Upper Normal Limit (ULN), Low=lower than Lower Normal Limit (LLN). LLN/ULN= Hemoglobin (HGB): &gt;3 g/dL decrease from Baseline (BL); Hematocrit: &lt;0.75 x BL; Erythrocytes: &lt;0.75 x BL; Platelets (PLT): &lt;0.67 x LLN/&gt;1.5 x ULN; Leukocytes: &lt;0.75 x LLN/ &gt;1.25 x ULN; neutrophils+bands: &lt;1.0 x 10^3 c/uL; lymphocytes: &lt;0.750 x 10^3 c/uL/ &gt;7.50 x 10^3 c/uL; monocytes: &gt;2000 mm3; eosinophils: &gt;0.750 x 10^3 c/uL;</description>
  </primary_outcome>
  <primary_outcome>
    <measure>OL; Number of Participants With Select Blood Chemistry Laboratory Abnormalities</measure>
    <time_frame>From Day 366 through end of OL (range from 1.9 months to 42.3 months)</time_frame>
    <description>Low=lower than LLN, High=greater than ULN. LLN/ULN= Alkaline phosphatase (ALP): &gt;2 x ULN; aspartate aminotransferase (AST): &gt;3 x ULN; alanine aminotransferase (ALT): &gt;3 x ULN; G-Glutamyl transferase (GGT): &gt;2 x ULN; Bilirubin: &gt;2 x ULN; blood urea nitrogen (BUN): &gt;2 x BL; creatinine: &gt;4 x BL</description>
  </primary_outcome>
  <primary_outcome>
    <measure>OL; Mean Change From Baseline to Day 365 in Hemoglobin, Total Protein, and Albumin</measure>
    <time_frame>Baseline (Day 1), Day 365</time_frame>
    <description>Hemoglobin (HGB): &gt;3 g/dL decrease from BL; total protein: &lt; 0.9 x LLN, &gt;1.1 x ULN; albumin:&lt;0.9 x LLN</description>
  </primary_outcome>
  <primary_outcome>
    <measure>OL; Mean Change From Baseline to Day 365 in Platelets</measure>
    <time_frame>Baseline (Day 1), Day 365</time_frame>
    <description>Platelets (PLT): &lt;0.67 x LLN, &gt;1.5 x ULN</description>
  </primary_outcome>
  <primary_outcome>
    <measure>OL; Mean Change From Baseline to Day 365 in Hematocrit</measure>
    <time_frame>Baseline (Day 1), Day 365</time_frame>
    <description>Hematocrit: &lt;0.75 x BL</description>
  </primary_outcome>
  <primary_outcome>
    <measure>OL; Mean Change From Baseline to Day 365 in White Blood Cells</measure>
    <time_frame>Baseline (Day 1), Day 365</time_frame>
    <description>Leukocytes: &lt;0.75 x LLN, &gt;1.25 x ULN; neutrophils+bands: &lt;1.0 x 10^3 c/uL; eosinophils: &gt;0.750 x 10^3 c/uL; basophils: &gt; 400 mm3; monocytes: &gt;2000 mm3; lymphocytes: &lt;0.750 x 10^3 c/uL, &gt;7.50 x 10^3 c/uL.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>OL; Mean Change From Baseline to Day 365 in Erythrocytes</measure>
    <time_frame>Baseline (Day 1), Day 365</time_frame>
    <description>Erythrocytes: &lt;0.75 x BL</description>
  </primary_outcome>
  <primary_outcome>
    <measure>OL; Mean Change From Baseline to Day 365 in Electrolytes</measure>
    <time_frame>Baseline (Day 1), Day 365</time_frame>
    <description>Sodium (Na): &lt;0.95 x LLN, &gt;1.05 x ULN; potassium (K): &lt;0.9 x LLN, &gt;1.1 x ULN; chloride (Cl): &lt;0.9 x LLN, &gt;1.1 x ULN</description>
  </primary_outcome>
  <primary_outcome>
    <measure>OL; Mean Change From Baseline to Day 365 in Bilirubin, Blood Urea Nitrogen, Creatinine, Calcium, Phosphorous, Serum Glucose, Fasting Serum Glucose, and Uric Acid</measure>
    <time_frame>Baseline (Day 1), Day 365</time_frame>
    <description>Bilirubin: &gt;2 x ULN; blood urea nitrogen (BUN): &gt;2 x BL; creatinine: &gt;4 x BL; calcium (Ca): &lt;0.8 x LLN, &gt;1.2 x ULN; phosphorous (P): &lt;0.75 x LLN, &gt;1.2 5 x ULN; serum glucose (Glu): &lt;65 mg/dL, &gt;220 mg/dL; fasting serum Glu: &lt;0.8 x LLN, &gt;1.5 x ULN; uric acid: &gt;1.5 x ULN;</description>
  </primary_outcome>
  <primary_outcome>
    <measure>OL; Mean Change From Baseline to Day 365 in Alanine Aminotransferase, Aspartate Aminotransferase, G-Glutamyl Transferase, and Alkaline Phosphatase</measure>
    <time_frame>Baseline (Day 1), Day 365</time_frame>
    <description>alanine aminotransferase (ALT): &gt;3 x ULN; aspartate aminotransferase (AST): &gt;3 x ULN; G-Glutamyl transferase (GGT): &gt;2 x ULN; Alkaline phosphatase (ALP): &gt;2 x ULN</description>
  </primary_outcome>
  <primary_outcome>
    <measure>OL; Mean Change From Baseline to Day 729 in Hemoglobin, Total Protein, and Albumin</measure>
    <time_frame>Baseline (Day 1), Day 729</time_frame>
    <description>Hemoglobin (HGB): &gt;3 g/dL decrease from BL; total protein: &lt; 0.9 x LLN, &gt;1.1 x ULN; albumin:&lt;0.9 x LLN</description>
  </primary_outcome>
  <primary_outcome>
    <measure>OL; Mean Change From Baseline to Day 729 in Platelets</measure>
    <time_frame>Baseline (Day 1), Day 729</time_frame>
    <description>Platelets (PLT): &lt;0.67 x LLN, &gt;1.5 x ULN</description>
  </primary_outcome>
  <primary_outcome>
    <measure>OL; Mean Change From Baseline to Day 729 in Hematocrit</measure>
    <time_frame>Baseline (Day 1), Day 729</time_frame>
    <description>Hematocrit: &lt;0.75 x BL</description>
  </primary_outcome>
  <primary_outcome>
    <measure>OL; Mean Change From Baseline to Day 729 in White Blood Cells</measure>
    <time_frame>Baseline (Day 1), Day 729</time_frame>
    <description>Leukocytes: &lt;0.75 x LLN, &gt;1.25 x ULN; neutrophils+bands: &lt;1.0 x 10^3 c/uL; eosinophils: &gt;0.750 x 10^3 c/uL; basophils: &gt; 400 mm3; monocytes: &gt;2000 mm3; lymphocytes: &lt;0.750 x 10^3 c/uL, &gt;7.50 x 10^3 c/uL.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>OL; Mean Change From Baseline to Day 729 in Erythrocytes</measure>
    <time_frame>Baseline (Day 1), Day 729</time_frame>
    <description>Erythrocytes: &lt;0.75 x BL</description>
  </primary_outcome>
  <primary_outcome>
    <measure>OL; Mean Change From Baseline to Day 729 in Electrolytes</measure>
    <time_frame>Baseline (Day 1), Day 729</time_frame>
    <description>Sodium (Na): &lt;0.95 x LLN, &gt;1.05 x ULN; potassium (K): &lt;0.9 x LLN, &gt;1.1 x ULN; chloride (Cl): &lt;0.9 x LLN, &gt;1.1 x ULN</description>
  </primary_outcome>
  <primary_outcome>
    <measure>OL; Mean Change From Baseline to Day 729 in Bilirubin, Blood Urea Nitrogen, Creatinine, Calcium, Phosphorous, Serum Glucose, Fasting Serum Glucose, and Uric Acid</measure>
    <time_frame>Baseline (Day 1), Day 729</time_frame>
    <description>Bilirubin: &gt;2 x ULN; blood urea nitrogen (BUN): &gt;2 x BL; creatinine: &gt;4 x BL; calcium (Ca): &lt;0.8 x LLN, &gt;1.2 x ULN; phosphorous (P): &lt;0.75 x LLN, &gt;1.2 5 x ULN; serum glucose (Glu): &lt;65 mg/dL, &gt;220 mg/dL; fasting serum Glu: &lt;0.8 x LLN, &gt;1.5 x ULN; uric acid: &gt;1.5 x ULN;</description>
  </primary_outcome>
  <primary_outcome>
    <measure>OL; Mean Change From Baseline to Day 729 in Alanine Aminotransferase, Aspartate Aminotransferase, G-Glutamyl Transferase, and Alkaline Phosphatase</measure>
    <time_frame>Baseline (Day 1), Day 729</time_frame>
    <description>alanine aminotransferase (ALT): &gt;3 x ULN; aspartate aminotransferase (AST): &gt;3 x ULN; G-Glutamyl transferase (GGT): &gt;2 x ULN; Alkaline phosphatase (ALP): &gt;2 x ULN</description>
  </primary_outcome>
  <primary_outcome>
    <measure>OL; Mean Change From Baseline to Day 1121 in Hemoglobin, Total Protein, and Albumin</measure>
    <time_frame>Baseline (Day 1), Day 1121</time_frame>
    <description>Hemoglobin (HGB): &gt;3 g/dL decrease from BL; total protein: &lt; 0.9 x LLN, &gt;1.1 x ULN; albumin:&lt;0.9 x LLN</description>
  </primary_outcome>
  <primary_outcome>
    <measure>OL; Mean Change From Baseline to Day 1121 in Platelets</measure>
    <time_frame>Baseline (Day 1), Day 1121</time_frame>
    <description>Platelets (PLT): &lt;0.67 x LLN, &gt;1.5 x ULN</description>
  </primary_outcome>
  <primary_outcome>
    <measure>OL; Mean Change From Baseline to Day 1121 in Hematocrit</measure>
    <time_frame>Baseline (Day 1), Day 1121</time_frame>
    <description>Hematocrit: &lt;0.75 x BL</description>
  </primary_outcome>
  <primary_outcome>
    <measure>OL; Mean Change From Baseline to Day 1121 in White Blood Cells</measure>
    <time_frame>Baseline (Day 1), Day 1121</time_frame>
    <description>Leukocytes: &lt;0.75 x LLN, &gt;1.25 x ULN; neutrophils+bands: &lt;1.0 x 10^3 c/uL; eosinophils: &gt;0.750 x 10^3 c/uL; basophils: &gt; 400 mm3; monocytes: &gt;2000 mm3; lymphocytes: &lt;0.750 x 10^3 c/uL, &gt;7.50 x 10^3 c/uL.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>OL; Mean Change From Baseline to Day 1121 in Erythrocytes</measure>
    <time_frame>Baseline (Day 1), Day 1121</time_frame>
    <description>Erythrocytes: &lt;0.75 x BL</description>
  </primary_outcome>
  <primary_outcome>
    <measure>OL; Mean Change From Baseline to Day 1121 in Electrolytes</measure>
    <time_frame>Baseline (Day 1), Day 1121</time_frame>
    <description>Sodium (Na): &lt;0.95 x LLN, &gt;1.05 x ULN; potassium (K): &lt;0.9 x LLN, &gt;1.1 x ULN; chloride (Cl): &lt;0.9 x LLN, &gt;1.1 x ULN</description>
  </primary_outcome>
  <primary_outcome>
    <measure>OL; Mean Change From Baseline to Day 1121 in Bilirubin, Blood Urea Nitrogen, Creatinine, Calcium, Phosphorous, Serum Glucose, Fasting Serum Glucose, and Uric Acid</measure>
    <time_frame>Baseline (Day 1), Day 1121</time_frame>
    <description>Bilirubin: &gt;2 x ULN; blood urea nitrogen (BUN): &gt;2 x BL; creatinine: &gt;4 x BL; calcium (Ca): &lt;0.8 x LLN, &gt;1.2 x ULN; phosphorous (P): &lt;0.75 x LLN, &gt;1.2 5 x ULN; serum glucose (Glu): &lt;65 mg/dL, &gt;220 mg/dL; fasting serum Glu: &lt;0.8 x LLN, &gt;1.5 x ULN; uric acid: &gt;1.5 x ULN;</description>
  </primary_outcome>
  <primary_outcome>
    <measure>OL; Mean Change From Baseline to Day 1121 in Alanine Aminotransferase, Aspartate Aminotransferase, G-Glutamyl Transferase, and Alkaline Phosphatase</measure>
    <time_frame>Baseline (Day 1), Day 1121</time_frame>
    <description>alanine aminotransferase (ALT): &gt;3 x ULN; aspartate aminotransferase (AST): &gt;3 x ULN; G-Glutamyl transferase (GGT): &gt;2 x ULN; Alkaline phosphatase (ALP): &gt;2 x ULN</description>
  </primary_outcome>
  <primary_outcome>
    <measure>OL; Mean Change From Baseline to Day 1513 in Hemoglobin, Total Protein, and Albumin</measure>
    <time_frame>Baseline (Day 1), Day 1513</time_frame>
    <description>Hemoglobin (HGB): &gt;3 g/dL decrease from BL; total protein: &lt; 0.9 x LLN, &gt;1.1 x ULN; albumin:&lt;0.9 x LLN</description>
  </primary_outcome>
  <primary_outcome>
    <measure>OL; Mean Change From Baseline to Day 1513 in Platelets</measure>
    <time_frame>Baseline (Day 1), Day 1513</time_frame>
    <description>Platelets (PLT): &lt;0.67 x LLN, &gt;1.5 x ULN</description>
  </primary_outcome>
  <primary_outcome>
    <measure>OL; Mean Change From Baseline to Day 1513 in Hematocrit</measure>
    <time_frame>Baseline (Day 1), Day 1513</time_frame>
    <description>Hematocrit: &lt;0.75 x BL</description>
  </primary_outcome>
  <primary_outcome>
    <measure>OL; Mean Change From Baseline to Day 1513 in White Blood Cells</measure>
    <time_frame>Baseline (Day 1), Day 1513</time_frame>
    <description>Leukocytes: &lt;0.75 x LLN, &gt;1.25 x ULN; neutrophils+bands: &lt;1.0 x 10^3 c/uL; eosinophils: &gt;0.750 x 10^3 c/uL; basophils: &gt; 400 mm3; monocytes: &gt;2000 mm3; lymphocytes: &lt;0.750 x 10^3 c/uL, &gt;7.50 x 10^3 c/uL.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>OL; Mean Change From Baseline to Day 1513 in Erythrocytes</measure>
    <time_frame>Baseline (Day 1), Day 1513</time_frame>
    <description>Erythrocytes: &lt;0.75 x BL</description>
  </primary_outcome>
  <primary_outcome>
    <measure>OL; Mean Change From Baseline to Day 1513 in Electrolytes</measure>
    <time_frame>Baseline (Day 1), Day 1513</time_frame>
    <description>Sodium (Na): &lt;0.95 x LLN, &gt;1.05 x ULN; potassium (K): &lt;0.9 x LLN, &gt;1.1 x ULN; chloride (Cl): &lt;0.9 x LLN, &gt;1.1 x ULN</description>
  </primary_outcome>
  <primary_outcome>
    <measure>OL; Mean Change From Baseline to Day 1513 in Bilirubin, Blood Urea Nitrogen, Creatinine, Calcium, Phosphorous, Serum Glucose, Fasting Serum Glucose, and Uric Acid</measure>
    <time_frame>Baseline (Day 1), Day 1513</time_frame>
    <description>Bilirubin: &gt;2 x ULN; blood urea nitrogen (BUN): &gt;2 x BL; creatinine: &gt;4 x BL; calcium (Ca): &lt;0.8 x LLN, &gt;1.2 x ULN; phosphorous (P): &lt;0.75 x LLN, &gt;1.2 5 x ULN; serum glucose (Glu): &lt;65 mg/dL, &gt;220 mg/dL; fasting serum Glu: &lt;0.8 x LLN, &gt;1.5 x ULN; uric acid: &gt;1.5 x ULN;</description>
  </primary_outcome>
  <primary_outcome>
    <measure>OL; Mean Change From Baseline to Day 1513 in Alanine Aminotransferase, Aspartate Aminotransferase, G-Glutamyl Transferase, and Alkaline Phosphatase</measure>
    <time_frame>Baseline (Day 1), Day 1513</time_frame>
    <description>alanine aminotransferase (ALT): &gt;3 x ULN; aspartate aminotransferase (AST): &gt;3 x ULN; G-Glutamyl transferase (GGT): &gt;2 x ULN; Alkaline phosphatase (ALP): &gt;2 x ULN</description>
  </primary_outcome>
  <primary_outcome>
    <measure>OL; Mean Systolic (SBP) and Diastolic (DBP) Blood Pressure During Open Label Period</measure>
    <time_frame>Days 365, 729, 1121, and 1513</time_frame>
    <description>Seated Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP), units=mm mercury (Hg)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>OL; Mean Heart Rate (HR) During Open Label Period</measure>
    <time_frame>Days 365, 729, 1121, and 1513</time_frame>
    <description>Heart Rate (HR), units=beats per minute (bpm)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>OL; Mean Temperature (T) During Open Label Period</measure>
    <time_frame>Days 365, 729, 1121, and 1513</time_frame>
    <description>Temperature (T), units=degrees Celcius</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>DB; Adjusted Mean Change From Baseline to Day 197 in DAS 28 Score (ESR) For INF Versus PLA (LOCF Analysis)</measure>
    <time_frame>Baseline (Day 1), 6 months (Day 197)</time_frame>
    <description>The DAS28 is a continuous disease measure which is a composite of 4 variables: the 28 tender joint count, the 28 swollen joint count, ESR or CRP, and participant assessment of disease activity measure on a visual analogue scale. The DAS28 has numeric thresholds that define high disease activity (&gt; 5.1), low disease activity (&lt; 3.2) and remission (&lt; 2.6). A clinically significant response is a decrease in DAS28 score of &gt;1.2 from baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DB; DAS 28 (ESR) Area Under The Curve (AUC) Over 12 Months For ABA Versus INF</measure>
    <time_frame>From Day 1 through Day 365 (12 months)</time_frame>
    <description>The DAS28 is a continuous disease measure which is a composite of 4 variables: the 28 tender joint count, the 28 swollen joint count, ESR or CRP, and participant assessment of disease activity measure on a visual analogue scale. The DAS28 has numeric thresholds that define high disease activity (&gt; 5.1), low disease activity (&lt; 3.2) and remission (&lt; 2.6). Clinically significant response= decrease in DAS28 score of &gt;1.2 from baseline. DAS28 AUC can be calculated from the DAS28 score versus time curve, which provides an assessment of changes in disease activity over time.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DB; Percentage of Participants With Clinically Meaningful Health Assessment Questionnaire-Disability Index (HAQ-DI) Response at Day 197</measure>
    <time_frame>DB Day 197</time_frame>
    <description>The disability section of the full HAQ includes 20 questions to assess physical functions in 8 domains: dressing, arising, eating, walking, hygiene, reach, grip and common activities. The questions are evaluated on a 4-point scale: 0=without any difficulty, 1= with some difficulty, 2= with much difficulty, and 3= unable to do. Higher scores= greater dysfunction. A disability index was calculated by summing the worst scores in each domain and dividing by the number of domains answered. Clinically meaningful HAQ response=an improvement of at least 0.3 units from baseline in HAQ disability Index.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DB; Percentage of Participants With Clinically Meaningful Health Assessment Questionnaire-Disability Index (HAQ-DI) Response at Day 365</measure>
    <time_frame>DB Day 365</time_frame>
    <description>The disability section of the full HAQ includes 20 questions to assess physical functions in 8 domains: dressing, arising, eating, walking, hygiene, reach, grip and common activities. The questions are evaluated on a 4-point scale: 0=without any difficulty, 1= with some difficulty, 2= with much difficulty, and 3= unable to do. Higher scores= greater dysfunction. A disability index was calculated by summing the worst scores in each domain and dividing by the number of domains answered. Clinically meaningful HAQ response=an improvement of at least 0.3 units from baseline in HAQ disability Index.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DB; Adjusted Mean Change From Baseline to Day 197 in HAQ-DI (LOCF Analysis)</measure>
    <time_frame>Baseline (Day 1), 6 months (Day 197)</time_frame>
    <description>The disability section of the full HAQ includes 20 questions to assess physical functions in 8 domains: dressing, arising, eating, walking, hygiene, reach, grip and common activities. The questions are evaluated on a 4-point scale: 0=without any difficulty, 1= with some difficulty, 2= with much difficulty, and 3= unable to do. Higher scores= greater dysfunction. A disability index was calculated by summing the worst scores in each domain and dividing by the number of domains answered. Clinically meaningful HAQ response=an improvement of at least 0.3 units from baseline in HAQ disability Index.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DB; Adjusted Mean Change From Baseline to Day 365 in HAQ-DI (LOCF Analysis)</measure>
    <time_frame>Baseline (Day 1), 12 months (Day 365)</time_frame>
    <description>The disability section of the full HAQ includes 20 questions to assess physical functions in 8 domains: dressing, arising, eating, walking, hygiene, reach, grip and common activities. The questions are evaluated on a 4-point scale: 0=without any difficulty, 1= with some difficulty, 2= with much difficulty, and 3= unable to do. Higher scores= greater dysfunction. A disability index was calculated by summing the worst scores in each domain and dividing by the number of domains answered. Clinically meaningful HAQ response=an improvement of at least 0.3 units from baseline in HAQ disability Index.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DB; Adjusted Mean Change From Baseline to Day 197 in SF-36 Physical Component Summary (PCS) and Mental Component Summary (MCS)</measure>
    <time_frame>Baseline (Day 1), 6 months (Day 197)</time_frame>
    <description>The SF-36 is a validated instrument measuring health-related quality of life across multiple disease states. It has 36 questions with 8 subscale scores and 2 summary scores (1) physical component summary=physical functioning, role-physical, bodily pain, and general health; (2) mental component summary=vitality, social functioning, role-emotional, and mental health. There is no total overall score; scoring is done for both subscores and summary scores. For subscores and summary scores, 0 =worst score (or quality of life) and 100=best score. Change from Baseline= post-Baseline - Baseline value.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DB; Adjusted Mean Change From Baseline to Day 365 in SF-36 Physical Component Summary (PCS) and Mental Component Summary (MCS)</measure>
    <time_frame>Baseline (Day 1), 12 months (Day 365)</time_frame>
    <description>The SF-36 is a validated instrument measuring health-related quality of life across multiple disease states. It has 36 questions with 8 subscale scores and 2 summary scores (1) physical component summary=physical functioning, role-physical, bodily pain, and general health; (2) mental component summary=vitality, social functioning, role-emotional, and mental health. There is no total overall score; scoring is done for both subscores and summary scores. For subscores and summary scores, 0 =worst score (or quality of life) and 100=best score. Change from Baseline= post-Baseline - Baseline value.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DB; Percentage of Participants With Good, Moderate, or No Response According to European League Against Rheumatism (EULAR) at Day 365</measure>
    <time_frame>DB Day 365</time_frame>
    <description>The DAS28 is a continuous disease measure composite of 4 variables: 28 tender joint count, 28 swollen joint count, ESR or CRP, and participant assessment of disease activity measure on a visual analogue scale. High disease activity= &gt; 5.1, low disease activity= &lt; 3.2, and remission= &lt; 2.6. Clinically significant response= decrease of &gt;1.2 from baseline. Utilizing EULAR response criteria, DAS28 categorical responses define a good (absolute: &lt;3.2 or &gt;1.2 improvement from baseline [BL]), moderate (absolute: 3.2-5.1 or 0.6-1.2 change from BL), or no response (absolute: &gt;5.1 or &lt;0.6 change from BL)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DB; Percentage of Participants With American College of Rheumatology (ACR) Responses at Day 197</measure>
    <time_frame>DB Day 197</time_frame>
    <description>The ACR 20 definition of improvement is a 20% improvement from baseline in the number of tender and swollen joint counts, and a 20% improvement from baseline in 3 of the remaining 5 core set measures: participant global assessment of pain, participant global assessment of disease activity, physician global assessment of disease activity, participant assessment of physical function and acute phase reactant value (C-reactive protein [CRP]). The evaluation for 50% improvement (ACR 50) and 70% improvement (ACR 70) follow similarly.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DB; Percentage of Participants With American College of Rheumatology (ACR) Responses at Day 365</measure>
    <time_frame>DB Day 365</time_frame>
    <description>The ACR 20 definition of improvement is a 20% improvement from baseline in the number of tender and swollen joint counts, and a 20% improvement from baseline in 3 of the remaining 5 core set measures: participant global assessment of pain, participant global assessment of disease activity, physician global assessment of disease activity, participant assessment of physical function and acute phase reactant value (C-reactive protein [CRP]). The evaluation for 50% improvement (ACR 50) and 70% improvement (ACR 70) follow similarly.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DB; Number of Participants With Death, Serious Adverse Events (SAEs), Related SAEs, SAEs Leading to Discontinuation, AEs, Related AEs, and AEs Leading to Discontinuation From Day 1 Through Day 197</measure>
    <time_frame>From Baseline (Day 1) through Day 197, and up to 56 days after last dose if occurring on-study</time_frame>
    <description>AE=any new untoward medical occurrence or worsening of a pre-existing medical condition which does not necessarily have a causal relationship with this treatment. SAE=any untoward medical occurrence that at any dose: results in death, is life-threatening, requires inpatient hospitalization or causes prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, results in development of drug dependency or drug abuse, is an important medical event.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DB; Number of Participants With AEs of Special Interest From Day 1 Through Day 197</measure>
    <time_frame>From Baseline (Day 1) through Day 197, and up to 56 days after last dose if occurring on-study</time_frame>
    <description>AE=any new untoward medical occurrence or worsening of a pre-existing medical condition which does not necessarily have a causal relationship with this treatment. AEs of special interest are those AEs that may be associated with the use of immunomodulatory drugs, including all infections, serious infections, autoimmune disorders; malignancies; and acute infusional AEs (pre-specified AEs occurring within 1 hour of start of infusion).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DB; Number of Participants With Death, Serious Adverse Events (SAEs), Related SAEs, SAEs Leading to Discontinuation, AEs, Related AEs, and AEs Leading to Discontinuation From Day 1 Through Day 365</measure>
    <time_frame>From Baseline (Day 1) through Day 365, and up to 56 days after last dose if occurring on-study</time_frame>
    <description>AE=any new untoward medical occurrence or worsening of a pre-existing medical condition which does not necessarily have a causal relationship with this treatment. SAE=any untoward medical occurrence that at any dose: results in death, is life-threatening, requires inpatient hospitalization or causes prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, results in development of drug dependency or drug abuse, is an important medical event.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DB; Number of Participants With Death, Serious Adverse Events (SAEs), Related SAEs, SAEs Leading to Discontinuation, AEs, Related AEs, and AEs Leading to Discontinuation From Day 198 Through Day 365 in Participants Receiving Placebo Switched to Abatacept</measure>
    <time_frame>From Day 198 through Day 365, and up to 56 days after last dose if occurring on-study</time_frame>
    <description>AE=any new untoward medical occurrence or worsening of a pre-existing medical condition which does not necessarily have a causal relationship with this treatment. SAE=any untoward medical occurrence that at any dose: results in death, is life-threatening, requires inpatient hospitalization or causes prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, results in development of drug dependency or drug abuse, is an important medical event.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DB; Number of Participants With AEs of Special Interest From Day 1 Through Day 365</measure>
    <time_frame>From Baseline (Day 1) through Day 365, and up to 56 days after last dose if occurring on-study</time_frame>
    <description>AE=any new untoward medical occurrence or worsening of a pre-existing medical condition which does not necessarily have a causal relationship with this treatment. AEs of special interest are those AEs that may be associated with the use of immunomodulatory drugs, including all infections, serious infections, autoimmune disorders; malignancies; and acute infusional AEs (pre-specified AEs occurring within 1 hour of start of infusion).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DB; Number of Participants With AEs of Special Interest From Day 198 Through Day 365 in Participants Receiving Placebo Switched to Abatacept</measure>
    <time_frame>From Day 198 through Day 365, and up to 56 days after last dose if occurring on-study</time_frame>
    <description>AE=any new untoward medical occurrence or worsening of a pre-existing medical condition which does not necessarily have a causal relationship with this treatment. AEs of special interest are those AEs that may be associated with the use of immunomodulatory drugs, including all infections, serious infections, autoimmune disorders; malignancies; and acute infusional AEs (pre-specified AEs occurring within 1 hour of start of infusion).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DB; Number of Participants With Significant Changes in Mean Systolic and Diastolic Blood Pressure During Days 1 Through 197 and Days 1 Through 365</measure>
    <time_frame>From Baseline (Day 1) through Day 197, or Day 1 through Day 365, and up to 56 days after last dose if occurring on-study</time_frame>
    <description>Seated Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) were assessed as clinically significant or relevant at the discretion of the Clinical Investigator. Criteria may have varied between institutions.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DB; Number of Participants With Significant Changes in Mean Heart Rate During Days 1 Through 197 and Days 1 Through 365</measure>
    <time_frame>From Baseline (Day 1) through Day 197, or Day 1 through Day 365, and up to 56 days after last dose if occurring on-study</time_frame>
    <description>Heart Rate (HR) was assessed as clinically significant or relevant at the discretion of the Clinical Investigator. Criteria may have varied between institutions.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DB; Number of Participants With Significant Changes in Mean Temperature During Days 1 Through 197 and Days 1 Through 365</measure>
    <time_frame>From Baseline (Day 1) through Day 197, and up to 56 days after last dose if occurring on-study</time_frame>
    <description>Temperature (T) was assessed as clinically significant or relevant at the discretion of the Clinical Investigator. Criteria may have varied between institutions.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DB; Number of Participants With Select Hematologic and Blood Chemistry Laboratory Abnormalities on Days 1 Through 197</measure>
    <time_frame>From Baseline (Day 1) through Day 197, and up to 56 days after last dose if occurring on-study</time_frame>
    <description>High=greater than Upper Normal Limit (ULN), Low=lower than Lower Normal Limit (LLN). LLN/ULN= Hemoglobin (HGB): &gt;3 g/dL decrease from Baseline (BL); Hematocrit: &lt;0.75 x BL; Platelets (PLT): &lt;0.67 x LLN/&gt;1.5 x ULN; Leukocytes: &lt;0.75 x LLN/ &gt;1.25 x ULN; neutrophils+bands: &lt;1.0 x 10^3 c/uL; aspartate aminotransferase (AST): &gt;3 x ULN; alanine aminotransferase (ALT): &gt;3 x ULN; creatinine: &gt;4 x BL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DB; Number of Participants With Select Hematologic and Blood Chemistry Laboratory Abnormalities on Days 1 Through 365</measure>
    <time_frame>From Baseline (Day 1) through Day 365, and up to 56 days after last dose if occurring on-study</time_frame>
    <description>High=greater than Upper Normal Limit (ULN), Low=lower than Lower Normal Limit (LLN). LLN/ULN= Hemoglobin (HGB): &gt;3 g/dL decrease from Baseline (BL); Hematocrit: &lt;0.75 x BL; Platelets (PLT): &lt;0.67 x LLN/&gt;1.5 x ULN; Leukocytes: &lt;0.75 x LLN/ &gt;1.25 x ULN; neutrophils+bands: &lt;1.0 x 10^3 c/uL; aspartate aminotransferase (AST): &gt;3 x ULN; alanine aminotransferase (ALT): &gt;3 x ULN; creatinine: &gt;4 x BL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DB; Number of Participants With Anti-Abatacept Antibodies From Day 1 Through Day 365 (Electrochemiluminescent [ECL] Immunoassay)</measure>
    <time_frame>Day 1 through day 365</time_frame>
    <description>ECL screened sera for drug-specific antibodies, immunocompetition was used to identify specific anti-Abatacept reactivity. Cytotoxic leukocyte antigen 4 (CTLA4) and Possibly Immunoglobulin (Ig) Category=reactivity against extracellular domain of human CTLA4, constant regions of human IgG1, or both (CTLA4Ig; Abatacept molecule). Ig and/or Junction Category=reactivity against constant regions and/or hinge region of human IgG1. Drug-induced seropositivity was defined as a post-baseline titer higher than Baseline, or any post-baseline positivity if Baseline value was missing.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DB; Percentage of Participants With Antibodies Against Infliximab (Human Anti-chimeric Antibody [HACA]) From Day 1 Through Day 365</measure>
    <time_frame>Day 1 through day 365</time_frame>
    <description>Infliximab levels were measured using a microplate enzyme-linked immunosorbant assay (ELISA) with infliximab bound to immobilized recombinant tumor necrosis factor (TNF)-alpha. Bound infliximab is detected utilizing a horseradish peroxidase-conjugated anti-human IgG Fc(fragment, crystallizable region)-specific). The enzyme turns over the substrate O-phenlenediamine to a chromogenic product that is measured at 490 nm. The cut-off value was 1.40 ug/mL; this was based on the mean (+ 3 SD) value in serum samples from 40 participants who had never received infliximab.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>OL; Mean Change From Baseline Over Time in DAS 28 (ESR) Score</measure>
    <time_frame>Baseline (Day 1), Day 365, Day 533, Day 729</time_frame>
    <description>The DAS28 is a continuous disease measure which is a composite of 4 variables: the 28 tender joint count, the 28 swollen joint count, ESR or CRP, and participant assessment of disease activity measure on a visual analogue scale. The DAS28 has numeric thresholds that define high disease activity (&gt; 5.1), low disease activity (&lt; 3.2) and remission (&lt; 2.6). A clinically significant response is a decrease in DAS28 score of &gt;1.2 from baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>OL; Percentage of Participants With DAS28 (ESR) Remission and Low Disease Activity (LDAS) Over Time</measure>
    <time_frame>Baseline (Day 1), Day 365, Day 533, Day 729</time_frame>
    <description>The DAS28 is a continuous disease measure which is a composite of 4 variables: the 28 tender joint count, the 28 swollen joint count, ESR or CRP, and participant assessment of disease activity measure on a visual analogue scale. The DAS28 has numeric thresholds that define high disease activity (&gt; 5.1), low disease activity (&lt; 3.2) and remission (&lt; 2.6). A clinically significant response is a decrease in DAS28 score of &gt;1.2 from baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>OL; Percentage of Participants With Good, Moderate, or No Response According to European League Against Rheumatism (EULAR) Over Time</measure>
    <time_frame>DB Days 365, 533, and 729</time_frame>
    <description>The DAS28 is a continuous disease measure composite of 4 variables: 28 tender joint count, 28 swollen joint count, ESR or CRP, and participant assessment of disease activity measure on a visual analogue scale. High disease activity= &gt; 5.1, low disease activity= &lt; 3.2, and remission= &lt; 2.6. Clinically significant response= decrease of &gt;1.2 from baseline. Utilizing EULAR response criteria, DAS28 categorical responses define a good (absolute &lt;3.2 or &gt;1.2 improvement from baseline [BL]), moderate (absolute 3.2-5.1 or 0.6-1.2 change from BL), or no response (absolute &gt;5.1 or &lt;0.6 change from BL)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>OL; Percentage of Participants With American College of Rheumatology (ACR) Responses Over Time</measure>
    <time_frame>DB Day 197, Day 365, Day 533, Day 729</time_frame>
    <description>The ACR 20 definition of improvement is a 20% improvement from baseline in the number of tender and swollen joint counts, and a 20% improvement from baseline in 3 of the remaining 5 core set measures: participant global assessment of pain, participant global assessment of disease activity, physician global assessment of disease activity, participant assessment of physical function and acute phase reactant value (C-reactive protein [CRP]). The evaluation for 50% improvement (ACR 50) and 70% improvement (ACR 70) follow similarly.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>OL; Percentage of Participants Who Achieved Major Clinical Response</measure>
    <time_frame>Defined from the date of achieving ACR 70 response to 6 months post response</time_frame>
    <description>Major Clinical Response was defined as a continuous ACR 70 for six months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>OL; Percentage of Participants With Clinically Meaningful Health Assessment Questionnaire-Disability Index (HAQ-DI) Response Over Time</measure>
    <time_frame>OL Days 197, 253, 281, 309, 337, 365, 449, 533, 617, and 729</time_frame>
    <description>The disability section of the full HAQ includes 20 questions to assess physical functions in 8 domains: dressing, arising, eating, walking, hygiene, reach, grip and common activities. The questions are evaluated on a 4-point scale: 0=without any difficulty, 1= with some difficulty, 2= with much difficulty, and 3= unable to do. Higher scores= greater dysfunction. A disability index was calculated by summing the worst scores in each domain and dividing by the number of domains answered. Clinically meaningful HAQ response=an improvement of at least 0.3 units from baseline in HAQ disability Index.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>OL; Adjusted Mean Change From Baseline to Day 729 in HAQ-DI</measure>
    <time_frame>Day 1 (Baseline), Day 729</time_frame>
    <description>The disability section of the full HAQ includes 20 questions to assess physical functions in 8 domains: dressing, arising, eating, walking, hygiene, reach, grip and common activities. The questions are evaluated on a 4-point scale: 0=without any difficulty, 1= with some difficulty, 2= with much difficulty, and 3= unable to do. Higher scores= greater dysfunction. A disability index was calculated by summing the worst scores in each domain and dividing by the number of domains answered. Clinically meaningful HAQ response=an improvement of at least 0.3 units from baseline in HAQ disability Index.</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">431</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <arm_group>
    <arm_group_label>Abatacept (ABA) + Methotrexate (MTX) (double-blind [DB])</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Days 1-365</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Infliximab + MTX (DB)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Days 1-365</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo + MTX (DB)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Days 1-197</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo + MTX switched to abatacept + MTX (DB)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received placebo plus methotrexate for days 1-197, and abatacept plus methotrexate for days 198-365</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Abatacept (open-label)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Days 365 to 729 All participants receive Active Drug</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Abatacept (ABA) + Methotrexate (MTX), double-blind (DB)</intervention_name>
    <description>Abatacept, intravenous (IV) Solution, Infusion, Depends on participant weight, Monthly, 12 months.</description>
    <arm_group_label>Abatacept (ABA) + Methotrexate (MTX) (double-blind [DB])</arm_group_label>
    <other_name>Orencia</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Infliximab (INF) + MTX, DB</intervention_name>
    <description>Infliximab, IV Solution, Infusion, Depends on participant weight, Every 2 Months, 12 months.</description>
    <arm_group_label>Infliximab + MTX (DB)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo (PLA) + MTX, DB</intervention_name>
    <description>Placebo, IV Solution, Infusion, Depends on participant weight, Monthly, 6 months.</description>
    <arm_group_label>Placebo + MTX (DB)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PLA + MTX switched to ABA+ MTX, DB</intervention_name>
    <description>Placebo=IV Solution, Infusion, Depends on participant weight, Monthly, 6 months. Abatacept=IV Solution, Infusion, Depends on participant weight, Monthly, 6 months</description>
    <arm_group_label>Placebo + MTX switched to abatacept + MTX (DB)</arm_group_label>
    <other_name>Orencia</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ABA, open-label (OL)</intervention_name>
    <description>Abatacept, IV solution, Infusion. Depends on participant weight, Monthly, 12+ months</description>
    <arm_group_label>Abatacept (open-label)</arm_group_label>
    <other_name>Orencia</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of Rheumatoid Arthritis

          -  At least 3 months prior treatment with Methotrexate (MTX)

          -  At least 10 swollen joints and 12 tender joints and C-Reactive Protein of at least 1
             mg/dl

          -  Washout required for other disease modifying anti-rheumatic drugs (DMARDS)

        Exclusion Criteria:

          -  participants who have failed more than 3 DMARDs

          -  participants previously treated with an approved biologic drug

          -  History of cancer in the last 5 years

          -  Severe or recurrent bacterial infection

          -  Any previous or current medical conditions that are contraindications to the use of
             TNF blocking agents

          -  Women of Child Bearing Potential
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bristol-Myers Squibb</last_name>
    <role>Study Director</role>
    <affiliation>Bristol-Myers Squibb</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Huntsville</city>
        <state>Alabama</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Boca Raton</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Ft Lauderdale</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Largo</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Springfield</city>
        <state>Massachusetts</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Worcester</city>
        <state>Massachusetts</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Flowood</city>
        <state>Mississippi</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Syracuse</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Tulsa</city>
        <state>Oklahoma</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Bethlehem</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Willow Grove</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Capital Federal</city>
        <state>Buenos Aires</state>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Quilmes</city>
        <state>Buenos Aires</state>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Buenos Aires</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Cordoba</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Tucuman</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Cairns</city>
        <state>Queensland</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Cotton Tree</city>
        <state>Queensland</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Clayton</city>
        <state>Victoria</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Heidelberg</city>
        <state>Victoria</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Malvern</city>
        <state>Victoria</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Parkville</city>
        <state>Victoria</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Perth</city>
        <state>Western Australia</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Curitiba</city>
        <state>Parana</state>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Recife</city>
        <state>Pernambuco</state>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Porto Alegre</city>
        <state>Rio Grande Do Sul</state>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Rio De Janeiro</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Sao Paulo</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Winnipeg</city>
        <state>Manitoba</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>St. Johns</city>
        <state>Newfoundland and Labrador</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Kitchener</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Ste-Foy</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Saskatoon</city>
        <state>Saskatchewan</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Kitchener</city>
        <zip>ON</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Prague 2</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Copenhagen</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Tijuana</city>
        <state>Baja California</state>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Mexico</city>
        <state>Distrito Federal</state>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Leon</city>
        <state>Guanajuato</state>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Guadalajara</city>
        <state>Jalisco</state>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Monterrey</city>
        <state>Nuevo Leon</state>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>San Luis Potosi</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Lima</city>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Poznan</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Sopot</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Warszawa</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Rio Piedras</city>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Muckleneuk</city>
        <state>Gauteng</state>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Berea</city>
        <state>Kwa Zulu Natal</state>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Panorama</city>
        <state>Western Cape</state>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>A Coruna</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Cordoba</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Falun</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Linkoping</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Lund</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Stockholm</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Uppsala</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Bern</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>St. Gallen</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Australia</country>
    <country>Brazil</country>
    <country>Canada</country>
    <country>Czech Republic</country>
    <country>Denmark</country>
    <country>Korea, Republic of</country>
    <country>Mexico</country>
    <country>Peru</country>
    <country>Poland</country>
    <country>Puerto Rico</country>
    <country>Russian Federation</country>
    <country>South Africa</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>Switzerland</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.fda.gov/MEDWATCH/safety.htm</url>
    <description>For FDA Safety Alerts and Recalls refer to the following link www.fda.gov/MEDWATCH/safety.htm</description>
  </link>
  <verification_date>March 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 1, 2004</study_first_submitted>
  <study_first_submitted_qc>November 1, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 2, 2004</study_first_posted>
  <results_first_submitted>October 26, 2010</results_first_submitted>
  <results_first_submitted_qc>December 21, 2010</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 21, 2011</results_first_posted>
  <last_update_submitted>March 4, 2015</last_update_submitted>
  <last_update_submitted_qc>March 4, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 24, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methotrexate</mesh_term>
    <mesh_term>Infliximab</mesh_term>
    <mesh_term>Abatacept</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>748 participants enrolled in this study; 317 participants were not randomized or treated. 384 participants completed the double-blind period; 12 participants did not enter the open-label period.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Abatacept (ABA) + Methotrexate (MTX) [Double-blind (DB)]</title>
          <description>Abatacept was administered intravenously (IV) on Days 1, 15, 29 and every 28 days thereafter for a total of 14 doses. Administration was as follows: 500 mg for participants &lt; 60 kg, 750 mg for participants 60 to 100 kg and 1 gram for participants &gt; 100 kg. All participants received a stable dose of MTX (minimum 15 mg weekly).</description>
        </group>
        <group group_id="P2">
          <title>Infliximab (INF) + MTX [DB]</title>
          <description>Infliximab was given 3 mg/kg IV (approved labeled dose) on Days 1, 15, 43, 85 and every 56 days thereafter for a total of 8 doses. All participants received a stable dose of MTX (minimum 15 mg weekly)</description>
        </group>
        <group group_id="P3">
          <title>Placebo (PLA) + MTX [DB]</title>
          <description>Normal saline was administered as placebo. All participants received a stable dose of MTX (minimum 15 mg weekly)</description>
        </group>
        <group group_id="P4">
          <title>PLA Switched to ABA + MTX [DB]</title>
          <description>Normal saline was administered as placebo. All participants received a stable dose of MTX (minimum 15 mg weekly). After placebo treatment from Day 1-197, participants were reallocated to receive abatacept (weight based) plus a stable dose of MTX (minimum 15 mg weekly).</description>
        </group>
        <group group_id="P5">
          <title>ABA + MTX [Open-label (OL)]</title>
          <description>All participants received ABA at a weight-tiered dose of 10 mg/kg plus a stable dose of MTX (minimum 15 mg weekly).</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Double-blind Period 1 (Days 1-197)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="156"/>
                <participants group_id="P2" count="165"/>
                <participants group_id="P3" count="110"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="147"/>
                <participants group_id="P2" count="152"/>
                <participants group_id="P3" count="107"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="13"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal of consent</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Pregnancy</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Double-blind Period 2 (Days 198-365)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="147"/>
                <participants group_id="P2" count="152"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="107"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="139"/>
                <participants group_id="P2" count="141"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="104"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="11"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal of consent</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Participant relocation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Long-term Extension Period</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="372"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="327"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="45"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="11"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="9"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal of consent</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="12"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Pregnancy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>No longer meets study criteria</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Participant chose to use Revellex</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Leaving country</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>ABA + MTX [DB]</title>
          <description>Abatacept was administered intravenously (IV) on Days 1, 15, 29 and every 28 days thereafter for a total of 14 doses. Administration was as follows: 500 mg for participants &lt; 60 kg, 750 mg for participants 60 to 100 kg and 1 gram for participants &gt; 100 kg. All participants received a stable dose of MTX (minimum 15 mg weekly).</description>
        </group>
        <group group_id="B2">
          <title>INF + MTX [DB]</title>
          <description>Infliximab was given 3 mg/kg IV (approved labeled dose) on Days 1, 15, 43, 85 and every 56 days thereafter for a total of 8 doses. All participants received a stable dose of MTX (minimum 15 mg weekly)</description>
        </group>
        <group group_id="B3">
          <title>PLA + MTX [DB]</title>
          <description>Normal saline was administered as placebo. All participants received a stable dose of MTX (minimum 15 mg weekly)</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="156"/>
            <count group_id="B2" value="165"/>
            <count group_id="B3" value="110"/>
            <count group_id="B4" value="431"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="49.0" spread="12.5"/>
                    <measurement group_id="B2" value="49.1" spread="12.0"/>
                    <measurement group_id="B3" value="49.4" spread="11.5"/>
                    <measurement group_id="B4" value="49.1" spread="12.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="130"/>
                    <measurement group_id="B2" value="136"/>
                    <measurement group_id="B3" value="96"/>
                    <measurement group_id="B4" value="362"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                    <measurement group_id="B2" value="29"/>
                    <measurement group_id="B3" value="14"/>
                    <measurement group_id="B4" value="69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline Disease Activity Score (DAS) 28 (Erythrocyte Sedimentation Rate [ESR])</title>
          <description>The DAS28 is a continuous disease measure which is a composite of 4 variables: the 28 tender joint count, the 28 swollen joint count, ESR or C-reactive protein (CRP), and participant assessment of disease activity measure on a visual analogue scale. The DAS28 has numeric thresholds that define high disease activity (&gt; 5.1), low disease activity (&lt; 3.2) and remission (&lt; 2.6). A clinically significant response= decrease in DAS28 score of &gt;1.2 from baseline.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6.9" spread="1.0"/>
                    <measurement group_id="B2" value="6.8" spread="0.9"/>
                    <measurement group_id="B3" value="6.8" spread="1.0"/>
                    <measurement group_id="B4" value="6.8" spread="1.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>DB; Adjusted Mean Change From Baseline to Day 197 in Disease Activity Score (DAS) 28 Score (Erythrocyte Sedimentation Rate [ESR]) For ABA Versus PLA (Last Observation Carried Forward [LOCF] Analysis)</title>
        <description>The DAS28 is a continuous disease measure which is a composite of 4 variables: the 28 tender joint count, the 28 swollen joint count, ESR or C-reactive protein (CRP), and participant assessment of disease activity measure on a visual analogue scale. The DAS28 has numeric thresholds that define high disease activity (&gt; 5.1), low disease activity (&lt; 3.2) and remission (&lt; 2.6). A clinically significant response is a decrease in DAS28 score of &gt;1.2 from baseline.</description>
        <time_frame>Baseline (Day 1), 6 months (Day 197)</time_frame>
        <population>The Intent-to-Treat (ITT) analysis population was defined to include all participants randomized into the study who received study medication. Participants were grouped according to the treatment or treatment regimen to which they were randomized. All participants who were randomized but never received study medication were excluded.</population>
        <group_list>
          <group group_id="O1">
            <title>ABA + MTX [DB]</title>
            <description>Abatacept was administered intravenously (IV) on Days 1, 15, 29 and every 28 days thereafter for a total of 14 doses. Administration was as follows: 500 mg for participants &lt; 60 kg, 750 mg for participants 60 to 100 kg and 1 gram for participants &gt; 100 kg. All participants received a stable dose of MTX (minimum 15 mg weekly).</description>
          </group>
          <group group_id="O2">
            <title>PLA + MTX [DB]</title>
            <description>Normal saline was administered as placebo. All participants received a stable dose of MTX (minimum 15 mg weekly)</description>
          </group>
        </group_list>
        <measure>
          <title>DB; Adjusted Mean Change From Baseline to Day 197 in Disease Activity Score (DAS) 28 Score (Erythrocyte Sedimentation Rate [ESR]) For ABA Versus PLA (Last Observation Carried Forward [LOCF] Analysis)</title>
          <description>The DAS28 is a continuous disease measure which is a composite of 4 variables: the 28 tender joint count, the 28 swollen joint count, ESR or C-reactive protein (CRP), and participant assessment of disease activity measure on a visual analogue scale. The DAS28 has numeric thresholds that define high disease activity (&gt; 5.1), low disease activity (&lt; 3.2) and remission (&lt; 2.6). A clinically significant response is a decrease in DAS28 score of &gt;1.2 from baseline.</description>
          <population>The Intent-to-Treat (ITT) analysis population was defined to include all participants randomized into the study who received study medication. Participants were grouped according to the treatment or treatment regimen to which they were randomized. All participants who were randomized but never received study medication were excluded.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="150"/>
                <count group_id="O2" value="102"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.53" spread="0.12"/>
                    <measurement group_id="O2" value="-1.48" spread="0.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The primary analysis was the comparison of abatacept versus placebo for changes from baseline to 6 months (Day 197) in the DAS28. This comparison was done using an analysis of covariance (ANCOVA) model with treatment group as the effect and baseline value as the covariate. A 95% confidence interval was computed for the treatment difference within the framework of the ANCOVA model.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>adjusted mean change from baseline</param_type>
            <param_value>-1.04</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.42</ci_lower_limit>
            <ci_upper_limit>-0.67</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>DB; Adjusted Mean Change From Baseline to Day 197 in DAS 28 Score (ESR) For INF Versus PLA (LOCF Analysis)</title>
        <description>The DAS28 is a continuous disease measure which is a composite of 4 variables: the 28 tender joint count, the 28 swollen joint count, ESR or CRP, and participant assessment of disease activity measure on a visual analogue scale. The DAS28 has numeric thresholds that define high disease activity (&gt; 5.1), low disease activity (&lt; 3.2) and remission (&lt; 2.6). A clinically significant response is a decrease in DAS28 score of &gt;1.2 from baseline.</description>
        <time_frame>Baseline (Day 1), 6 months (Day 197)</time_frame>
        <population>The Intent-to-Treat (ITT) analysis population was defined to include all participants randomized into the study who received study medication. Participants were grouped according to the treatment or treatment regimen to which they were randomized. All participants who were randomized but never received study medication were excluded.</population>
        <group_list>
          <group group_id="O1">
            <title>INF + MTX [DB]</title>
            <description>Infliximab was given 3 mg/kg IV (approved labeled dose) on Days 1, 15, 43, 85 and every 56 days thereafter for a total of 8 doses. All participants received a stable dose of MTX (minimum 15 mg weekly)</description>
          </group>
          <group group_id="O2">
            <title>PLA + MTX [DB]</title>
            <description>Normal saline was administered as placebo. All participants received a stable dose of MTX (minimum 15 mg weekly)</description>
          </group>
        </group_list>
        <measure>
          <title>DB; Adjusted Mean Change From Baseline to Day 197 in DAS 28 Score (ESR) For INF Versus PLA (LOCF Analysis)</title>
          <description>The DAS28 is a continuous disease measure which is a composite of 4 variables: the 28 tender joint count, the 28 swollen joint count, ESR or CRP, and participant assessment of disease activity measure on a visual analogue scale. The DAS28 has numeric thresholds that define high disease activity (&gt; 5.1), low disease activity (&lt; 3.2) and remission (&lt; 2.6). A clinically significant response is a decrease in DAS28 score of &gt;1.2 from baseline.</description>
          <population>The Intent-to-Treat (ITT) analysis population was defined to include all participants randomized into the study who received study medication. Participants were grouped according to the treatment or treatment regimen to which they were randomized. All participants who were randomized but never received study medication were excluded.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="156"/>
                <count group_id="O2" value="102"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.25" spread="0.12"/>
                    <measurement group_id="O2" value="-1.48" spread="0.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Infliximab versus placebo were compared for changes from baseline to 6 months (Day 197) in the DAS28. This comparison was done using an analysis of covariance (ANCOVA) model with treatment group as the effect and baseline value as the covariate. A 95% confidence interval was computed for the treatment difference within the framework of the ANCOVA model.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>adjusted mean change from baseline</param_type>
            <param_value>-0.77</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.14</ci_lower_limit>
            <ci_upper_limit>-0.39</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>DB; DAS 28 (ESR) Area Under The Curve (AUC) Over 12 Months For ABA Versus INF</title>
        <description>The DAS28 is a continuous disease measure which is a composite of 4 variables: the 28 tender joint count, the 28 swollen joint count, ESR or CRP, and participant assessment of disease activity measure on a visual analogue scale. The DAS28 has numeric thresholds that define high disease activity (&gt; 5.1), low disease activity (&lt; 3.2) and remission (&lt; 2.6). Clinically significant response= decrease in DAS28 score of &gt;1.2 from baseline. DAS28 AUC can be calculated from the DAS28 score versus time curve, which provides an assessment of changes in disease activity over time.</description>
        <time_frame>From Day 1 through Day 365 (12 months)</time_frame>
        <population>The Intent-to-Treat (ITT) analysis population was defined to include all participants randomized into the study who received study medication. Participants were grouped according to the treatment or treatment regimen to which they were randomized. All participants who were randomized but never received study medication were excluded.</population>
        <group_list>
          <group group_id="O1">
            <title>ABA + MTX [DB[</title>
            <description>Abatacept was administered intravenously (IV) on Days 1, 15, 29 and every 28 days thereafter for a total of 14 doses. Administration was as follows: 500 mg for participants &lt; 60 kg, 750 mg for participants 60 to 100 kg and 1 gram for participants &gt; 100 kg. All participants received a stable dose of MTX (minimum 15 mg weekly).</description>
          </group>
          <group group_id="O2">
            <title>INF + MTX [DB]</title>
            <description>Infliximab was given 3 mg/kg IV (approved labeled dose) on Days 1, 15, 43, 85 and every 56 days thereafter for a total of 8 doses. All participants received a stable dose of MTX (minimum 15 mg weekly)</description>
          </group>
        </group_list>
        <measure>
          <title>DB; DAS 28 (ESR) Area Under The Curve (AUC) Over 12 Months For ABA Versus INF</title>
          <description>The DAS28 is a continuous disease measure which is a composite of 4 variables: the 28 tender joint count, the 28 swollen joint count, ESR or CRP, and participant assessment of disease activity measure on a visual analogue scale. The DAS28 has numeric thresholds that define high disease activity (&gt; 5.1), low disease activity (&lt; 3.2) and remission (&lt; 2.6). Clinically significant response= decrease in DAS28 score of &gt;1.2 from baseline. DAS28 AUC can be calculated from the DAS28 score versus time curve, which provides an assessment of changes in disease activity over time.</description>
          <population>The Intent-to-Treat (ITT) analysis population was defined to include all participants randomized into the study who received study medication. Participants were grouped according to the treatment or treatment regimen to which they were randomized. All participants who were randomized but never received study medication were excluded.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="150"/>
                <count group_id="O2" value="156"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1638.6" spread="395.81"/>
                    <measurement group_id="O2" value="1657.5" spread="460.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>DB; Percentage of Participants With Clinically Meaningful Health Assessment Questionnaire-Disability Index (HAQ-DI) Response at Day 197</title>
        <description>The disability section of the full HAQ includes 20 questions to assess physical functions in 8 domains: dressing, arising, eating, walking, hygiene, reach, grip and common activities. The questions are evaluated on a 4-point scale: 0=without any difficulty, 1= with some difficulty, 2= with much difficulty, and 3= unable to do. Higher scores= greater dysfunction. A disability index was calculated by summing the worst scores in each domain and dividing by the number of domains answered. Clinically meaningful HAQ response=an improvement of at least 0.3 units from baseline in HAQ disability Index.</description>
        <time_frame>DB Day 197</time_frame>
        <population>The Intent-to-Treat (ITT) analysis population was defined to include all participants randomized into the study who received study medication. Participants were grouped according to the treatment or treatment regimen to which they were randomized. All participants who were randomized but never received study medication were excluded.</population>
        <group_list>
          <group group_id="O1">
            <title>ABA + MTX [DB]</title>
            <description>Abatacept was administered intravenously (IV) on Days 1, 15, 29 and every 28 days thereafter for a total of 14 doses. Administration was as follows: 500 mg for participants &lt; 60 kg, 750 mg for participants 60 to 100 kg and 1 gram for participants &gt; 100 kg. All participants received a stable dose of MTX (minimum 15 mg weekly).</description>
          </group>
          <group group_id="O2">
            <title>INF + MTX [DB]</title>
            <description>Infliximab was given 3 mg/kg IV (approved labeled dose) on Days 1, 15, 43, 85 and every 56 days thereafter for a total of 8 doses. All participants received a stable dose of MTX (minimum 15 mg weekly)</description>
          </group>
          <group group_id="O3">
            <title>PLA + MTX [DB]</title>
            <description>Normal saline was administered as placebo. All participants received a stable dose of MTX (minimum 15 mg weekly)</description>
          </group>
        </group_list>
        <measure>
          <title>DB; Percentage of Participants With Clinically Meaningful Health Assessment Questionnaire-Disability Index (HAQ-DI) Response at Day 197</title>
          <description>The disability section of the full HAQ includes 20 questions to assess physical functions in 8 domains: dressing, arising, eating, walking, hygiene, reach, grip and common activities. The questions are evaluated on a 4-point scale: 0=without any difficulty, 1= with some difficulty, 2= with much difficulty, and 3= unable to do. Higher scores= greater dysfunction. A disability index was calculated by summing the worst scores in each domain and dividing by the number of domains answered. Clinically meaningful HAQ response=an improvement of at least 0.3 units from baseline in HAQ disability Index.</description>
          <population>The Intent-to-Treat (ITT) analysis population was defined to include all participants randomized into the study who received study medication. Participants were grouped according to the treatment or treatment regimen to which they were randomized. All participants who were randomized but never received study medication were excluded.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="156"/>
                <count group_id="O2" value="165"/>
                <count group_id="O3" value="110"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61.5"/>
                    <measurement group_id="O2" value="58.8"/>
                    <measurement group_id="O3" value="40.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Comparisons were made between ABA and PLA at Day 197 using a continuity corrected Chi-square test. All tests and confidence intervals for treatment comparison were two-sided.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.001</p_value>
            <method>Chi-squared, Corrected</method>
            <param_type>Estimate of difference from placebo</param_type>
            <param_value>20.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>7.7</ci_lower_limit>
            <ci_upper_limit>33.6</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Comparisons were made between INF and PLA at Day 197 using a continuity corrected Chi-square test. All tests and confidence intervals for treatment comparison were two-sided.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.005</p_value>
            <method>Chi-squared, Corrected</method>
            <param_type>Estimate of difference from placebo</param_type>
            <param_value>17.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>5.1</ci_lower_limit>
            <ci_upper_limit>30.7</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>DB; Percentage of Participants With Clinically Meaningful Health Assessment Questionnaire-Disability Index (HAQ-DI) Response at Day 365</title>
        <description>The disability section of the full HAQ includes 20 questions to assess physical functions in 8 domains: dressing, arising, eating, walking, hygiene, reach, grip and common activities. The questions are evaluated on a 4-point scale: 0=without any difficulty, 1= with some difficulty, 2= with much difficulty, and 3= unable to do. Higher scores= greater dysfunction. A disability index was calculated by summing the worst scores in each domain and dividing by the number of domains answered. Clinically meaningful HAQ response=an improvement of at least 0.3 units from baseline in HAQ disability Index.</description>
        <time_frame>DB Day 365</time_frame>
        <population>The Intent-to-Treat (ITT) analysis population was defined to include all participants randomized into the study who received study medication. Participants were grouped according to the treatment or treatment regimen to which they were randomized. All participants who were randomized but never received study medication were excluded.</population>
        <group_list>
          <group group_id="O1">
            <title>ABA + MTX [DB]</title>
            <description>Abatacept was administered intravenously (IV) on Days 1, 15, 29 and every 28 days thereafter for a total of 14 doses. Administration was as follows: 500 mg for participants &lt; 60 kg, 750 mg for participants 60 to 100 kg and 1 gram for participants &gt; 100 kg. All participants received a stable dose of MTX (minimum 15 mg weekly).</description>
          </group>
          <group group_id="O2">
            <title>INF + MTX [DB]</title>
            <description>Infliximab was given 3 mg/kg IV (approved labeled dose) on Days 1, 15, 43, 85 and every 56 days thereafter for a total of 8 doses. All participants received a stable dose of MTX (minimum 15 mg weekly)</description>
          </group>
          <group group_id="O3">
            <title>PLA + MTX [DB]</title>
            <description>Normal saline was administered as placebo. All participants received a stable dose of MTX (minimum 15 mg weekly). After placebo treatment from Day 1-197, participants were reallocated to receive abatacept (weight based) plus a stable dose of MTX (minimum 15 mg weekly).</description>
          </group>
        </group_list>
        <measure>
          <title>DB; Percentage of Participants With Clinically Meaningful Health Assessment Questionnaire-Disability Index (HAQ-DI) Response at Day 365</title>
          <description>The disability section of the full HAQ includes 20 questions to assess physical functions in 8 domains: dressing, arising, eating, walking, hygiene, reach, grip and common activities. The questions are evaluated on a 4-point scale: 0=without any difficulty, 1= with some difficulty, 2= with much difficulty, and 3= unable to do. Higher scores= greater dysfunction. A disability index was calculated by summing the worst scores in each domain and dividing by the number of domains answered. Clinically meaningful HAQ response=an improvement of at least 0.3 units from baseline in HAQ disability Index.</description>
          <population>The Intent-to-Treat (ITT) analysis population was defined to include all participants randomized into the study who received study medication. Participants were grouped according to the treatment or treatment regimen to which they were randomized. All participants who were randomized but never received study medication were excluded.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="156"/>
                <count group_id="O2" value="165"/>
                <count group_id="O3" value="110"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57.7"/>
                    <measurement group_id="O2" value="52.7"/>
                    <measurement group_id="O3" value="57.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>DB; Adjusted Mean Change From Baseline to Day 197 in HAQ-DI (LOCF Analysis)</title>
        <description>The disability section of the full HAQ includes 20 questions to assess physical functions in 8 domains: dressing, arising, eating, walking, hygiene, reach, grip and common activities. The questions are evaluated on a 4-point scale: 0=without any difficulty, 1= with some difficulty, 2= with much difficulty, and 3= unable to do. Higher scores= greater dysfunction. A disability index was calculated by summing the worst scores in each domain and dividing by the number of domains answered. Clinically meaningful HAQ response=an improvement of at least 0.3 units from baseline in HAQ disability Index.</description>
        <time_frame>Baseline (Day 1), 6 months (Day 197)</time_frame>
        <population>The Intent-to-Treat (ITT) analysis population was defined to include all participants randomized into the study who received study medication. Participants were grouped according to the treatment or treatment regimen to which they were randomized. All participants who were randomized but never received study medication were excluded.</population>
        <group_list>
          <group group_id="O1">
            <title>ABA + MTX [DB]</title>
            <description>Abatacept was administered intravenously (IV) on Days 1, 15, 29 and every 28 days thereafter for a total of 14 doses. Administration was as follows: 500 mg for participants &lt; 60 kg, 750 mg for participants 60 to 100 kg and 1 gram for participants &gt; 100 kg. All participants received a stable dose of MTX (minimum 15 mg weekly).</description>
          </group>
          <group group_id="O2">
            <title>INF + MTX [DB]</title>
            <description>Infliximab was given 3 mg/kg IV (approved labeled dose) on Days 1, 15, 43, 85 and every 56 days thereafter for a total of 8 doses. All participants received a stable dose of MTX (minimum 15 mg weekly)</description>
          </group>
          <group group_id="O3">
            <title>PLA + MTX [DB]</title>
            <description>Normal saline was administered as placebo. All participants received a stable dose of MTX (minimum 15 mg weekly)</description>
          </group>
        </group_list>
        <measure>
          <title>DB; Adjusted Mean Change From Baseline to Day 197 in HAQ-DI (LOCF Analysis)</title>
          <description>The disability section of the full HAQ includes 20 questions to assess physical functions in 8 domains: dressing, arising, eating, walking, hygiene, reach, grip and common activities. The questions are evaluated on a 4-point scale: 0=without any difficulty, 1= with some difficulty, 2= with much difficulty, and 3= unable to do. Higher scores= greater dysfunction. A disability index was calculated by summing the worst scores in each domain and dividing by the number of domains answered. Clinically meaningful HAQ response=an improvement of at least 0.3 units from baseline in HAQ disability Index.</description>
          <population>The Intent-to-Treat (ITT) analysis population was defined to include all participants randomized into the study who received study medication. Participants were grouped according to the treatment or treatment regimen to which they were randomized. All participants who were randomized but never received study medication were excluded.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="156"/>
                <count group_id="O2" value="164"/>
                <count group_id="O3" value="109"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>HAQ-DI</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.69" spread="0.05"/>
                    <measurement group_id="O2" value="-0.61" spread="0.05"/>
                    <measurement group_id="O3" value="-0.31" spread="0.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HAQ-DI component: activities</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.61" spread="0.06"/>
                    <measurement group_id="O2" value="-0.54" spread="0.06"/>
                    <measurement group_id="O3" value="-0.22" spread="0.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HAQ-DI component: dressing and grooming</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.69" spread="0.06"/>
                    <measurement group_id="O2" value="-0.57" spread="0.06"/>
                    <measurement group_id="O3" value="-0.37" spread="0.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HAQ-DI component: eating</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.79" spread="0.06"/>
                    <measurement group_id="O2" value="-0.77" spread="0.06"/>
                    <measurement group_id="O3" value="-0.36" spread="0.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HAQ-DI component: grip</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.73" spread="0.07"/>
                    <measurement group_id="O2" value="-0.70" spread="0.07"/>
                    <measurement group_id="O3" value="-0.26" spread="0.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HAQ-DI component: hygiene</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.64" spread="0.07"/>
                    <measurement group_id="O2" value="-0.48" spread="0.07"/>
                    <measurement group_id="O3" value="-0.26" spread="0.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HAQ-DI component: reach</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.72" spread="0.07"/>
                    <measurement group_id="O2" value="-0.64" spread="0.07"/>
                    <measurement group_id="O3" value="-0.30" spread="0.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HAQ-DI component: arising</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.70" spread="0.06"/>
                    <measurement group_id="O2" value="-0.68" spread="0.06"/>
                    <measurement group_id="O3" value="-0.39" spread="0.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HAQ-DI component: walking</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.58" spread="0.06"/>
                    <measurement group_id="O2" value="-0.56" spread="0.06"/>
                    <measurement group_id="O3" value="-0.23" spread="0.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Adjusted mean change in HAQ-DI from baseline to 6 months (Day 197) was compared between ABA and PLA. This comparison was done using an analysis of covariance (ANCOVA) model with treatment group as the effect and baseline value as the covariate. A 95% confidence interval was computed for the treatment difference within the framework of the ANCOVA model.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>Difference from placebo</param_type>
            <param_value>-0.38</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.53</ci_lower_limit>
            <ci_upper_limit>-0.23</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Adjusted mean change in HAQ-DI from baseline to 6 months (Day 197) was compared between INF and PLA. This comparison was done using an analysis of covariance (ANCOVA) model with treatment group as the effect and baseline value as the covariate. A 95% confidence interval was computed for the treatment difference within the framework of the ANCOVA model.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>Difference from placebo</param_type>
            <param_value>-0.30</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.45</ci_lower_limit>
            <ci_upper_limit>-0.15</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>DB; Adjusted Mean Change From Baseline to Day 365 in HAQ-DI (LOCF Analysis)</title>
        <description>The disability section of the full HAQ includes 20 questions to assess physical functions in 8 domains: dressing, arising, eating, walking, hygiene, reach, grip and common activities. The questions are evaluated on a 4-point scale: 0=without any difficulty, 1= with some difficulty, 2= with much difficulty, and 3= unable to do. Higher scores= greater dysfunction. A disability index was calculated by summing the worst scores in each domain and dividing by the number of domains answered. Clinically meaningful HAQ response=an improvement of at least 0.3 units from baseline in HAQ disability Index.</description>
        <time_frame>Baseline (Day 1), 12 months (Day 365)</time_frame>
        <population>Intent-to-Treat (ITT) Population: all participants randomized into the study receiving study medication, grouped according to randomization treatment. All participants randomized but never receiving study medication excluded. Although 3 participants in PLA group discontinued before Day 197, 2 of these patients were included in the LOCF analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>ABA + MTX [DB]</title>
            <description>Abatacept was administered intravenously (IV) on Days 1, 15, 29 and every 28 days thereafter for a total of 14 doses. Administration was as follows: 500 mg for participants &lt; 60 kg, 750 mg for participants 60 to 100 kg and 1 gram for participants &gt; 100 kg. All participants received a stable dose of MTX (minimum 15 mg weekly).</description>
          </group>
          <group group_id="O2">
            <title>INF + MTX [DB]</title>
            <description>Infliximab was given 3 mg/kg IV (approved labeled dose) on Days 1, 15, 43, 85 and every 56 days thereafter for a total of 8 doses. All participants received a stable dose of MTX (minimum 15 mg weekly)</description>
          </group>
          <group group_id="O3">
            <title>PLA + MTX [DB]</title>
            <description>Normal saline was administered as placebo. All participants received a stable dose of MTX (minimum 15 mg weekly). After placebo treatment from Day 1-197, participants were reallocated to receive abatacept (weight based) plus a stable dose of MTX (minimum 15 mg weekly).</description>
          </group>
        </group_list>
        <measure>
          <title>DB; Adjusted Mean Change From Baseline to Day 365 in HAQ-DI (LOCF Analysis)</title>
          <description>The disability section of the full HAQ includes 20 questions to assess physical functions in 8 domains: dressing, arising, eating, walking, hygiene, reach, grip and common activities. The questions are evaluated on a 4-point scale: 0=without any difficulty, 1= with some difficulty, 2= with much difficulty, and 3= unable to do. Higher scores= greater dysfunction. A disability index was calculated by summing the worst scores in each domain and dividing by the number of domains answered. Clinically meaningful HAQ response=an improvement of at least 0.3 units from baseline in HAQ disability Index.</description>
          <population>Intent-to-Treat (ITT) Population: all participants randomized into the study receiving study medication, grouped according to randomization treatment. All participants randomized but never receiving study medication excluded. Although 3 participants in PLA group discontinued before Day 197, 2 of these patients were included in the LOCF analysis.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="156"/>
                <count group_id="O2" value="164"/>
                <count group_id="O3" value="109"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>HAQ-DI</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.67" spread="0.05"/>
                    <measurement group_id="O2" value="-0.59" spread="0.05"/>
                    <measurement group_id="O3" value="-0.56" spread="0.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HAQ-DI component: activities</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.55" spread="0.07"/>
                    <measurement group_id="O2" value="-0.52" spread="0.07"/>
                    <measurement group_id="O3" value="-0.55" spread="0.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HAQ-DI component: dressing and grooming</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.72" spread="0.06"/>
                    <measurement group_id="O2" value="-0.60" spread="0.06"/>
                    <measurement group_id="O3" value="-0.56" spread="0.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HAQ-DI component: eating</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.80" spread="0.06"/>
                    <measurement group_id="O2" value="-0.73" spread="0.06"/>
                    <measurement group_id="O3" value="-0.71" spread="0.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HAQ-DI component: grip</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.77" spread="0.07"/>
                    <measurement group_id="O2" value="-0.64" spread="0.07"/>
                    <measurement group_id="O3" value="-0.56" spread="0.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HAQ-DI component: hygiene</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.53" spread="0.07"/>
                    <measurement group_id="O2" value="-0.45" spread="0.07"/>
                    <measurement group_id="O3" value="-0.42" spread="0.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HAQ-DI component: reach</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.77" spread="0.07"/>
                    <measurement group_id="O2" value="-0.66" spread="0.07"/>
                    <measurement group_id="O3" value="-0.53" spread="0.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HAQ-DI component: arising</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.68" spread="0.06"/>
                    <measurement group_id="O2" value="-0.64" spread="0.06"/>
                    <measurement group_id="O3" value="-0.61" spread="0.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HAQ-DI component: walking</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.54" spread="0.06"/>
                    <measurement group_id="O2" value="-0.55" spread="0.06"/>
                    <measurement group_id="O3" value="-0.47" spread="0.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>DB; Adjusted Mean Change From Baseline to Day 197 in SF-36 Physical Component Summary (PCS) and Mental Component Summary (MCS)</title>
        <description>The SF-36 is a validated instrument measuring health-related quality of life across multiple disease states. It has 36 questions with 8 subscale scores and 2 summary scores (1) physical component summary=physical functioning, role-physical, bodily pain, and general health; (2) mental component summary=vitality, social functioning, role-emotional, and mental health. There is no total overall score; scoring is done for both subscores and summary scores. For subscores and summary scores, 0 =worst score (or quality of life) and 100=best score. Change from Baseline= post-Baseline - Baseline value.</description>
        <time_frame>Baseline (Day 1), 6 months (Day 197)</time_frame>
        <population>ITT population, all participants randomized into the study receiving study medication. Participants grouped according to the treatment to which they were randomized. All randomized participants who never received study medication were excluded. SF-36 component scores were not presented in tabular form.</population>
        <group_list>
          <group group_id="O1">
            <title>ABA + MTX [DB]</title>
            <description>Abatacept was administered intravenously (IV) on Days 1, 15, 29 and every 28 days thereafter for a total of 14 doses. Administration was as follows: 500 mg for participants &lt; 60 kg, 750 mg for participants 60 to 100 kg and 1 gram for participants &gt; 100 kg. All participants received a stable dose of MTX (minimum 15 mg weekly).</description>
          </group>
          <group group_id="O2">
            <title>INF + MTX [DB]</title>
            <description>Infliximab was given 3 mg/kg IV (approved labeled dose) on Days 1, 15, 43, 85 and every 56 days thereafter for a total of 8 doses. All participants received a stable dose of MTX (minimum 15 mg weekly)</description>
          </group>
          <group group_id="O3">
            <title>PLA + MTX [DB]</title>
            <description>Normal saline was administered as placebo. All participants received a stable dose of MTX (minimum 15 mg weekly)</description>
          </group>
        </group_list>
        <measure>
          <title>DB; Adjusted Mean Change From Baseline to Day 197 in SF-36 Physical Component Summary (PCS) and Mental Component Summary (MCS)</title>
          <description>The SF-36 is a validated instrument measuring health-related quality of life across multiple disease states. It has 36 questions with 8 subscale scores and 2 summary scores (1) physical component summary=physical functioning, role-physical, bodily pain, and general health; (2) mental component summary=vitality, social functioning, role-emotional, and mental health. There is no total overall score; scoring is done for both subscores and summary scores. For subscores and summary scores, 0 =worst score (or quality of life) and 100=best score. Change from Baseline= post-Baseline - Baseline value.</description>
          <population>ITT population, all participants randomized into the study receiving study medication. Participants grouped according to the treatment to which they were randomized. All randomized participants who never received study medication were excluded. SF-36 component scores were not presented in tabular form.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="154"/>
                <count group_id="O2" value="163"/>
                <count group_id="O3" value="109"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>SF-36 Physical Component Summary</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.36" spread="0.69"/>
                    <measurement group_id="O2" value="7.66" spread="0.67"/>
                    <measurement group_id="O3" value="4.34" spread="0.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SF-36 Mental Component Summary</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.14" spread="0.79"/>
                    <measurement group_id="O2" value="4.32" spread="0.76"/>
                    <measurement group_id="O3" value="1.64" spread="0.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Adjusted mean change in SF-36 physical component summary from baseline to 6 months (Day 197) was compared between ABA and PLA. This comparison was done using an analysis of covariance (ANCOVA) model with treatment group as the effect and baseline value as the covariate. A 95% confidence interval was computed for the treatment difference within the framework of the ANCOVA model.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>Difference from placebo (PCS)</param_type>
            <param_value>4.02</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.92</ci_lower_limit>
            <ci_upper_limit>6.12</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Adjusted mean change in SF-36 mental component summary from baseline to 6 months (Day 197) was compared between ABA and PLA. This comparison was done using an analysis of covariance (ANCOVA) model with treatment group as the effect and baseline value as the covariate. A 95% confidence interval was computed for the treatment difference within the framework of the ANCOVA model.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.004</p_value>
            <method>ANCOVA</method>
            <param_type>Difference from placebo (MCS)</param_type>
            <param_value>3.51</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.10</ci_lower_limit>
            <ci_upper_limit>5.91</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Adjusted mean change in SF-36 physical component summary from baseline to 6 months (Day 197) was compared between INF and PLA. This comparison was done using an analysis of covariance (ANCOVA) model with treatment group as the effect and baseline value as the covariate. A 95% confidence interval was computed for the treatment difference within the framework of the ANCOVA model.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.002</p_value>
            <method>ANCOVA</method>
            <param_type>Difference from placebo (PCS)</param_type>
            <param_value>3.32</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.25</ci_lower_limit>
            <ci_upper_limit>5.40</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Adjusted mean change in SF-36 mental component summary from baseline to 6 months (Day 197) was compared between INF and PLA. This comparison was done using an analysis of covariance (ANCOVA) model with treatment group as the effect and baseline value as the covariate. A 95% confidence interval was computed for the treatment difference within the framework of the ANCOVA model.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.027</p_value>
            <method>ANCOVA</method>
            <param_type>Difference from placebo (MCS)</param_type>
            <param_value>2.68</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.31</ci_lower_limit>
            <ci_upper_limit>5.05</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>DB; Adjusted Mean Change From Baseline to Day 365 in SF-36 Physical Component Summary (PCS) and Mental Component Summary (MCS)</title>
        <description>The SF-36 is a validated instrument measuring health-related quality of life across multiple disease states. It has 36 questions with 8 subscale scores and 2 summary scores (1) physical component summary=physical functioning, role-physical, bodily pain, and general health; (2) mental component summary=vitality, social functioning, role-emotional, and mental health. There is no total overall score; scoring is done for both subscores and summary scores. For subscores and summary scores, 0 =worst score (or quality of life) and 100=best score. Change from Baseline= post-Baseline - Baseline value.</description>
        <time_frame>Baseline (Day 1), 12 months (Day 365)</time_frame>
        <population>ITT Population: all participants randomized into the study receiving study medication, grouped according to randomization treatment. Although 3 participants in PLA group discontinued before Day 197, 2 of these patients were included in the LOCF analysis. SF-36 component scores were not presented in tabular form.</population>
        <group_list>
          <group group_id="O1">
            <title>ABA + MTX [DB]</title>
            <description>Abatacept was administered intravenously (IV) on Days 1, 15, 29 and every 28 days thereafter for a total of 14 doses. Administration was as follows: 500 mg for participants &lt; 60 kg, 750 mg for participants 60 to 100 kg and 1 gram for participants &gt; 100 kg. All participants received a stable dose of MTX (minimum 15 mg weekly).</description>
          </group>
          <group group_id="O2">
            <title>INF + MTX [DB]</title>
            <description>Infliximab was given 3 mg/kg IV (approved labeled dose) on Days 1, 15, 43, 85 and every 56 days thereafter for a total of 8 doses. All participants received a stable dose of MTX (minimum 15 mg weekly)</description>
          </group>
          <group group_id="O3">
            <title>PLA + MTX [DB]</title>
            <description>Normal saline was administered as placebo. All participants received a stable dose of MTX (minimum 15 mg weekly). After placebo treatment from Day 1-197, participants were reallocated to receive abatacept (weight based) plus a stable dose of MTX (minimum 15 mg weekly).</description>
          </group>
        </group_list>
        <measure>
          <title>DB; Adjusted Mean Change From Baseline to Day 365 in SF-36 Physical Component Summary (PCS) and Mental Component Summary (MCS)</title>
          <description>The SF-36 is a validated instrument measuring health-related quality of life across multiple disease states. It has 36 questions with 8 subscale scores and 2 summary scores (1) physical component summary=physical functioning, role-physical, bodily pain, and general health; (2) mental component summary=vitality, social functioning, role-emotional, and mental health. There is no total overall score; scoring is done for both subscores and summary scores. For subscores and summary scores, 0 =worst score (or quality of life) and 100=best score. Change from Baseline= post-Baseline - Baseline value.</description>
          <population>ITT Population: all participants randomized into the study receiving study medication, grouped according to randomization treatment. Although 3 participants in PLA group discontinued before Day 197, 2 of these patients were included in the LOCF analysis. SF-36 component scores were not presented in tabular form.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="154"/>
                <count group_id="O2" value="163"/>
                <count group_id="O3" value="109"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>SF-36 Physical Component Summary</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.52" spread="0.70"/>
                    <measurement group_id="O2" value="7.59" spread="0.68"/>
                    <measurement group_id="O3" value="8.00" spread="0.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SF-36 Mental Component Summary</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.96" spread="0.81"/>
                    <measurement group_id="O2" value="4.03" spread="0.79"/>
                    <measurement group_id="O3" value="5.85" spread="0.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>DB; Percentage of Participants With Good, Moderate, or No Response According to European League Against Rheumatism (EULAR) at Day 365</title>
        <description>The DAS28 is a continuous disease measure composite of 4 variables: 28 tender joint count, 28 swollen joint count, ESR or CRP, and participant assessment of disease activity measure on a visual analogue scale. High disease activity= &gt; 5.1, low disease activity= &lt; 3.2, and remission= &lt; 2.6. Clinically significant response= decrease of &gt;1.2 from baseline. Utilizing EULAR response criteria, DAS28 categorical responses define a good (absolute: &lt;3.2 or &gt;1.2 improvement from baseline [BL]), moderate (absolute: 3.2-5.1 or 0.6-1.2 change from BL), or no response (absolute: &gt;5.1 or &lt;0.6 change from BL)</description>
        <time_frame>DB Day 365</time_frame>
        <population>The Intent-to-Treat (ITT) analysis population was defined to include all participants randomized into the study who received study medication. Participants were grouped according to the treatment or treatment regimen to which they were randomized. All participants who were randomized but never received study medication were excluded.</population>
        <group_list>
          <group group_id="O1">
            <title>ABA + MTX [DB]</title>
            <description>Abatacept was administered intravenously (IV) on Days 1, 15, 29 and every 28 days thereafter for a total of 14 doses. Administration was as follows: 500 mg for participants &lt; 60 kg, 750 mg for participants 60 to 100 kg and 1 gram for participants &gt; 100 kg. All participants received a stable dose of MTX (minimum 15 mg weekly).</description>
          </group>
          <group group_id="O2">
            <title>INF + MTX [DB]</title>
            <description>Infliximab was given 3 mg/kg IV (approved labeled dose) on Days 1, 15, 43, 85 and every 56 days thereafter for a total of 8 doses. All participants received a stable dose of MTX (minimum 15 mg weekly)</description>
          </group>
          <group group_id="O3">
            <title>PLA + MTX [DB]</title>
            <description>Normal saline was administered as placebo. All participants received a stable dose of MTX (minimum 15 mg weekly). After placebo treatment from Day 1-197, participants were reallocated to receive abatacept (weight based) plus a stable dose of MTX (minimum 15 mg weekly).</description>
          </group>
        </group_list>
        <measure>
          <title>DB; Percentage of Participants With Good, Moderate, or No Response According to European League Against Rheumatism (EULAR) at Day 365</title>
          <description>The DAS28 is a continuous disease measure composite of 4 variables: 28 tender joint count, 28 swollen joint count, ESR or CRP, and participant assessment of disease activity measure on a visual analogue scale. High disease activity= &gt; 5.1, low disease activity= &lt; 3.2, and remission= &lt; 2.6. Clinically significant response= decrease of &gt;1.2 from baseline. Utilizing EULAR response criteria, DAS28 categorical responses define a good (absolute: &lt;3.2 or &gt;1.2 improvement from baseline [BL]), moderate (absolute: 3.2-5.1 or 0.6-1.2 change from BL), or no response (absolute: &gt;5.1 or &lt;0.6 change from BL)</description>
          <population>The Intent-to-Treat (ITT) analysis population was defined to include all participants randomized into the study who received study medication. Participants were grouped according to the treatment or treatment regimen to which they were randomized. All participants who were randomized but never received study medication were excluded.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="150"/>
                <count group_id="O2" value="157"/>
                <count group_id="O3" value="102"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>No response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.3"/>
                    <measurement group_id="O2" value="36.3"/>
                    <measurement group_id="O3" value="23.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderate response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.7"/>
                    <measurement group_id="O2" value="45.2"/>
                    <measurement group_id="O3" value="49.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Good response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.0"/>
                    <measurement group_id="O2" value="18.5"/>
                    <measurement group_id="O3" value="27.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>DB; Percentage of Participants With American College of Rheumatology (ACR) Responses at Day 197</title>
        <description>The ACR 20 definition of improvement is a 20% improvement from baseline in the number of tender and swollen joint counts, and a 20% improvement from baseline in 3 of the remaining 5 core set measures: participant global assessment of pain, participant global assessment of disease activity, physician global assessment of disease activity, participant assessment of physical function and acute phase reactant value (C-reactive protein [CRP]). The evaluation for 50% improvement (ACR 50) and 70% improvement (ACR 70) follow similarly.</description>
        <time_frame>DB Day 197</time_frame>
        <population>The Intent-to-Treat (ITT) analysis population was defined to include all participants randomized into the study who received study medication. Participants were grouped according to the treatment or treatment regimen to which they were randomized. All participants who were randomized but never received study medication were excluded.</population>
        <group_list>
          <group group_id="O1">
            <title>ABA + MTX [DB]</title>
            <description>Abatacept was administered intravenously (IV) on Days 1, 15, 29 and every 28 days thereafter for a total of 14 doses. Administration was as follows: 500 mg for participants &lt; 60 kg, 750 mg for participants 60 to 100 kg and 1 gram for participants &gt; 100 kg. All participants received a stable dose of MTX (minimum 15 mg weekly).</description>
          </group>
          <group group_id="O2">
            <title>INF + MTX [DB]</title>
            <description>Infliximab was given 3 mg/kg IV (approved labeled dose) on Days 1, 15, 43, 85 and every 56 days thereafter for a total of 8 doses. All participants received a stable dose of MTX (minimum 15 mg weekly)</description>
          </group>
          <group group_id="O3">
            <title>PLA + MTX [DB]</title>
            <description>Normal saline was administered as placebo. All participants received a stable dose of MTX (minimum 15 mg weekly)</description>
          </group>
        </group_list>
        <measure>
          <title>DB; Percentage of Participants With American College of Rheumatology (ACR) Responses at Day 197</title>
          <description>The ACR 20 definition of improvement is a 20% improvement from baseline in the number of tender and swollen joint counts, and a 20% improvement from baseline in 3 of the remaining 5 core set measures: participant global assessment of pain, participant global assessment of disease activity, physician global assessment of disease activity, participant assessment of physical function and acute phase reactant value (C-reactive protein [CRP]). The evaluation for 50% improvement (ACR 50) and 70% improvement (ACR 70) follow similarly.</description>
          <population>The Intent-to-Treat (ITT) analysis population was defined to include all participants randomized into the study who received study medication. Participants were grouped according to the treatment or treatment regimen to which they were randomized. All participants who were randomized but never received study medication were excluded.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="156"/>
                <count group_id="O2" value="165"/>
                <count group_id="O3" value="110"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 197, ACR 20</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66.7"/>
                    <measurement group_id="O2" value="59.4"/>
                    <measurement group_id="O3" value="41.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 197, ACR 50</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.4"/>
                    <measurement group_id="O2" value="37.0"/>
                    <measurement group_id="O3" value="20.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 197, ACR 70</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.5"/>
                    <measurement group_id="O2" value="24.2"/>
                    <measurement group_id="O3" value="9.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>DB; Percentage of Participants With American College of Rheumatology (ACR) Responses at Day 365</title>
        <description>The ACR 20 definition of improvement is a 20% improvement from baseline in the number of tender and swollen joint counts, and a 20% improvement from baseline in 3 of the remaining 5 core set measures: participant global assessment of pain, participant global assessment of disease activity, physician global assessment of disease activity, participant assessment of physical function and acute phase reactant value (C-reactive protein [CRP]). The evaluation for 50% improvement (ACR 50) and 70% improvement (ACR 70) follow similarly.</description>
        <time_frame>DB Day 365</time_frame>
        <population>The Intent-to-Treat (ITT) analysis population was defined to include all participants randomized into the study who received study medication. Participants were grouped according to the treatment or treatment regimen to which they were randomized. All participants who were randomized but never received study medication were excluded.</population>
        <group_list>
          <group group_id="O1">
            <title>ABA + MTX [DB]</title>
            <description>Abatacept was administered intravenously (IV) on Days 1, 15, 29 and every 28 days thereafter for a total of 14 doses. Administration was as follows: 500 mg for participants &lt; 60 kg, 750 mg for participants 60 to 100 kg and 1 gram for participants &gt; 100 kg. All participants received a stable dose of MTX (minimum 15 mg weekly).</description>
          </group>
          <group group_id="O2">
            <title>INF + MTX [DB]</title>
            <description>Infliximab was given 3 mg/kg IV (approved labeled dose) on Days 1, 15, 43, 85 and every 56 days thereafter for a total of 8 doses. All participants received a stable dose of MTX (minimum 15 mg weekly)</description>
          </group>
          <group group_id="O3">
            <title>PLA + MTX [DB]</title>
            <description>Normal saline was administered as placebo. All participants received a stable dose of MTX (minimum 15 mg weekly). After placebo treatment from Day 1-197, participants were reallocated to receive abatacept (weight based) plus a stable dose of MTX (minimum 15 mg weekly).</description>
          </group>
        </group_list>
        <measure>
          <title>DB; Percentage of Participants With American College of Rheumatology (ACR) Responses at Day 365</title>
          <description>The ACR 20 definition of improvement is a 20% improvement from baseline in the number of tender and swollen joint counts, and a 20% improvement from baseline in 3 of the remaining 5 core set measures: participant global assessment of pain, participant global assessment of disease activity, physician global assessment of disease activity, participant assessment of physical function and acute phase reactant value (C-reactive protein [CRP]). The evaluation for 50% improvement (ACR 50) and 70% improvement (ACR 70) follow similarly.</description>
          <population>The Intent-to-Treat (ITT) analysis population was defined to include all participants randomized into the study who received study medication. Participants were grouped according to the treatment or treatment regimen to which they were randomized. All participants who were randomized but never received study medication were excluded.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="156"/>
                <count group_id="O2" value="165"/>
                <count group_id="O3" value="110"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 365, ACR 20</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72.4"/>
                    <measurement group_id="O2" value="55.8"/>
                    <measurement group_id="O3" value="68.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 365, ACR 50</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.5"/>
                    <measurement group_id="O2" value="36.4"/>
                    <measurement group_id="O3" value="50.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 365, ACR 70</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.3"/>
                    <measurement group_id="O2" value="20.6"/>
                    <measurement group_id="O3" value="29.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>DB; Number of Participants With Death, Serious Adverse Events (SAEs), Related SAEs, SAEs Leading to Discontinuation, AEs, Related AEs, and AEs Leading to Discontinuation From Day 1 Through Day 197</title>
        <description>AE=any new untoward medical occurrence or worsening of a pre-existing medical condition which does not necessarily have a causal relationship with this treatment. SAE=any untoward medical occurrence that at any dose: results in death, is life-threatening, requires inpatient hospitalization or causes prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, results in development of drug dependency or drug abuse, is an important medical event.</description>
        <time_frame>From Baseline (Day 1) through Day 197, and up to 56 days after last dose if occurring on-study</time_frame>
        <population>The As-Treated analysis population contained all participants who received at least one dose of double-blind study medication, and participants were grouped on an as-assigned or randomized basis unless the participant received the incorrect medication for the entire period of treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>ABA + MTX [DB]</title>
            <description>Abatacept was administered intravenously (IV) on Days 1, 15, 29 and every 28 days thereafter for a total of 14 doses. Administration was as follows: 500 mg for participants &lt; 60 kg, 750 mg for participants 60 to 100 kg and 1 gram for participants &gt; 100 kg. All participants received a stable dose of MTX (minimum 15 mg weekly).</description>
          </group>
          <group group_id="O2">
            <title>INF + MTX [DB]</title>
            <description>Infliximab was given 3 mg/kg IV (approved labeled dose) on Days 1, 15, 43, 85 and every 56 days thereafter for a total of 8 doses. All participants received a stable dose of MTX (minimum 15 mg weekly)</description>
          </group>
          <group group_id="O3">
            <title>PLA + MTX [DB]</title>
            <description>Normal saline was administered as placebo. All participants received a stable dose of MTX (minimum 15 mg weekly)</description>
          </group>
        </group_list>
        <measure>
          <title>DB; Number of Participants With Death, Serious Adverse Events (SAEs), Related SAEs, SAEs Leading to Discontinuation, AEs, Related AEs, and AEs Leading to Discontinuation From Day 1 Through Day 197</title>
          <description>AE=any new untoward medical occurrence or worsening of a pre-existing medical condition which does not necessarily have a causal relationship with this treatment. SAE=any untoward medical occurrence that at any dose: results in death, is life-threatening, requires inpatient hospitalization or causes prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, results in development of drug dependency or drug abuse, is an important medical event.</description>
          <population>The As-Treated analysis population contained all participants who received at least one dose of double-blind study medication, and participants were grouped on an as-assigned or randomized basis unless the participant received the incorrect medication for the entire period of treatment.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="156"/>
                <count group_id="O2" value="165"/>
                <count group_id="O3" value="110"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Deaths</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="19"/>
                    <measurement group_id="O3" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related SAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SAEs Leading to Discontinuation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="129"/>
                    <measurement group_id="O2" value="140"/>
                    <measurement group_id="O3" value="92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64"/>
                    <measurement group_id="O2" value="74"/>
                    <measurement group_id="O3" value="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AEs Leading to discontinuation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>DB; Number of Participants With AEs of Special Interest From Day 1 Through Day 197</title>
        <description>AE=any new untoward medical occurrence or worsening of a pre-existing medical condition which does not necessarily have a causal relationship with this treatment. AEs of special interest are those AEs that may be associated with the use of immunomodulatory drugs, including all infections, serious infections, autoimmune disorders; malignancies; and acute infusional AEs (pre-specified AEs occurring within 1 hour of start of infusion).</description>
        <time_frame>From Baseline (Day 1) through Day 197, and up to 56 days after last dose if occurring on-study</time_frame>
        <population>The As-Treated analysis population contained all participants who received at least one dose of double-blind study medication, and participants were grouped on an as-assigned or randomized basis unless the participant received the incorrect medication for the entire period of treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>ABA + MTX [DB]</title>
            <description>Abatacept was administered intravenously (IV) on Days 1, 15, 29 and every 28 days thereafter for a total of 14 doses. Administration was as follows: 500 mg for participants &lt; 60 kg, 750 mg for participants 60 to 100 kg and 1 gram for participants &gt; 100 kg. All participants received a stable dose of MTX (minimum 15 mg weekly).</description>
          </group>
          <group group_id="O2">
            <title>INF + MTX [DB]</title>
            <description>Infliximab was given 3 mg/kg IV (approved labeled dose) on Days 1, 15, 43, 85 and every 56 days thereafter for a total of 8 doses. All participants received a stable dose of MTX (minimum 15 mg weekly)</description>
          </group>
          <group group_id="O3">
            <title>PLA + MTX [DB]</title>
            <description>Normal saline was administered as placebo. All participants received a stable dose of MTX (minimum 15 mg weekly)</description>
          </group>
        </group_list>
        <measure>
          <title>DB; Number of Participants With AEs of Special Interest From Day 1 Through Day 197</title>
          <description>AE=any new untoward medical occurrence or worsening of a pre-existing medical condition which does not necessarily have a causal relationship with this treatment. AEs of special interest are those AEs that may be associated with the use of immunomodulatory drugs, including all infections, serious infections, autoimmune disorders; malignancies; and acute infusional AEs (pre-specified AEs occurring within 1 hour of start of infusion).</description>
          <population>The As-Treated analysis population contained all participants who received at least one dose of double-blind study medication, and participants were grouped on an as-assigned or randomized basis unless the participant received the incorrect medication for the entire period of treatment.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="156"/>
                <count group_id="O2" value="165"/>
                <count group_id="O3" value="110"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pre-specified infections</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="18"/>
                    <measurement group_id="O3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Neoplasms: Benign, malignant, and unspecified</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Prespecified autoimmune symptoms and disorders</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pre-specified infusional AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="30"/>
                    <measurement group_id="O3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>DB; Number of Participants With Death, Serious Adverse Events (SAEs), Related SAEs, SAEs Leading to Discontinuation, AEs, Related AEs, and AEs Leading to Discontinuation From Day 1 Through Day 365</title>
        <description>AE=any new untoward medical occurrence or worsening of a pre-existing medical condition which does not necessarily have a causal relationship with this treatment. SAE=any untoward medical occurrence that at any dose: results in death, is life-threatening, requires inpatient hospitalization or causes prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, results in development of drug dependency or drug abuse, is an important medical event.</description>
        <time_frame>From Baseline (Day 1) through Day 365, and up to 56 days after last dose if occurring on-study</time_frame>
        <population>The As-Treated analysis population contained all participants who received at least one dose of double-blind study medication, and participants were grouped on an as-assigned or randomized basis unless the participant received the incorrect medication for the entire period of treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>ABA + MTX [DB]</title>
            <description>Abatacept was administered intravenously (IV) on Days 1, 15, 29 and every 28 days thereafter for a total of 14 doses. Administration was as follows: 500 mg for participants &lt; 60 kg, 750 mg for participants 60 to 100 kg and 1 gram for participants &gt; 100 kg. All participants received a stable dose of MTX (minimum 15 mg weekly).</description>
          </group>
          <group group_id="O2">
            <title>INF + MTX [DB]</title>
            <description>Infliximab was given 3 mg/kg IV (approved labeled dose) on Days 1, 15, 43, 85 and every 56 days thereafter for a total of 8 doses. All participants received a stable dose of MTX (minimum 15 mg weekly)</description>
          </group>
        </group_list>
        <measure>
          <title>DB; Number of Participants With Death, Serious Adverse Events (SAEs), Related SAEs, SAEs Leading to Discontinuation, AEs, Related AEs, and AEs Leading to Discontinuation From Day 1 Through Day 365</title>
          <description>AE=any new untoward medical occurrence or worsening of a pre-existing medical condition which does not necessarily have a causal relationship with this treatment. SAE=any untoward medical occurrence that at any dose: results in death, is life-threatening, requires inpatient hospitalization or causes prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, results in development of drug dependency or drug abuse, is an important medical event.</description>
          <population>The As-Treated analysis population contained all participants who received at least one dose of double-blind study medication, and participants were grouped on an as-assigned or randomized basis unless the participant received the incorrect medication for the entire period of treatment.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="156"/>
                <count group_id="O2" value="165"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Deaths</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related SAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SAEs Leading to Discontinuation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="139"/>
                    <measurement group_id="O2" value="154"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72"/>
                    <measurement group_id="O2" value="96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AEs Leading to discontinuation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>DB; Number of Participants With Death, Serious Adverse Events (SAEs), Related SAEs, SAEs Leading to Discontinuation, AEs, Related AEs, and AEs Leading to Discontinuation From Day 198 Through Day 365 in Participants Receiving Placebo Switched to Abatacept</title>
        <description>AE=any new untoward medical occurrence or worsening of a pre-existing medical condition which does not necessarily have a causal relationship with this treatment. SAE=any untoward medical occurrence that at any dose: results in death, is life-threatening, requires inpatient hospitalization or causes prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, results in development of drug dependency or drug abuse, is an important medical event.</description>
        <time_frame>From Day 198 through Day 365, and up to 56 days after last dose if occurring on-study</time_frame>
        <population>The As-Treated analysis population contained all participants who received at least one dose of double-blind study medication, and participants were grouped on an as-assigned or randomized basis unless the participant received the incorrect medication for the entire period of treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>PLA Switched to ABA + MTX [DB]</title>
            <description>Normal saline was administered as placebo. All participants received a stable dose of MTX (minimum 15 mg weekly). After placebo treatment from Day 1-197, participants were reallocated to receive abatacept (weight based) plus a stable dose of MTX (minimum 15 mg weekly).</description>
          </group>
        </group_list>
        <measure>
          <title>DB; Number of Participants With Death, Serious Adverse Events (SAEs), Related SAEs, SAEs Leading to Discontinuation, AEs, Related AEs, and AEs Leading to Discontinuation From Day 198 Through Day 365 in Participants Receiving Placebo Switched to Abatacept</title>
          <description>AE=any new untoward medical occurrence or worsening of a pre-existing medical condition which does not necessarily have a causal relationship with this treatment. SAE=any untoward medical occurrence that at any dose: results in death, is life-threatening, requires inpatient hospitalization or causes prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, results in development of drug dependency or drug abuse, is an important medical event.</description>
          <population>The As-Treated analysis population contained all participants who received at least one dose of double-blind study medication, and participants were grouped on an as-assigned or randomized basis unless the participant received the incorrect medication for the entire period of treatment.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="110"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Deaths</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related SAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SAEs Leading to Discontinuation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AEs Leading to discontinuation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>OL; Number of Participants With Death, Serious Adverse Events (SAEs), Related SAEs, SAEs Leading to Discontinuation, Adverse Events (AEs), Related AEs, and AEs Leading to Discontinuation</title>
        <description>AE=any new untoward medical occurrence or worsening of a pre-existing medical condition which does not necessarily have a causal relationship with this treatment. SAE=any untoward medical occurrence that at any dose: results in death, is life-threatening, requires inpatient hospitalization or causes prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, results in development of drug dependency or drug abuse, is an important medical event.</description>
        <time_frame>From beginning of OL (Day 366) through end of OL (range from 1.9 months to 42.3 months)</time_frame>
        <population>All Treated Population, all participants who entered the open-label period and received at least one dose of abatacept at any time during this period.</population>
        <group_list>
          <group group_id="O1">
            <title>ABA + MTX [OL]</title>
            <description>All participants received ABA at a weight-tiered dose of 10 mg/kg plus a stable dose of MTX (minimum 15 mg weekly).</description>
          </group>
        </group_list>
        <measure>
          <title>OL; Number of Participants With Death, Serious Adverse Events (SAEs), Related SAEs, SAEs Leading to Discontinuation, Adverse Events (AEs), Related AEs, and AEs Leading to Discontinuation</title>
          <description>AE=any new untoward medical occurrence or worsening of a pre-existing medical condition which does not necessarily have a causal relationship with this treatment. SAE=any untoward medical occurrence that at any dose: results in death, is life-threatening, requires inpatient hospitalization or causes prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, results in development of drug dependency or drug abuse, is an important medical event.</description>
          <population>All Treated Population, all participants who entered the open-label period and received at least one dose of abatacept at any time during this period.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="372"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Deaths</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related SAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SAEs Leading to Discontinuation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="349"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="165"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AEs Leading to discontinuation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>OL; Number of Participants With AEs of Special Interest</title>
        <description>AE=any new untoward medical occurrence or worsening of a pre-existing medical condition which does not necessarily have a causal relationship with this treatment. AEs of special interest are those AEs that may be associated with the use of immunomodulatory drugs, including all infections, serious infections, autoimmune disorders; malignancies; and acute infusional AEs (pre-specified AEs occurring within 1 hour of start of infusion).</description>
        <time_frame>From beginning of OL (Day 366) through end of OL (range from 1.9 months to 42.3 months)</time_frame>
        <population>All Treated Population, all participants who entered the open-label period and received at least one dose of abatacept at any time during this period.</population>
        <group_list>
          <group group_id="O1">
            <title>ABA + MTX [OL]</title>
            <description>All participants received ABA at a weight-tiered dose of 10 mg/kg plus a stable dose of MTX (minimum 15 mg weekly).</description>
          </group>
        </group_list>
        <measure>
          <title>OL; Number of Participants With AEs of Special Interest</title>
          <description>AE=any new untoward medical occurrence or worsening of a pre-existing medical condition which does not necessarily have a causal relationship with this treatment. AEs of special interest are those AEs that may be associated with the use of immunomodulatory drugs, including all infections, serious infections, autoimmune disorders; malignancies; and acute infusional AEs (pre-specified AEs occurring within 1 hour of start of infusion).</description>
          <population>All Treated Population, all participants who entered the open-label period and received at least one dose of abatacept at any time during this period.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="372"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Infections</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="277"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Malignant neoplasms</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Benign and unspecified neoplasms</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Prespecified autoimmune symptoms and disorders</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pre-specified peri-infusional AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pre-specified acute infusional AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>OL; Number of Participants With Select Hematologic Laboratory Abnormalities</title>
        <description>High=greater than Upper Normal Limit (ULN), Low=lower than Lower Normal Limit (LLN). LLN/ULN= Hemoglobin (HGB): &gt;3 g/dL decrease from Baseline (BL); Hematocrit: &lt;0.75 x BL; Erythrocytes: &lt;0.75 x BL; Platelets (PLT): &lt;0.67 x LLN/&gt;1.5 x ULN; Leukocytes: &lt;0.75 x LLN/ &gt;1.25 x ULN; neutrophils+bands: &lt;1.0 x 10^3 c/uL; lymphocytes: &lt;0.750 x 10^3 c/uL/ &gt;7.50 x 10^3 c/uL; monocytes: &gt;2000 mm3; eosinophils: &gt;0.750 x 10^3 c/uL;</description>
        <time_frame>From Day 366 through end of OL (range from 1.9 months to 42.3 months)</time_frame>
        <population>All Treated Population, all participants who entered the open-label period and received at least one dose of abatacept at any time during this period.</population>
        <group_list>
          <group group_id="O1">
            <title>ABA + MTX [OL]</title>
            <description>All participants received ABA at a weight-tiered dose of 10 mg/kg plus a stable dose of MTX (minimum 15 mg weekly).</description>
          </group>
        </group_list>
        <measure>
          <title>OL; Number of Participants With Select Hematologic Laboratory Abnormalities</title>
          <description>High=greater than Upper Normal Limit (ULN), Low=lower than Lower Normal Limit (LLN). LLN/ULN= Hemoglobin (HGB): &gt;3 g/dL decrease from Baseline (BL); Hematocrit: &lt;0.75 x BL; Erythrocytes: &lt;0.75 x BL; Platelets (PLT): &lt;0.67 x LLN/&gt;1.5 x ULN; Leukocytes: &lt;0.75 x LLN/ &gt;1.25 x ULN; neutrophils+bands: &lt;1.0 x 10^3 c/uL; lymphocytes: &lt;0.750 x 10^3 c/uL/ &gt;7.50 x 10^3 c/uL; monocytes: &gt;2000 mm3; eosinophils: &gt;0.750 x 10^3 c/uL;</description>
          <population>All Treated Population, all participants who entered the open-label period and received at least one dose of abatacept at any time during this period.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="372"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Low HGB (&gt;3g/dL decrease from BL), n=372</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Low hematocrit (&lt; 0.75 x BL), n=372</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Low erythrocytes (&lt;0.75 x BL), n=372</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Low PLT (&lt;0.67 x LLN), n=370</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High leukocytes (&gt;1.25 x ULN), n=372</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Low neutrophils + bands (&lt;1.0 x 10^3 c/uL), n=372</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Low lymphocytes (&lt;0.75 x 10^3 c/uL), n=372</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High monocytes (&gt;2000/mm^3), n=372</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High eosinophils (&gt;0.750 x 10^3 c/uL), n=372</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>OL; Number of Participants With Select Blood Chemistry Laboratory Abnormalities</title>
        <description>Low=lower than LLN, High=greater than ULN. LLN/ULN= Alkaline phosphatase (ALP): &gt;2 x ULN; aspartate aminotransferase (AST): &gt;3 x ULN; alanine aminotransferase (ALT): &gt;3 x ULN; G-Glutamyl transferase (GGT): &gt;2 x ULN; Bilirubin: &gt;2 x ULN; blood urea nitrogen (BUN): &gt;2 x BL; creatinine: &gt;4 x BL</description>
        <time_frame>From Day 366 through end of OL (range from 1.9 months to 42.3 months)</time_frame>
        <population>All Treated Population, all participants who entered the open-label period and received at least one dose of abatacept at any time during this period.</population>
        <group_list>
          <group group_id="O1">
            <title>ABA + MTX [OL]</title>
            <description>All participants received ABA at a weight-tiered dose of 10 mg/kg plus a stable dose of MTX (minimum 15 mg weekly).</description>
          </group>
        </group_list>
        <measure>
          <title>OL; Number of Participants With Select Blood Chemistry Laboratory Abnormalities</title>
          <description>Low=lower than LLN, High=greater than ULN. LLN/ULN= Alkaline phosphatase (ALP): &gt;2 x ULN; aspartate aminotransferase (AST): &gt;3 x ULN; alanine aminotransferase (ALT): &gt;3 x ULN; G-Glutamyl transferase (GGT): &gt;2 x ULN; Bilirubin: &gt;2 x ULN; blood urea nitrogen (BUN): &gt;2 x BL; creatinine: &gt;4 x BL</description>
          <population>All Treated Population, all participants who entered the open-label period and received at least one dose of abatacept at any time during this period.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="371"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>High ALP (&gt;2 x ULN)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High AST (&gt;3 x ULN)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High ALT (&gt;3 x ULN)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High GGT (&gt;2 x ULN)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High total bilirubin (&gt;2 x ULN)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High BUN (&gt;2 x BL)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High creatinine (&gt;1.5 increase from BL)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>DB; Number of Participants With AEs of Special Interest From Day 1 Through Day 365</title>
        <description>AE=any new untoward medical occurrence or worsening of a pre-existing medical condition which does not necessarily have a causal relationship with this treatment. AEs of special interest are those AEs that may be associated with the use of immunomodulatory drugs, including all infections, serious infections, autoimmune disorders; malignancies; and acute infusional AEs (pre-specified AEs occurring within 1 hour of start of infusion).</description>
        <time_frame>From Baseline (Day 1) through Day 365, and up to 56 days after last dose if occurring on-study</time_frame>
        <population>The As-Treated analysis population contained all participants who received at least one dose of double-blind study medication, and participants were grouped on an as-assigned or randomized basis unless the participant received the incorrect medication for the entire period of treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>ABA + MTX [DB]</title>
            <description>Abatacept was administered intravenously (IV) on Days 1, 15, 29 and every 28 days thereafter for a total of 14 doses. Administration was as follows: 500 mg for participants &lt; 60 kg, 750 mg for participants 60 to 100 kg and 1 gram for participants &gt; 100 kg. All participants received a stable dose of MTX (minimum 15 mg weekly).</description>
          </group>
          <group group_id="O2">
            <title>INF + MTX [DB]</title>
            <description>Infliximab was given 3 mg/kg IV (approved labeled dose) on Days 1, 15, 43, 85 and every 56 days thereafter for a total of 8 doses. All participants received a stable dose of MTX (minimum 15 mg weekly)</description>
          </group>
        </group_list>
        <measure>
          <title>DB; Number of Participants With AEs of Special Interest From Day 1 Through Day 365</title>
          <description>AE=any new untoward medical occurrence or worsening of a pre-existing medical condition which does not necessarily have a causal relationship with this treatment. AEs of special interest are those AEs that may be associated with the use of immunomodulatory drugs, including all infections, serious infections, autoimmune disorders; malignancies; and acute infusional AEs (pre-specified AEs occurring within 1 hour of start of infusion).</description>
          <population>The As-Treated analysis population contained all participants who received at least one dose of double-blind study medication, and participants were grouped on an as-assigned or randomized basis unless the participant received the incorrect medication for the entire period of treatment.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="156"/>
                <count group_id="O2" value="165"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pre-specified infections</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Neoplasms:Benign, malignant, and unspecified</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Prespecified autoimmune symptoms and disorders</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pre-specified infusional AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>DB; Number of Participants With AEs of Special Interest From Day 198 Through Day 365 in Participants Receiving Placebo Switched to Abatacept</title>
        <description>AE=any new untoward medical occurrence or worsening of a pre-existing medical condition which does not necessarily have a causal relationship with this treatment. AEs of special interest are those AEs that may be associated with the use of immunomodulatory drugs, including all infections, serious infections, autoimmune disorders; malignancies; and acute infusional AEs (pre-specified AEs occurring within 1 hour of start of infusion).</description>
        <time_frame>From Day 198 through Day 365, and up to 56 days after last dose if occurring on-study</time_frame>
        <population>The As-Treated analysis population contained all participants who received at least one dose of double-blind study medication, and participants were grouped on an as-assigned or randomized basis unless the participant received the incorrect medication for the entire period of treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>PLA Switched to ABA + MTX [DB]</title>
            <description>Normal saline was administered as placebo. All participants received a stable dose of MTX (minimum 15 mg weekly). After placebo treatment from Day 1-197, participants were reallocated to receive abatacept (weight based) plus a stable dose of MTX (minimum 15 mg weekly).</description>
          </group>
        </group_list>
        <measure>
          <title>DB; Number of Participants With AEs of Special Interest From Day 198 Through Day 365 in Participants Receiving Placebo Switched to Abatacept</title>
          <description>AE=any new untoward medical occurrence or worsening of a pre-existing medical condition which does not necessarily have a causal relationship with this treatment. AEs of special interest are those AEs that may be associated with the use of immunomodulatory drugs, including all infections, serious infections, autoimmune disorders; malignancies; and acute infusional AEs (pre-specified AEs occurring within 1 hour of start of infusion).</description>
          <population>The As-Treated analysis population contained all participants who received at least one dose of double-blind study medication, and participants were grouped on an as-assigned or randomized basis unless the participant received the incorrect medication for the entire period of treatment.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="110"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pre-specified infections</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Prespecified autoimmune symptoms and disorders</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pre-specified infusional AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>DB; Number of Participants With Significant Changes in Mean Systolic and Diastolic Blood Pressure During Days 1 Through 197 and Days 1 Through 365</title>
        <description>Seated Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) were assessed as clinically significant or relevant at the discretion of the Clinical Investigator. Criteria may have varied between institutions.</description>
        <time_frame>From Baseline (Day 1) through Day 197, or Day 1 through Day 365, and up to 56 days after last dose if occurring on-study</time_frame>
        <population>As-Treated Population</population>
        <group_list>
          <group group_id="O1">
            <title>ABA + MTX [DB]</title>
            <description>Abatacept was administered intravenously (IV) on Days 1, 15, 29 and every 28 days thereafter for a total of 14 doses. Administration was as follows: 500 mg for participants &lt; 60 kg, 750 mg for participants 60 to 100 kg and 1 gram for participants &gt; 100 kg. All participants received a stable dose of MTX (minimum 15 mg weekly).</description>
          </group>
          <group group_id="O2">
            <title>INF + MTX [DB]</title>
            <description>Infliximab was given 3 mg/kg IV (approved labeled dose) on Days 1, 15, 43, 85 and every 56 days thereafter for a total of 8 doses. All participants received a stable dose of MTX (minimum 15 mg weekly)</description>
          </group>
          <group group_id="O3">
            <title>PLA + MTX [DB]</title>
            <description>Normal saline was administered as placebo. All participants received a stable dose of MTX (minimum 15 mg weekly)</description>
          </group>
        </group_list>
        <measure>
          <title>DB; Number of Participants With Significant Changes in Mean Systolic and Diastolic Blood Pressure During Days 1 Through 197 and Days 1 Through 365</title>
          <description>Seated Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) were assessed as clinically significant or relevant at the discretion of the Clinical Investigator. Criteria may have varied between institutions.</description>
          <population>As-Treated Population</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="156"/>
                <count group_id="O2" value="165"/>
                <count group_id="O3" value="110"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Days 1-197</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Days 1-365</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>DB; Number of Participants With Significant Changes in Mean Heart Rate During Days 1 Through 197 and Days 1 Through 365</title>
        <description>Heart Rate (HR) was assessed as clinically significant or relevant at the discretion of the Clinical Investigator. Criteria may have varied between institutions.</description>
        <time_frame>From Baseline (Day 1) through Day 197, or Day 1 through Day 365, and up to 56 days after last dose if occurring on-study</time_frame>
        <population>As Treated Population.</population>
        <group_list>
          <group group_id="O1">
            <title>ABA + MTX [DB]</title>
            <description>Abatacept was administered intravenously (IV) on Days 1, 15, 29 and every 28 days thereafter for a total of 14 doses. Administration was as follows: 500 mg for participants &lt; 60 kg, 750 mg for participants 60 to 100 kg and 1 gram for participants &gt; 100 kg. All participants received a stable dose of MTX (minimum 15 mg weekly).</description>
          </group>
          <group group_id="O2">
            <title>INF + MTX [DB]</title>
            <description>Infliximab was given 3 mg/kg IV (approved labeled dose) on Days 1, 15, 43, 85 and every 56 days thereafter for a total of 8 doses. All participants received a stable dose of MTX (minimum 15 mg weekly)</description>
          </group>
          <group group_id="O3">
            <title>PLA + MTX [DB]</title>
            <description>Normal saline was administered as placebo. All participants received a stable dose of MTX (minimum 15 mg weekly)</description>
          </group>
        </group_list>
        <measure>
          <title>DB; Number of Participants With Significant Changes in Mean Heart Rate During Days 1 Through 197 and Days 1 Through 365</title>
          <description>Heart Rate (HR) was assessed as clinically significant or relevant at the discretion of the Clinical Investigator. Criteria may have varied between institutions.</description>
          <population>As Treated Population.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="156"/>
                <count group_id="O2" value="165"/>
                <count group_id="O3" value="110"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Days 1-197</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Days 1-365</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>DB; Number of Participants With Significant Changes in Mean Temperature During Days 1 Through 197 and Days 1 Through 365</title>
        <description>Temperature (T) was assessed as clinically significant or relevant at the discretion of the Clinical Investigator. Criteria may have varied between institutions.</description>
        <time_frame>From Baseline (Day 1) through Day 197, and up to 56 days after last dose if occurring on-study</time_frame>
        <population>As Treated Population.</population>
        <group_list>
          <group group_id="O1">
            <title>ABA + MTX [DB]</title>
            <description>Abatacept was administered intravenously (IV) on Days 1, 15, 29 and every 28 days thereafter for a total of 14 doses. Administration was as follows: 500 mg for participants &lt; 60 kg, 750 mg for participants 60 to 100 kg and 1 gram for participants &gt; 100 kg. All participants received a stable dose of MTX (minimum 15 mg weekly).</description>
          </group>
          <group group_id="O2">
            <title>INF + MTX [DB]</title>
            <description>Infliximab was given 3 mg/kg IV (approved labeled dose) on Days 1, 15, 43, 85 and every 56 days thereafter for a total of 8 doses. All participants received a stable dose of MTX (minimum 15 mg weekly)</description>
          </group>
          <group group_id="O3">
            <title>PLA + MTX [DB]</title>
            <description>Normal saline was administered as placebo. All participants received a stable dose of MTX (minimum 15 mg weekly)</description>
          </group>
        </group_list>
        <measure>
          <title>DB; Number of Participants With Significant Changes in Mean Temperature During Days 1 Through 197 and Days 1 Through 365</title>
          <description>Temperature (T) was assessed as clinically significant or relevant at the discretion of the Clinical Investigator. Criteria may have varied between institutions.</description>
          <population>As Treated Population.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="156"/>
                <count group_id="O2" value="165"/>
                <count group_id="O3" value="110"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Days 1-197</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Days 1-365</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>DB; Number of Participants With Select Hematologic and Blood Chemistry Laboratory Abnormalities on Days 1 Through 197</title>
        <description>High=greater than Upper Normal Limit (ULN), Low=lower than Lower Normal Limit (LLN). LLN/ULN= Hemoglobin (HGB): &gt;3 g/dL decrease from Baseline (BL); Hematocrit: &lt;0.75 x BL; Platelets (PLT): &lt;0.67 x LLN/&gt;1.5 x ULN; Leukocytes: &lt;0.75 x LLN/ &gt;1.25 x ULN; neutrophils+bands: &lt;1.0 x 10^3 c/uL; aspartate aminotransferase (AST): &gt;3 x ULN; alanine aminotransferase (ALT): &gt;3 x ULN; creatinine: &gt;4 x BL</description>
        <time_frame>From Baseline (Day 1) through Day 197, and up to 56 days after last dose if occurring on-study</time_frame>
        <population>The As-Treated analysis population contained all participants who received at least one dose of double-blind study medication, and participants were grouped on an as-assigned or randomized basis unless the participant received the incorrect medication for the entire period of treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>ABA + MTX [DB]</title>
            <description>Abatacept was administered intravenously (IV) on Days 1, 15, 29 and every 28 days thereafter for a total of 14 doses. Administration was as follows: 500 mg for participants &lt; 60 kg, 750 mg for participants 60 to 100 kg and 1 gram for participants &gt; 100 kg. All participants received a stable dose of MTX (minimum 15 mg weekly).</description>
          </group>
          <group group_id="O2">
            <title>INF + MTX [DB]</title>
            <description>Infliximab was given 3 mg/kg IV (approved labeled dose) on Days 1, 15, 43, 85 and every 56 days thereafter for a total of 8 doses. All participants received a stable dose of MTX (minimum 15 mg weekly)</description>
          </group>
          <group group_id="O3">
            <title>PLA + MTX [DB]</title>
            <description>Normal saline was administered as placebo. All participants received a stable dose of MTX (minimum 15 mg weekly)</description>
          </group>
        </group_list>
        <measure>
          <title>DB; Number of Participants With Select Hematologic and Blood Chemistry Laboratory Abnormalities on Days 1 Through 197</title>
          <description>High=greater than Upper Normal Limit (ULN), Low=lower than Lower Normal Limit (LLN). LLN/ULN= Hemoglobin (HGB): &gt;3 g/dL decrease from Baseline (BL); Hematocrit: &lt;0.75 x BL; Platelets (PLT): &lt;0.67 x LLN/&gt;1.5 x ULN; Leukocytes: &lt;0.75 x LLN/ &gt;1.25 x ULN; neutrophils+bands: &lt;1.0 x 10^3 c/uL; aspartate aminotransferase (AST): &gt;3 x ULN; alanine aminotransferase (ALT): &gt;3 x ULN; creatinine: &gt;4 x BL</description>
          <population>The As-Treated analysis population contained all participants who received at least one dose of double-blind study medication, and participants were grouped on an as-assigned or randomized basis unless the participant received the incorrect medication for the entire period of treatment.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="155"/>
                <count group_id="O2" value="162"/>
                <count group_id="O3" value="108"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Low HGB (n=155, n=162, n=108)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Low hematocrit (n=155, n=162, n=108)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Low PLT (n=154, n=160, n=108)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High PLT (n=154, n=160, n=108)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Low leukocytes (n=155, n=162, n=108)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High leukocytes (n=155, n=162, n=108)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="12"/>
                    <measurement group_id="O3" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Low neutrophils + bands (n=155, n=162, n=108)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High AST (n=155, n=162, n=108)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High ALT (n=155, n=162, n=108)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High creatinine (n=155, n=162, n=108)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>DB; Number of Participants With Select Hematologic and Blood Chemistry Laboratory Abnormalities on Days 1 Through 365</title>
        <description>High=greater than Upper Normal Limit (ULN), Low=lower than Lower Normal Limit (LLN). LLN/ULN= Hemoglobin (HGB): &gt;3 g/dL decrease from Baseline (BL); Hematocrit: &lt;0.75 x BL; Platelets (PLT): &lt;0.67 x LLN/&gt;1.5 x ULN; Leukocytes: &lt;0.75 x LLN/ &gt;1.25 x ULN; neutrophils+bands: &lt;1.0 x 10^3 c/uL; aspartate aminotransferase (AST): &gt;3 x ULN; alanine aminotransferase (ALT): &gt;3 x ULN; creatinine: &gt;4 x BL</description>
        <time_frame>From Baseline (Day 1) through Day 365, and up to 56 days after last dose if occurring on-study</time_frame>
        <population>The As-Treated analysis population contained all participants who received at least one dose of double-blind study medication, and participants were grouped on an as-assigned or randomized basis unless the participant received the incorrect medication for the entire period of treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>ABA + MTX [DB]</title>
            <description>Abatacept was administered intravenously (IV) on Days 1, 15, 29 and every 28 days thereafter for a total of 14 doses. Administration was as follows: 500 mg for participants &lt; 60 kg, 750 mg for participants 60 to 100 kg and 1 gram for participants &gt; 100 kg. All participants received a stable dose of MTX (minimum 15 mg weekly).</description>
          </group>
          <group group_id="O2">
            <title>INF + MTX [DB]</title>
            <description>Infliximab was given 3 mg/kg IV (approved labeled dose) on Days 1, 15, 43, 85 and every 56 days thereafter for a total of 8 doses. All participants received a stable dose of MTX (minimum 15 mg weekly)</description>
          </group>
          <group group_id="O3">
            <title>PLA Switched to ABA + MTX [DB]</title>
            <description>Normal saline was administered as placebo. All participants received a stable dose of MTX (minimum 15 mg weekly). After placebo treatment from Day 1-197, participants were reallocated to receive abatacept (weight based) plus a stable dose of MTX (minimum 15 mg weekly).</description>
          </group>
        </group_list>
        <measure>
          <title>DB; Number of Participants With Select Hematologic and Blood Chemistry Laboratory Abnormalities on Days 1 Through 365</title>
          <description>High=greater than Upper Normal Limit (ULN), Low=lower than Lower Normal Limit (LLN). LLN/ULN= Hemoglobin (HGB): &gt;3 g/dL decrease from Baseline (BL); Hematocrit: &lt;0.75 x BL; Platelets (PLT): &lt;0.67 x LLN/&gt;1.5 x ULN; Leukocytes: &lt;0.75 x LLN/ &gt;1.25 x ULN; neutrophils+bands: &lt;1.0 x 10^3 c/uL; aspartate aminotransferase (AST): &gt;3 x ULN; alanine aminotransferase (ALT): &gt;3 x ULN; creatinine: &gt;4 x BL</description>
          <population>The As-Treated analysis population contained all participants who received at least one dose of double-blind study medication, and participants were grouped on an as-assigned or randomized basis unless the participant received the incorrect medication for the entire period of treatment.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="156"/>
                <count group_id="O2" value="164"/>
                <count group_id="O3" value="109"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Low HGB (n=156, n=164, n=109)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Low hematocrit (n=156, n=164, n=109)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Low PLT (n=155, n=162, n=109)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High PLT (n=155, n=162, n=109)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Low leukocytes (n=156, n=164, n=109)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High leukocytes (n=156, n=164, n=109)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="22"/>
                    <measurement group_id="O3" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Low neutrophils + bands (n=156, n=164, n=109)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High AST (n=156, n=164, n=109)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High ALT (n=156, n=164, n=109)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High creatinine (n=156, n=164, n=109)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="13"/>
                    <measurement group_id="O3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>DB; Number of Participants With Anti-Abatacept Antibodies From Day 1 Through Day 365 (Electrochemiluminescent [ECL] Immunoassay)</title>
        <description>ECL screened sera for drug-specific antibodies, immunocompetition was used to identify specific anti-Abatacept reactivity. Cytotoxic leukocyte antigen 4 (CTLA4) and Possibly Immunoglobulin (Ig) Category=reactivity against extracellular domain of human CTLA4, constant regions of human IgG1, or both (CTLA4Ig; Abatacept molecule). Ig and/or Junction Category=reactivity against constant regions and/or hinge region of human IgG1. Drug-induced seropositivity was defined as a post-baseline titer higher than Baseline, or any post-baseline positivity if Baseline value was missing.</description>
        <time_frame>Day 1 through day 365</time_frame>
        <population>The immunogenicity analysis population included participants who received at least one dose of abatacept and had immunogenicity samples collected at baseline and at least one post-baseline treatment visit.</population>
        <group_list>
          <group group_id="O1">
            <title>ABA + MTX [DB]</title>
            <description>Abatacept was administered intravenously (IV) on Days 1, 15, 29 and every 28 days thereafter for a total of 14 doses. Administration was as follows: 500 mg for participants &lt; 60 kg, 750 mg for participants 60 to 100 kg and 1 gram for participants &gt; 100 kg. All participants received a stable dose of MTX (minimum 15 mg weekly).</description>
          </group>
          <group group_id="O2">
            <title>PLA Switched to ABA + MTX [DB]</title>
            <description>Normal saline was administered as placebo. All participants received a stable dose of MTX (minimum 15 mg weekly). After placebo treatment from Day 1-197, participants were reallocated to receive abatacept (weight based) plus a stable dose of MTX (minimum 15 mg weekly).</description>
          </group>
        </group_list>
        <measure>
          <title>DB; Number of Participants With Anti-Abatacept Antibodies From Day 1 Through Day 365 (Electrochemiluminescent [ECL] Immunoassay)</title>
          <description>ECL screened sera for drug-specific antibodies, immunocompetition was used to identify specific anti-Abatacept reactivity. Cytotoxic leukocyte antigen 4 (CTLA4) and Possibly Immunoglobulin (Ig) Category=reactivity against extracellular domain of human CTLA4, constant regions of human IgG1, or both (CTLA4Ig; Abatacept molecule). Ig and/or Junction Category=reactivity against constant regions and/or hinge region of human IgG1. Drug-induced seropositivity was defined as a post-baseline titer higher than Baseline, or any post-baseline positivity if Baseline value was missing.</description>
          <population>The immunogenicity analysis population included participants who received at least one dose of abatacept and had immunogenicity samples collected at baseline and at least one post-baseline treatment visit.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="156"/>
                <count group_id="O2" value="110"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>CTLA4 and Possibly Ig</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ig and/or Junction</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>DB; Percentage of Participants With Antibodies Against Infliximab (Human Anti-chimeric Antibody [HACA]) From Day 1 Through Day 365</title>
        <description>Infliximab levels were measured using a microplate enzyme-linked immunosorbant assay (ELISA) with infliximab bound to immobilized recombinant tumor necrosis factor (TNF)-alpha. Bound infliximab is detected utilizing a horseradish peroxidase-conjugated anti-human IgG Fc(fragment, crystallizable region)-specific). The enzyme turns over the substrate O-phenlenediamine to a chromogenic product that is measured at 490 nm. The cut-off value was 1.40 ug/mL; this was based on the mean (+ 3 SD) value in serum samples from 40 participants who had never received infliximab.</description>
        <time_frame>Day 1 through day 365</time_frame>
        <population>The immunogenicity analysis population included participants who received at least one dose of infliximab and had immunogenicity samples collected at baseline and at least one post-baseline treatment visit.</population>
        <group_list>
          <group group_id="O1">
            <title>INF + MTX [DB]</title>
            <description>Infliximab was given 3 mg/kg IV (approved labeled dose) on Days 1, 15, 43, 85 and every 56 days thereafter for a total of 8 doses. All participants received a stable dose of MTX (minimum 15 mg weekly)</description>
          </group>
        </group_list>
        <measure>
          <title>DB; Percentage of Participants With Antibodies Against Infliximab (Human Anti-chimeric Antibody [HACA]) From Day 1 Through Day 365</title>
          <description>Infliximab levels were measured using a microplate enzyme-linked immunosorbant assay (ELISA) with infliximab bound to immobilized recombinant tumor necrosis factor (TNF)-alpha. Bound infliximab is detected utilizing a horseradish peroxidase-conjugated anti-human IgG Fc(fragment, crystallizable region)-specific). The enzyme turns over the substrate O-phenlenediamine to a chromogenic product that is measured at 490 nm. The cut-off value was 1.40 ug/mL; this was based on the mean (+ 3 SD) value in serum samples from 40 participants who had never received infliximab.</description>
          <population>The immunogenicity analysis population included participants who received at least one dose of infliximab and had immunogenicity samples collected at baseline and at least one post-baseline treatment visit.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="163"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Overall anti-HACA</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Overall indeterminate anti-HACA</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1 anti-HACA</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1 indeterminate anti-HACA</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 113 anti-HACA</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 113 indeterminate anti-HACA</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 197 anti-HACA</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 197 indeterminate anti-HACA</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 309 anti-HACA</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 309 indeterminate anti-HACA</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post Day 28 anti-HACA</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post Day 28 indeterminate anti-HACA</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Discontinued, overall anti-HACA</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Discontinued, overall indeterminate anti-HACA</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Discontinued, post day 28 anti-HACA</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Discontinued, post day 28 indeterminate anti-HACA</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Discontinued, post day 56 anti-HACA</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Discontinued, post day 56 indeterminate anti-HACA</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Discontinued, post day 85 anti-HACA</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="88.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Discontinued, post day 85 indeterminate anti-HACA</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Missed doses, overall anti-HACA</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Missed doses, overall indeterminate anti-HACA</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Missed 1 dose, anti-HACA</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Missed 1 dose, indeterminate anti-HACA</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Missed &gt;1 dose, anti-HACA</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Missed &gt;1 dose, indeterminate anti-HACA</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>OL; Mean Change From Baseline to Day 365 in Hemoglobin, Total Protein, and Albumin</title>
        <description>Hemoglobin (HGB): &gt;3 g/dL decrease from BL; total protein: &lt; 0.9 x LLN, &gt;1.1 x ULN; albumin:&lt;0.9 x LLN</description>
        <time_frame>Baseline (Day 1), Day 365</time_frame>
        <population>Number of Participants Analyzed=All Treated Population, all participants who entered the open-label period and received at least one dose of abatacept at any time during this period. Treatment groups represent treatment received in the DB period. n=number of participants with data available.</population>
        <group_list>
          <group group_id="O1">
            <title>ABA + MTX [DB]</title>
            <description>Abatacept was administered intravenously (IV) on Days 1, 15, 29 and every 28 days thereafter for a total of 14 doses. Administration was as follows: 500 mg for participants &lt; 60 kg, 750 mg for participants 60 to 100 kg and 1 gram for participants &gt; 100 kg. All participants received a stable dose of MTX (minimum 15 mg weekly).</description>
          </group>
          <group group_id="O2">
            <title>INF + MTX [DB]</title>
            <description>Infliximab was given 3 mg/kg IV (approved labeled dose) on Days 1, 15, 43, 85 and every 56 days thereafter for a total of 8 doses. All participants received a stable dose of MTX (minimum 15 mg weekly)</description>
          </group>
          <group group_id="O3">
            <title>PLA + MTX [DB]</title>
            <description>Normal saline was administered as placebo. All participants received a stable dose of MTX (minimum 15 mg weekly)</description>
          </group>
        </group_list>
        <measure>
          <title>OL; Mean Change From Baseline to Day 365 in Hemoglobin, Total Protein, and Albumin</title>
          <description>Hemoglobin (HGB): &gt;3 g/dL decrease from BL; total protein: &lt; 0.9 x LLN, &gt;1.1 x ULN; albumin:&lt;0.9 x LLN</description>
          <population>Number of Participants Analyzed=All Treated Population, all participants who entered the open-label period and received at least one dose of abatacept at any time during this period. Treatment groups represent treatment received in the DB period. n=number of participants with data available.</population>
          <units>g/dL</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="131"/>
                <count group_id="O2" value="136"/>
                <count group_id="O3" value="104"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>HGB (n=131, n=135, n=103)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.53" spread="0.09"/>
                    <measurement group_id="O2" value="0.24" spread="0.09"/>
                    <measurement group_id="O3" value="0.43" spread="0.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total protein (n=131, n=136, n=104)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.09" spread="0.04"/>
                    <measurement group_id="O2" value="0.11" spread="0.04"/>
                    <measurement group_id="O3" value="-0.12" spread="0.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Albumin (n=131, n=136, n=104)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.12" spread="0.03"/>
                    <measurement group_id="O2" value="0.00" spread="0.03"/>
                    <measurement group_id="O3" value="0.05" spread="0.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>OL; Mean Change From Baseline to Day 365 in Platelets</title>
        <description>Platelets (PLT): &lt;0.67 x LLN, &gt;1.5 x ULN</description>
        <time_frame>Baseline (Day 1), Day 365</time_frame>
        <population>Number of Participants Analyzed=All Treated Population, all participants who entered the open-label period and received at least one dose of abatacept at any time during this period. Treatment groups represent treatment received in the DB period. n=number of participants with data available.</population>
        <group_list>
          <group group_id="O1">
            <title>ABA + MTX [DB]</title>
            <description>Abatacept was administered intravenously (IV) on Days 1, 15, 29 and every 28 days thereafter for a total of 14 doses. Administration was as follows: 500 mg for participants &lt; 60 kg, 750 mg for participants 60 to 100 kg and 1 gram for participants &gt; 100 kg. All participants received a stable dose of MTX (minimum 15 mg weekly).</description>
          </group>
          <group group_id="O2">
            <title>INF + MTX [DB]</title>
            <description>Infliximab was given 3 mg/kg IV (approved labeled dose) on Days 1, 15, 43, 85 and every 56 days thereafter for a total of 8 doses. All participants received a stable dose of MTX (minimum 15 mg weekly)</description>
          </group>
          <group group_id="O3">
            <title>PLA + MTX [DB]</title>
            <description>Normal saline was administered as placebo. All participants received a stable dose of MTX (minimum 15 mg weekly)</description>
          </group>
        </group_list>
        <measure>
          <title>OL; Mean Change From Baseline to Day 365 in Platelets</title>
          <description>Platelets (PLT): &lt;0.67 x LLN, &gt;1.5 x ULN</description>
          <population>Number of Participants Analyzed=All Treated Population, all participants who entered the open-label period and received at least one dose of abatacept at any time during this period. Treatment groups represent treatment received in the DB period. n=number of participants with data available.</population>
          <units>10^9 c/L</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="129"/>
                <count group_id="O2" value="129"/>
                <count group_id="O3" value="102"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-42.4" spread="5.20"/>
                    <measurement group_id="O2" value="-35.5" spread="6.93"/>
                    <measurement group_id="O3" value="-28.4" spread="6.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>OL; Mean Change From Baseline to Day 365 in Hematocrit</title>
        <description>Hematocrit: &lt;0.75 x BL</description>
        <time_frame>Baseline (Day 1), Day 365</time_frame>
        <population>Number of Participants Analyzed=All Treated Population, all participants who entered the open-label period and received at least one dose of abatacept at any time during this period. Treatment groups represent treatment received in the DB period. n=number of participants with data available.</population>
        <group_list>
          <group group_id="O1">
            <title>ABA + MTX [DB]</title>
            <description>Abatacept was administered intravenously (IV) on Days 1, 15, 29 and every 28 days thereafter for a total of 14 doses. Administration was as follows: 500 mg for participants &lt; 60 kg, 750 mg for participants 60 to 100 kg and 1 gram for participants &gt; 100 kg. All participants received a stable dose of MTX (minimum 15 mg weekly).</description>
          </group>
          <group group_id="O2">
            <title>INF + MTX [DB]</title>
            <description>Infliximab was given 3 mg/kg IV (approved labeled dose) on Days 1, 15, 43, 85 and every 56 days thereafter for a total of 8 doses. All participants received a stable dose of MTX (minimum 15 mg weekly)</description>
          </group>
          <group group_id="O3">
            <title>PLA + MTX [DB]</title>
            <description>Normal saline was administered as placebo. All participants received a stable dose of MTX (minimum 15 mg weekly)</description>
          </group>
        </group_list>
        <measure>
          <title>OL; Mean Change From Baseline to Day 365 in Hematocrit</title>
          <description>Hematocrit: &lt;0.75 x BL</description>
          <population>Number of Participants Analyzed=All Treated Population, all participants who entered the open-label period and received at least one dose of abatacept at any time during this period. Treatment groups represent treatment received in the DB period. n=number of participants with data available.</population>
          <units>percentage red blood cells</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="129"/>
                <count group_id="O2" value="134"/>
                <count group_id="O3" value="102"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.44" spread="0.29"/>
                    <measurement group_id="O2" value="0.51" spread="0.27"/>
                    <measurement group_id="O3" value="1.03" spread="0.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>OL; Mean Change From Baseline to Day 365 in White Blood Cells</title>
        <description>Leukocytes: &lt;0.75 x LLN, &gt;1.25 x ULN; neutrophils+bands: &lt;1.0 x 10^3 c/uL; eosinophils: &gt;0.750 x 10^3 c/uL; basophils: &gt; 400 mm3; monocytes: &gt;2000 mm3; lymphocytes: &lt;0.750 x 10^3 c/uL, &gt;7.50 x 10^3 c/uL.</description>
        <time_frame>Baseline (Day 1), Day 365</time_frame>
        <population>Number of Participants Analyzed=All Treated Population, all participants who entered the open-label period and received at least one dose of abatacept at any time during this period. Treatment groups represent treatment received in the DB period. n=number of participants with data available.</population>
        <group_list>
          <group group_id="O1">
            <title>ABA + MTX [DB]</title>
            <description>Abatacept was administered intravenously (IV) on Days 1, 15, 29 and every 28 days thereafter for a total of 14 doses. Administration was as follows: 500 mg for participants &lt; 60 kg, 750 mg for participants 60 to 100 kg and 1 gram for participants &gt; 100 kg. All participants received a stable dose of MTX (minimum 15 mg weekly).</description>
          </group>
          <group group_id="O2">
            <title>INF + MTX [DB]</title>
            <description>Infliximab was given 3 mg/kg IV (approved labeled dose) on Days 1, 15, 43, 85 and every 56 days thereafter for a total of 8 doses. All participants received a stable dose of MTX (minimum 15 mg weekly)</description>
          </group>
          <group group_id="O3">
            <title>PLA + MTX [DB]</title>
            <description>Normal saline was administered as placebo. All participants received a stable dose of MTX (minimum 15 mg weekly)</description>
          </group>
        </group_list>
        <measure>
          <title>OL; Mean Change From Baseline to Day 365 in White Blood Cells</title>
          <description>Leukocytes: &lt;0.75 x LLN, &gt;1.25 x ULN; neutrophils+bands: &lt;1.0 x 10^3 c/uL; eosinophils: &gt;0.750 x 10^3 c/uL; basophils: &gt; 400 mm3; monocytes: &gt;2000 mm3; lymphocytes: &lt;0.750 x 10^3 c/uL, &gt;7.50 x 10^3 c/uL.</description>
          <population>Number of Participants Analyzed=All Treated Population, all participants who entered the open-label period and received at least one dose of abatacept at any time during this period. Treatment groups represent treatment received in the DB period. n=number of participants with data available.</population>
          <units>10^3 c/uL</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="131"/>
                <count group_id="O2" value="134"/>
                <count group_id="O3" value="104"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Leukocytes (n=131, n=134, n=103)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.95" spread="0.23"/>
                    <measurement group_id="O2" value="-0.90" spread="0.21"/>
                    <measurement group_id="O3" value="-0.84" spread="0.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Neutrophils + bands (n=130, n=130, n=104)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.91" spread="0.20"/>
                    <measurement group_id="O2" value="-1.14" spread="0.20"/>
                    <measurement group_id="O3" value="-1.05" spread="0.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Basophils (n=130, n=130, n=101)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.01" spread="0.00"/>
                    <measurement group_id="O2" value="0.00" spread="0.00"/>
                    <measurement group_id="O3" value="0.00" spread="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Monocytes (n=130, n=130, n=101)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.01" spread="0.02"/>
                    <measurement group_id="O2" value="-0.01" spread="0.02"/>
                    <measurement group_id="O3" value="0.02" spread="0.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Eosinophils (n=130, n=130, n=101)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.04" spread="0.01"/>
                    <measurement group_id="O2" value="-0.02" spread="0.02"/>
                    <measurement group_id="O3" value="-0.03" spread="0.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lymphocytes (n=130, n=130, n=101)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.03" spread="0.07"/>
                    <measurement group_id="O2" value="0.24" spread="0.06"/>
                    <measurement group_id="O3" value="0.22" spread="0.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>OL; Mean Change From Baseline to Day 365 in Erythrocytes</title>
        <description>Erythrocytes: &lt;0.75 x BL</description>
        <time_frame>Baseline (Day 1), Day 365</time_frame>
        <population>Number of Participants Analyzed=All Treated Population, all participants who entered the open-label period and received at least one dose of abatacept at any time during this period. Treatment groups represent treatment received in the DB period. n=number of participants with data available.</population>
        <group_list>
          <group group_id="O1">
            <title>ABA + MTX [DB]</title>
            <description>Abatacept was administered intravenously (IV) on Days 1, 15, 29 and every 28 days thereafter for a total of 14 doses. Administration was as follows: 500 mg for participants &lt; 60 kg, 750 mg for participants 60 to 100 kg and 1 gram for participants &gt; 100 kg. All participants received a stable dose of MTX (minimum 15 mg weekly).</description>
          </group>
          <group group_id="O2">
            <title>INF + MTX [DB]</title>
            <description>Infliximab was given 3 mg/kg IV (approved labeled dose) on Days 1, 15, 43, 85 and every 56 days thereafter for a total of 8 doses. All participants received a stable dose of MTX (minimum 15 mg weekly)</description>
          </group>
          <group group_id="O3">
            <title>PLA + MTX [DB]</title>
            <description>Normal saline was administered as placebo. All participants received a stable dose of MTX (minimum 15 mg weekly)</description>
          </group>
        </group_list>
        <measure>
          <title>OL; Mean Change From Baseline to Day 365 in Erythrocytes</title>
          <description>Erythrocytes: &lt;0.75 x BL</description>
          <population>Number of Participants Analyzed=All Treated Population, all participants who entered the open-label period and received at least one dose of abatacept at any time during this period. Treatment groups represent treatment received in the DB period. n=number of participants with data available.</population>
          <units>10^6 c/uL</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="131"/>
                <count group_id="O2" value="135"/>
                <count group_id="O3" value="103"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.09" spread="0.03"/>
                    <measurement group_id="O2" value="0.00" spread="0.03"/>
                    <measurement group_id="O3" value="0.006" spread="0.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>OL; Mean Change From Baseline to Day 365 in Electrolytes</title>
        <description>Sodium (Na): &lt;0.95 x LLN, &gt;1.05 x ULN; potassium (K): &lt;0.9 x LLN, &gt;1.1 x ULN; chloride (Cl): &lt;0.9 x LLN, &gt;1.1 x ULN</description>
        <time_frame>Baseline (Day 1), Day 365</time_frame>
        <population>Number of Participants Analyzed=All Treated Population, all participants who entered the open-label period and received at least one dose of abatacept at any time during this period. Treatment groups represent treatment received in the DB period. n=number of participants with data available.</population>
        <group_list>
          <group group_id="O1">
            <title>ABA + MTX [DB]</title>
            <description>Abatacept was administered intravenously (IV) on Days 1, 15, 29 and every 28 days thereafter for a total of 14 doses. Administration was as follows: 500 mg for participants &lt; 60 kg, 750 mg for participants 60 to 100 kg and 1 gram for participants &gt; 100 kg. All participants received a stable dose of MTX (minimum 15 mg weekly).</description>
          </group>
          <group group_id="O2">
            <title>INF + MTX [DB]</title>
            <description>Infliximab was given 3 mg/kg IV (approved labeled dose) on Days 1, 15, 43, 85 and every 56 days thereafter for a total of 8 doses. All participants received a stable dose of MTX (minimum 15 mg weekly)</description>
          </group>
          <group group_id="O3">
            <title>PLA + MTX [DB]</title>
            <description>Normal saline was administered as placebo. All participants received a stable dose of MTX (minimum 15 mg weekly)</description>
          </group>
        </group_list>
        <measure>
          <title>OL; Mean Change From Baseline to Day 365 in Electrolytes</title>
          <description>Sodium (Na): &lt;0.95 x LLN, &gt;1.05 x ULN; potassium (K): &lt;0.9 x LLN, &gt;1.1 x ULN; chloride (Cl): &lt;0.9 x LLN, &gt;1.1 x ULN</description>
          <population>Number of Participants Analyzed=All Treated Population, all participants who entered the open-label period and received at least one dose of abatacept at any time during this period. Treatment groups represent treatment received in the DB period. n=number of participants with data available.</population>
          <units>mEq/L</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="131"/>
                <count group_id="O2" value="136"/>
                <count group_id="O3" value="104"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Na (n=131, n=136, n=104)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.62" spread="0.29"/>
                    <measurement group_id="O2" value="-1.57" spread="0.33"/>
                    <measurement group_id="O3" value="-1.09" spread="0.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>K (n=131, n=135, n=104)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.03" spread="0.04"/>
                    <measurement group_id="O2" value="-0.07" spread="0.04"/>
                    <measurement group_id="O3" value="-0.03" spread="0.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cl (n=131, n=136, n=104)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.40" spread="0.28"/>
                    <measurement group_id="O2" value="-1.18" spread="0.31"/>
                    <measurement group_id="O3" value="-1.06" spread="0.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>OL; Mean Change From Baseline to Day 365 in Bilirubin, Blood Urea Nitrogen, Creatinine, Calcium, Phosphorous, Serum Glucose, Fasting Serum Glucose, and Uric Acid</title>
        <description>Bilirubin: &gt;2 x ULN; blood urea nitrogen (BUN): &gt;2 x BL; creatinine: &gt;4 x BL; calcium (Ca): &lt;0.8 x LLN, &gt;1.2 x ULN; phosphorous (P): &lt;0.75 x LLN, &gt;1.2 5 x ULN; serum glucose (Glu): &lt;65 mg/dL, &gt;220 mg/dL; fasting serum Glu: &lt;0.8 x LLN, &gt;1.5 x ULN; uric acid: &gt;1.5 x ULN;</description>
        <time_frame>Baseline (Day 1), Day 365</time_frame>
        <population>Number of Participants Analyzed=All Treated Population, all participants who entered the open-label period and received at least one dose of abatacept at any time during this period. Treatment groups represent treatment received in the DB period. n=number of participants with data available.</population>
        <group_list>
          <group group_id="O1">
            <title>ABA + MTX [DB]</title>
            <description>Abatacept was administered intravenously (IV) on Days 1, 15, 29 and every 28 days thereafter for a total of 14 doses. Administration was as follows: 500 mg for participants &lt; 60 kg, 750 mg for participants 60 to 100 kg and 1 gram for participants &gt; 100 kg. All participants received a stable dose of MTX (minimum 15 mg weekly).</description>
          </group>
          <group group_id="O2">
            <title>INF + MTX [DB]</title>
            <description>Infliximab was given 3 mg/kg IV (approved labeled dose) on Days 1, 15, 43, 85 and every 56 days thereafter for a total of 8 doses. All participants received a stable dose of MTX (minimum 15 mg weekly)</description>
          </group>
          <group group_id="O3">
            <title>PLA + MTX [DB]</title>
            <description>Normal saline was administered as placebo. All participants received a stable dose of MTX (minimum 15 mg weekly)</description>
          </group>
        </group_list>
        <measure>
          <title>OL; Mean Change From Baseline to Day 365 in Bilirubin, Blood Urea Nitrogen, Creatinine, Calcium, Phosphorous, Serum Glucose, Fasting Serum Glucose, and Uric Acid</title>
          <description>Bilirubin: &gt;2 x ULN; blood urea nitrogen (BUN): &gt;2 x BL; creatinine: &gt;4 x BL; calcium (Ca): &lt;0.8 x LLN, &gt;1.2 x ULN; phosphorous (P): &lt;0.75 x LLN, &gt;1.2 5 x ULN; serum glucose (Glu): &lt;65 mg/dL, &gt;220 mg/dL; fasting serum Glu: &lt;0.8 x LLN, &gt;1.5 x ULN; uric acid: &gt;1.5 x ULN;</description>
          <population>Number of Participants Analyzed=All Treated Population, all participants who entered the open-label period and received at least one dose of abatacept at any time during this period. Treatment groups represent treatment received in the DB period. n=number of participants with data available.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="131"/>
                <count group_id="O2" value="136"/>
                <count group_id="O3" value="104"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Creatinine (n=131, n=136, n=104)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.03" spread="0.02"/>
                    <measurement group_id="O2" value="0.02" spread="0.01"/>
                    <measurement group_id="O3" value="0.01" spread="0.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BUN (n=131, n=136, n=104)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.31" spread="0.41"/>
                    <measurement group_id="O2" value="-0.52" spread="0.40"/>
                    <measurement group_id="O3" value="0.10" spread="0.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ca (n=131, n=136, n=104)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.14" spread="0.04"/>
                    <measurement group_id="O2" value="0.08" spread="0.03"/>
                    <measurement group_id="O3" value="0.14" spread="0.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>P (n=131, n=136, n=104)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.03" spread="0.05"/>
                    <measurement group_id="O2" value="-0.01" spread="0.05"/>
                    <measurement group_id="O3" value="0.05" spread="0.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Uric Acid (n=131, n=136, n=104)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.09" spread="0.08"/>
                    <measurement group_id="O2" value="0.08" spread="0.10"/>
                    <measurement group_id="O3" value="0.04" spread="0.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total bilirubin (n=131, n=134, n=104)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.06" spread="0.01"/>
                    <measurement group_id="O2" value="0.04" spread="0.02"/>
                    <measurement group_id="O3" value="0.03" spread="0.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serum glucose (n=131, n=136, n=104)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.66" spread="2.41"/>
                    <measurement group_id="O2" value="2.49" spread="3.15"/>
                    <measurement group_id="O3" value="3.03" spread="2.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>OL; Mean Change From Baseline to Day 365 in Alanine Aminotransferase, Aspartate Aminotransferase, G-Glutamyl Transferase, and Alkaline Phosphatase</title>
        <description>alanine aminotransferase (ALT): &gt;3 x ULN; aspartate aminotransferase (AST): &gt;3 x ULN; G-Glutamyl transferase (GGT): &gt;2 x ULN; Alkaline phosphatase (ALP): &gt;2 x ULN</description>
        <time_frame>Baseline (Day 1), Day 365</time_frame>
        <population>Number of Participants Analyzed=All Treated Population, all participants who entered the open-label period and received at least one dose of abatacept at any time during this period. Treatment groups represent treatment received in the DB period. n=number of participants with data available.</population>
        <group_list>
          <group group_id="O1">
            <title>ABA + MTX [DB]</title>
            <description>Abatacept was administered intravenously (IV) on Days 1, 15, 29 and every 28 days thereafter for a total of 14 doses. Administration was as follows: 500 mg for participants &lt; 60 kg, 750 mg for participants 60 to 100 kg and 1 gram for participants &gt; 100 kg. All participants received a stable dose of MTX (minimum 15 mg weekly).</description>
          </group>
          <group group_id="O2">
            <title>INF + MTX [DB]</title>
            <description>Infliximab was given 3 mg/kg IV (approved labeled dose) on Days 1, 15, 43, 85 and every 56 days thereafter for a total of 8 doses. All participants received a stable dose of MTX (minimum 15 mg weekly)</description>
          </group>
          <group group_id="O3">
            <title>PLA + MTX [DB]</title>
            <description>Normal saline was administered as placebo. All participants received a stable dose of MTX (minimum 15 mg weekly)</description>
          </group>
        </group_list>
        <measure>
          <title>OL; Mean Change From Baseline to Day 365 in Alanine Aminotransferase, Aspartate Aminotransferase, G-Glutamyl Transferase, and Alkaline Phosphatase</title>
          <description>alanine aminotransferase (ALT): &gt;3 x ULN; aspartate aminotransferase (AST): &gt;3 x ULN; G-Glutamyl transferase (GGT): &gt;2 x ULN; Alkaline phosphatase (ALP): &gt;2 x ULN</description>
          <population>Number of Participants Analyzed=All Treated Population, all participants who entered the open-label period and received at least one dose of abatacept at any time during this period. Treatment groups represent treatment received in the DB period. n=number of participants with data available.</population>
          <units>U/L</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="131"/>
                <count group_id="O2" value="136"/>
                <count group_id="O3" value="104"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>ALT (n=131, n=135, n=104)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.51" spread="1.33"/>
                    <measurement group_id="O2" value="2.19" spread="2.31"/>
                    <measurement group_id="O3" value="-0.04" spread="1.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AST (n=131, n=135, n=104)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.54" spread="1.04"/>
                    <measurement group_id="O2" value="-0.11" spread="1.51"/>
                    <measurement group_id="O3" value="-2.23" spread="1.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GGT (n=131, n=135, n=104)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.53" spread="2.81"/>
                    <measurement group_id="O2" value="-0.61" spread="1.76"/>
                    <measurement group_id="O3" value="-2.32" spread="2.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ALP (n=131, n=136, n=104)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.53" spread="2.16"/>
                    <measurement group_id="O2" value="-7.78" spread="2.24"/>
                    <measurement group_id="O3" value="-4.34" spread="2.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>OL; Mean Change From Baseline to Day 729 in Hemoglobin, Total Protein, and Albumin</title>
        <description>Hemoglobin (HGB): &gt;3 g/dL decrease from BL; total protein: &lt; 0.9 x LLN, &gt;1.1 x ULN; albumin:&lt;0.9 x LLN</description>
        <time_frame>Baseline (Day 1), Day 729</time_frame>
        <population>Number of Participants Analyzed=All Treated Population, all participants who entered the open-label period and received at least one dose of abatacept at any time during this period. Treatment groups represent treatment received in the DB period. n=number of participants with data available.</population>
        <group_list>
          <group group_id="O1">
            <title>ABA + MTX [DB]</title>
            <description>Abatacept was administered intravenously (IV) on Days 1, 15, 29 and every 28 days thereafter for a total of 14 doses. Administration was as follows: 500 mg for participants &lt; 60 kg, 750 mg for participants 60 to 100 kg and 1 gram for participants &gt; 100 kg. All participants received a stable dose of MTX (minimum 15 mg weekly).</description>
          </group>
          <group group_id="O2">
            <title>INF + MTX [DB]</title>
            <description>Infliximab was given 3 mg/kg IV (approved labeled dose) on Days 1, 15, 43, 85 and every 56 days thereafter for a total of 8 doses. All participants received a stable dose of MTX (minimum 15 mg weekly)</description>
          </group>
          <group group_id="O3">
            <title>PLA + MTX [DB]</title>
            <description>Normal saline was administered as placebo. All participants received a stable dose of MTX (minimum 15 mg weekly)</description>
          </group>
        </group_list>
        <measure>
          <title>OL; Mean Change From Baseline to Day 729 in Hemoglobin, Total Protein, and Albumin</title>
          <description>Hemoglobin (HGB): &gt;3 g/dL decrease from BL; total protein: &lt; 0.9 x LLN, &gt;1.1 x ULN; albumin:&lt;0.9 x LLN</description>
          <population>Number of Participants Analyzed=All Treated Population, all participants who entered the open-label period and received at least one dose of abatacept at any time during this period. Treatment groups represent treatment received in the DB period. n=number of participants with data available.</population>
          <units>g/dL</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="124"/>
                <count group_id="O2" value="127"/>
                <count group_id="O3" value="102"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>HGB (n=124, n=125, n=102)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.66" spread="0.10"/>
                    <measurement group_id="O2" value="0.48" spread="0.10"/>
                    <measurement group_id="O3" value="0.40" spread="0.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total protein (n=124, n=127, n=102)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.33" spread="0.05"/>
                    <measurement group_id="O2" value="-0.25" spread="0.04"/>
                    <measurement group_id="O3" value="-0.29" spread="0.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Albumin (n=124, n=127, n=102)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.13" spread="0.03"/>
                    <measurement group_id="O2" value="0.10" spread="0.03"/>
                    <measurement group_id="O3" value="0.06" spread="0.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>OL; Mean Change From Baseline to Day 729 in Platelets</title>
        <description>Platelets (PLT): &lt;0.67 x LLN, &gt;1.5 x ULN</description>
        <time_frame>Baseline (Day 1), Day 729</time_frame>
        <population>Number of Participants Analyzed=All Treated Population, all participants who entered the open-label period and received at least one dose of abatacept at any time during this period. Treatment groups represent treatment received in the DB period. n=number of participants with data available.</population>
        <group_list>
          <group group_id="O1">
            <title>ABA + MTX [DB]</title>
            <description>Abatacept was administered intravenously (IV) on Days 1, 15, 29 and every 28 days thereafter for a total of 14 doses. Administration was as follows: 500 mg for participants &lt; 60 kg, 750 mg for participants 60 to 100 kg and 1 gram for participants &gt; 100 kg. All participants received a stable dose of MTX (minimum 15 mg weekly).</description>
          </group>
          <group group_id="O2">
            <title>INF + MTX [DB]</title>
            <description>Infliximab was given 3 mg/kg IV (approved labeled dose) on Days 1, 15, 43, 85 and every 56 days thereafter for a total of 8 doses. All participants received a stable dose of MTX (minimum 15 mg weekly)</description>
          </group>
          <group group_id="O3">
            <title>PLA + MTX [DB]</title>
            <description>Normal saline was administered as placebo. All participants received a stable dose of MTX (minimum 15 mg weekly)</description>
          </group>
        </group_list>
        <measure>
          <title>OL; Mean Change From Baseline to Day 729 in Platelets</title>
          <description>Platelets (PLT): &lt;0.67 x LLN, &gt;1.5 x ULN</description>
          <population>Number of Participants Analyzed=All Treated Population, all participants who entered the open-label period and received at least one dose of abatacept at any time during this period. Treatment groups represent treatment received in the DB period. n=number of participants with data available.</population>
          <units>10^9 c/L</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="124"/>
                <count group_id="O2" value="122"/>
                <count group_id="O3" value="100"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-63.9" spread="6.04"/>
                    <measurement group_id="O2" value="-5832" spread="7.66"/>
                    <measurement group_id="O3" value="-47.7" spread="8.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>OL; Mean Change From Baseline to Day 729 in Hematocrit</title>
        <description>Hematocrit: &lt;0.75 x BL</description>
        <time_frame>Baseline (Day 1), Day 729</time_frame>
        <population>Number of Participants Analyzed=All Treated Population, all participants who entered the open-label period and received at least one dose of abatacept at any time during this period. Treatment groups represent treatment received in the DB period. n=number of participants with data available.</population>
        <group_list>
          <group group_id="O1">
            <title>ABA + MTX [DB]</title>
            <description>Abatacept was administered intravenously (IV) on Days 1, 15, 29 and every 28 days thereafter for a total of 14 doses. Administration was as follows: 500 mg for participants &lt; 60 kg, 750 mg for participants 60 to 100 kg and 1 gram for participants &gt; 100 kg. All participants received a stable dose of MTX (minimum 15 mg weekly).</description>
          </group>
          <group group_id="O2">
            <title>INF + MTX [DB]</title>
            <description>Infliximab was given 3 mg/kg IV (approved labeled dose) on Days 1, 15, 43, 85 and every 56 days thereafter for a total of 8 doses. All participants received a stable dose of MTX (minimum 15 mg weekly)</description>
          </group>
          <group group_id="O3">
            <title>PLA + MTX [DB]</title>
            <description>Normal saline was administered as placebo. All participants received a stable dose of MTX (minimum 15 mg weekly)</description>
          </group>
        </group_list>
        <measure>
          <title>OL; Mean Change From Baseline to Day 729 in Hematocrit</title>
          <description>Hematocrit: &lt;0.75 x BL</description>
          <population>Number of Participants Analyzed=All Treated Population, all participants who entered the open-label period and received at least one dose of abatacept at any time during this period. Treatment groups represent treatment received in the DB period. n=number of participants with data available.</population>
          <units>percentage of red blood cells</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="124"/>
                <count group_id="O2" value="124"/>
                <count group_id="O3" value="102"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.72" spread="0.29"/>
                    <measurement group_id="O2" value="1.23" spread="0.29"/>
                    <measurement group_id="O3" value="0.99" spread="0.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>OL; Mean Change From Baseline Over Time in DAS 28 (ESR) Score</title>
        <description>The DAS28 is a continuous disease measure which is a composite of 4 variables: the 28 tender joint count, the 28 swollen joint count, ESR or CRP, and participant assessment of disease activity measure on a visual analogue scale. The DAS28 has numeric thresholds that define high disease activity (&gt; 5.1), low disease activity (&lt; 3.2) and remission (&lt; 2.6). A clinically significant response is a decrease in DAS28 score of &gt;1.2 from baseline.</description>
        <time_frame>Baseline (Day 1), Day 365, Day 533, Day 729</time_frame>
        <population>Number of Participants Analyzed=All Treated Population, all participants who entered the open-label period and received at least one dose of abatacept at any time during this period. Treatment groups represent treatment received in the DB period.n=number of participants with data available.</population>
        <group_list>
          <group group_id="O1">
            <title>ABA + MTX [DB]</title>
            <description>Abatacept was administered intravenously (IV) on Days 1, 15, 29 and every 28 days thereafter for a total of 14 doses. Administration was as follows: 500 mg for participants &lt;60 kg, 750 mg for participants 60 to 100 kg and 1 gram for participants &gt;100 kg. All participants received a stable dose of MTX (minimum 15 mg weekly).</description>
          </group>
          <group group_id="O2">
            <title>INF + MTX [DB]</title>
            <description>Infliximab was given 3 mg/kg IV (approved labeled dose) on Days 1, 15, 43, 85 and every 56 days thereafter for a total of 8 doses. All participants received a stable dose of MTX (minimum 15 mg weekly)</description>
          </group>
          <group group_id="O3">
            <title>PLA + MTX [DB]</title>
            <description>Normal saline was administered as placebo. All participants received a stable dose of MTX (minimum 15 mg weekly)</description>
          </group>
        </group_list>
        <measure>
          <title>OL; Mean Change From Baseline Over Time in DAS 28 (ESR) Score</title>
          <description>The DAS28 is a continuous disease measure which is a composite of 4 variables: the 28 tender joint count, the 28 swollen joint count, ESR or CRP, and participant assessment of disease activity measure on a visual analogue scale. The DAS28 has numeric thresholds that define high disease activity (&gt; 5.1), low disease activity (&lt; 3.2) and remission (&lt; 2.6). A clinically significant response is a decrease in DAS28 score of &gt;1.2 from baseline.</description>
          <population>Number of Participants Analyzed=All Treated Population, all participants who entered the open-label period and received at least one dose of abatacept at any time during this period. Treatment groups represent treatment received in the DB period.n=number of participants with data available.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="132"/>
                <count group_id="O2" value="136"/>
                <count group_id="O3" value="104"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 365 (n=122, n=130, n=94)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.12" spread="0.13"/>
                    <measurement group_id="O2" value="-2.39" spread="0.13"/>
                    <measurement group_id="O3" value="-2.81" spread="0.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 533 (n=118, n=121, n=92)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.21" spread="0.13"/>
                    <measurement group_id="O2" value="-3.04" spread="0.13"/>
                    <measurement group_id="O3" value="-2.84" spread="0.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 729 (n=110, n=121, n=93)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.35" spread="0.14"/>
                    <measurement group_id="O2" value="-3.29" spread="0.12"/>
                    <measurement group_id="O3" value="-2.98" spread="0.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>OL; Percentage of Participants With DAS28 (ESR) Remission and Low Disease Activity (LDAS) Over Time</title>
        <description>The DAS28 is a continuous disease measure which is a composite of 4 variables: the 28 tender joint count, the 28 swollen joint count, ESR or CRP, and participant assessment of disease activity measure on a visual analogue scale. The DAS28 has numeric thresholds that define high disease activity (&gt; 5.1), low disease activity (&lt; 3.2) and remission (&lt; 2.6). A clinically significant response is a decrease in DAS28 score of &gt;1.2 from baseline.</description>
        <time_frame>Baseline (Day 1), Day 365, Day 533, Day 729</time_frame>
        <population>Number of Participants Analyzed=All Treated Population, all participants who entered the open-label period and received at least one dose of abatacept at any time during this period. Efficacy data was summarized for the 3 DB treatment cohorts.n=number of participants with data available.</population>
        <group_list>
          <group group_id="O1">
            <title>ABA + MTX [DB]</title>
            <description>Abatacept was administered intravenously (IV) on Days 1, 15, 29 and every 28 days thereafter for a total of 14 doses. Administration was as follows: 500 mg for participants &lt;60 kg, 750 mg for participants 60 to 100 kg and 1 gram for participants &gt;100 kg. All participants received a stable dose of MTX (minimum 15 mg weekly).</description>
          </group>
          <group group_id="O2">
            <title>INF + MTX [DB]</title>
            <description>Infliximab was given 3 mg/kg IV (approved labeled dose) on Days 1, 15, 43, 85 and every 56 days thereafter for a total of 8 doses. All participants received a stable dose of MTX (minimum 15 mg weekly)</description>
          </group>
          <group group_id="O3">
            <title>PLA + MTX [DB]</title>
            <description>Normal saline was administered as placebo. All participants received a stable dose of MTX (minimum 15 mg weekly)</description>
          </group>
        </group_list>
        <measure>
          <title>OL; Percentage of Participants With DAS28 (ESR) Remission and Low Disease Activity (LDAS) Over Time</title>
          <description>The DAS28 is a continuous disease measure which is a composite of 4 variables: the 28 tender joint count, the 28 swollen joint count, ESR or CRP, and participant assessment of disease activity measure on a visual analogue scale. The DAS28 has numeric thresholds that define high disease activity (&gt; 5.1), low disease activity (&lt; 3.2) and remission (&lt; 2.6). A clinically significant response is a decrease in DAS28 score of &gt;1.2 from baseline.</description>
          <population>Number of Participants Analyzed=All Treated Population, all participants who entered the open-label period and received at least one dose of abatacept at any time during this period. Efficacy data was summarized for the 3 DB treatment cohorts.n=number of participants with data available.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="132"/>
                <count group_id="O2" value="136"/>
                <count group_id="O3" value="104"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 365 Remission (n=127, n=135, n=102)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.7"/>
                    <measurement group_id="O2" value="13.3"/>
                    <measurement group_id="O3" value="15.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 365 LDAS (n=127, n=135, n=102)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.0"/>
                    <measurement group_id="O2" value="23.0"/>
                    <measurement group_id="O3" value="29.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 533 Remission (n=122, n=125, n=98)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.5"/>
                    <measurement group_id="O2" value="20.0"/>
                    <measurement group_id="O3" value="19.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 533 LDAS (n=122, n=125, n=98)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.7"/>
                    <measurement group_id="O2" value="33.6"/>
                    <measurement group_id="O3" value="35.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 729 Remission (n=115, n=126, n=100)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.1"/>
                    <measurement group_id="O2" value="28.6"/>
                    <measurement group_id="O3" value="22.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 729 LDAS (n=115, n=126, n=100)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.7"/>
                    <measurement group_id="O2" value="45.2"/>
                    <measurement group_id="O3" value="34.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>OL; Percentage of Participants With Good, Moderate, or No Response According to European League Against Rheumatism (EULAR) Over Time</title>
        <description>The DAS28 is a continuous disease measure composite of 4 variables: 28 tender joint count, 28 swollen joint count, ESR or CRP, and participant assessment of disease activity measure on a visual analogue scale. High disease activity= &gt; 5.1, low disease activity= &lt; 3.2, and remission= &lt; 2.6. Clinically significant response= decrease of &gt;1.2 from baseline. Utilizing EULAR response criteria, DAS28 categorical responses define a good (absolute &lt;3.2 or &gt;1.2 improvement from baseline [BL]), moderate (absolute 3.2-5.1 or 0.6-1.2 change from BL), or no response (absolute &gt;5.1 or &lt;0.6 change from BL)</description>
        <time_frame>DB Days 365, 533, and 729</time_frame>
        <population>Number of Participants Analyzed=All Treated Population, all participants who entered the open-label period and received at least one dose of abatacept at any time during this period. Treatment groups represent treatment received in the DB period.n=number of participants with data available.</population>
        <group_list>
          <group group_id="O1">
            <title>ABA + MTX [DB]</title>
            <description>Abatacept was administered intravenously (IV) on Days 1, 15, 29 and every 28 days thereafter for a total of 14 doses. Administration was as follows: 500 mg for participants &lt; 60 kg, 750 mg for participants 60 to 100 kg and 1 gram for participants &gt; 100 kg. All participants received a stable dose of MTX (minimum 15 mg weekly).</description>
          </group>
          <group group_id="O2">
            <title>INF + MTX [DB]</title>
            <description>Infliximab was given 3 mg/kg IV (approved labeled dose) on Days 1, 15, 43, 85 and every 56 days thereafter for a total of 8 doses. All participants received a stable dose of MTX (minimum 15 mg weekly)</description>
          </group>
          <group group_id="O3">
            <title>PLA + MTX [DB]</title>
            <description>Normal saline was administered as placebo. All participants received a stable dose of MTX (minimum 15 mg weekly). After placebo treatment from Day 1-197, participants were reallocated to receive abatacept (weight based) plus a stable dose of MTX (minimum 15 mg weekly).</description>
          </group>
        </group_list>
        <measure>
          <title>OL; Percentage of Participants With Good, Moderate, or No Response According to European League Against Rheumatism (EULAR) Over Time</title>
          <description>The DAS28 is a continuous disease measure composite of 4 variables: 28 tender joint count, 28 swollen joint count, ESR or CRP, and participant assessment of disease activity measure on a visual analogue scale. High disease activity= &gt; 5.1, low disease activity= &lt; 3.2, and remission= &lt; 2.6. Clinically significant response= decrease of &gt;1.2 from baseline. Utilizing EULAR response criteria, DAS28 categorical responses define a good (absolute &lt;3.2 or &gt;1.2 improvement from baseline [BL]), moderate (absolute 3.2-5.1 or 0.6-1.2 change from BL), or no response (absolute &gt;5.1 or &lt;0.6 change from BL)</description>
          <population>Number of Participants Analyzed=All Treated Population, all participants who entered the open-label period and received at least one dose of abatacept at any time during this period. Treatment groups represent treatment received in the DB period.n=number of participants with data available.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="132"/>
                <count group_id="O2" value="136"/>
                <count group_id="O3" value="104"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 365 Good response (n=122, n=130, n=94)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.5"/>
                    <measurement group_id="O2" value="23.1"/>
                    <measurement group_id="O3" value="30.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 365 Moderate response (n=122, n=130, n=94)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53.3"/>
                    <measurement group_id="O2" value="58.5"/>
                    <measurement group_id="O3" value="55.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 365 No response (n=122, n=130, n=94)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.2"/>
                    <measurement group_id="O2" value="18.5"/>
                    <measurement group_id="O3" value="13.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 533 Good response (n=118, n=121, n=92)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.1"/>
                    <measurement group_id="O2" value="33.1"/>
                    <measurement group_id="O3" value="35.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 533 Moderate response (n=118, n=121, n=92)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58.5"/>
                    <measurement group_id="O2" value="58.7"/>
                    <measurement group_id="O3" value="53.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 533 No response (n=118, n=121, n=92)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.4"/>
                    <measurement group_id="O2" value="8.3"/>
                    <measurement group_id="O3" value="10.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 729 Good response (n=110, n=121, n=93)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.8"/>
                    <measurement group_id="O2" value="45.5"/>
                    <measurement group_id="O3" value="34.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 729 Moderate response (n=110, n=121, n=93)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53.6"/>
                    <measurement group_id="O2" value="47.9"/>
                    <measurement group_id="O3" value="51.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 729 No response (n=110, n=121, n=93)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.5"/>
                    <measurement group_id="O2" value="6.6"/>
                    <measurement group_id="O3" value="14.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>OL; Percentage of Participants With American College of Rheumatology (ACR) Responses Over Time</title>
        <description>The ACR 20 definition of improvement is a 20% improvement from baseline in the number of tender and swollen joint counts, and a 20% improvement from baseline in 3 of the remaining 5 core set measures: participant global assessment of pain, participant global assessment of disease activity, physician global assessment of disease activity, participant assessment of physical function and acute phase reactant value (C-reactive protein [CRP]). The evaluation for 50% improvement (ACR 50) and 70% improvement (ACR 70) follow similarly.</description>
        <time_frame>DB Day 197, Day 365, Day 533, Day 729</time_frame>
        <population>Number of Participants Analyzed=All Treated Population, all participants who entered the open-label period and received at least one dose of abatacept at any time during this period. Treatment groups represent treatment received in the DB period. n=number of participants with data available.</population>
        <group_list>
          <group group_id="O1">
            <title>ABA + MTX [DB]</title>
            <description>Abatacept was administered intravenously (IV) on Days 1, 15, 29 and every 28 days thereafter for a total of 14 doses. Administration was as follows: 500 mg for participants &lt; 60 kg, 750 mg for participants 60 to 100 kg and 1 gram for participants &gt; 100 kg. All participants received a stable dose of MTX (minimum 15 mg weekly).</description>
          </group>
          <group group_id="O2">
            <title>INF + MTX [DB]</title>
            <description>Infliximab was given 3 mg/kg IV (approved labeled dose) on Days 1, 15, 43, 85 and every 56 days thereafter for a total of 8 doses. All participants received a stable dose of MTX (minimum 15 mg weekly)</description>
          </group>
          <group group_id="O3">
            <title>PLA + MTX [DB]</title>
            <description>Normal saline was administered as placebo. All participants received a stable dose of MTX (minimum 15 mg weekly). After placebo treatment from Day 1-197, participants were reallocated to receive abatacept (weight based) plus a stable dose of MTX (minimum 15 mg weekly).</description>
          </group>
        </group_list>
        <measure>
          <title>OL; Percentage of Participants With American College of Rheumatology (ACR) Responses Over Time</title>
          <description>The ACR 20 definition of improvement is a 20% improvement from baseline in the number of tender and swollen joint counts, and a 20% improvement from baseline in 3 of the remaining 5 core set measures: participant global assessment of pain, participant global assessment of disease activity, physician global assessment of disease activity, participant assessment of physical function and acute phase reactant value (C-reactive protein [CRP]). The evaluation for 50% improvement (ACR 50) and 70% improvement (ACR 70) follow similarly.</description>
          <population>Number of Participants Analyzed=All Treated Population, all participants who entered the open-label period and received at least one dose of abatacept at any time during this period. Treatment groups represent treatment received in the DB period. n=number of participants with data available.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="132"/>
                <count group_id="O2" value="136"/>
                <count group_id="O3" value="104"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 197, ACR 20 (n=130, n=133, n=102)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73.1"/>
                    <measurement group_id="O2" value="68.4"/>
                    <measurement group_id="O3" value="44.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 197, ACR 50 (n=129, n=134, n=103)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.7"/>
                    <measurement group_id="O2" value="42.5"/>
                    <measurement group_id="O3" value="21.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 197, ACR 70 (n=130, n=133, n=103)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.1"/>
                    <measurement group_id="O2" value="27.1"/>
                    <measurement group_id="O3" value="10.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 365, ACR 20 (n=130, n=136, n=103)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="88.5"/>
                    <measurement group_id="O2" value="69.1"/>
                    <measurement group_id="O3" value="75.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 365, ACR 50 (n=131, n=136, n=102)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55.0"/>
                    <measurement group_id="O2" value="43.4"/>
                    <measurement group_id="O3" value="54.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 365, ACR 70 (n=131, n=136, n=102)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.3"/>
                    <measurement group_id="O2" value="23.5"/>
                    <measurement group_id="O3" value="31.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 533, ACR 20 (n=128, n=128, n=102)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="82.8"/>
                    <measurement group_id="O2" value="82.8"/>
                    <measurement group_id="O3" value="74.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 533, ACR 50 (n=129, n=128, n=103)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58.1"/>
                    <measurement group_id="O2" value="57.0"/>
                    <measurement group_id="O3" value="47.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 533, ACR 70 (n=129, n=127, n=102)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.7"/>
                    <measurement group_id="O2" value="40.9"/>
                    <measurement group_id="O3" value="32.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 729, ACR 20 (n=119, n=127, n=102)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="86.6"/>
                    <measurement group_id="O2" value="84.3"/>
                    <measurement group_id="O3" value="76.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 729, ACR 50 (n=117, n=127, n=101)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60.7"/>
                    <measurement group_id="O2" value="70.9"/>
                    <measurement group_id="O3" value="49.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 729, ACR 70 (n=120, n=127, n=100)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.8"/>
                    <measurement group_id="O2" value="44.9"/>
                    <measurement group_id="O3" value="33.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>OL; Percentage of Participants Who Achieved Major Clinical Response</title>
        <description>Major Clinical Response was defined as a continuous ACR 70 for six months.</description>
        <time_frame>Defined from the date of achieving ACR 70 response to 6 months post response</time_frame>
        <population>Protocol-specified analyses of the proportion of participants achieving a Major Clinical Response were not performed since ACR responses in the open-label period could only be assessed at 6-month intervals due to the fact that CRP and ESR were only measured every 6 months during this period.</population>
        <group_list>
          <group group_id="O1">
            <title>ABA + MTX [DB]</title>
            <description>Abatacept was administered intravenously (IV) on Days 1, 15, 29 and every 28 days thereafter for a total of 14 doses. Administration was as follows: 500 mg for participants &lt;60 kg, 750 mg for participants 60 to 100 kg and 1 gram for participants &gt;100 kg. All participants received a stable dose of MTX (minimum 15 mg weekly).</description>
          </group>
          <group group_id="O2">
            <title>INF + MTX [DB]</title>
            <description>Infliximab was given 3 mg/kg IV (approved labeled dose) on Days 1, 15, 43, 85 and every 56 days thereafter for a total of 8 doses. All participants received a stable dose of MTX (minimum 15 mg weekly)</description>
          </group>
          <group group_id="O3">
            <title>PLA + MTX [DB]</title>
            <description>Normal saline was administered as placebo. All participants received a stable dose of MTX (minimum 15 mg weekly)</description>
          </group>
        </group_list>
        <measure>
          <title>OL; Percentage of Participants Who Achieved Major Clinical Response</title>
          <description>Major Clinical Response was defined as a continuous ACR 70 for six months.</description>
          <population>Protocol-specified analyses of the proportion of participants achieving a Major Clinical Response were not performed since ACR responses in the open-label period could only be assessed at 6-month intervals due to the fact that CRP and ESR were only measured every 6 months during this period.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>OL; Percentage of Participants With Clinically Meaningful Health Assessment Questionnaire-Disability Index (HAQ-DI) Response Over Time</title>
        <description>The disability section of the full HAQ includes 20 questions to assess physical functions in 8 domains: dressing, arising, eating, walking, hygiene, reach, grip and common activities. The questions are evaluated on a 4-point scale: 0=without any difficulty, 1= with some difficulty, 2= with much difficulty, and 3= unable to do. Higher scores= greater dysfunction. A disability index was calculated by summing the worst scores in each domain and dividing by the number of domains answered. Clinically meaningful HAQ response=an improvement of at least 0.3 units from baseline in HAQ disability Index.</description>
        <time_frame>OL Days 197, 253, 281, 309, 337, 365, 449, 533, 617, and 729</time_frame>
        <population>Number of Participants Analyzed=All Treated Population, all participants who entered the open-label period and received at least one dose of abatacept at any time during this period. Treatment groups represent treatment received in the DB period.n=number of participants with data available.</population>
        <group_list>
          <group group_id="O1">
            <title>ABA + MTX [DB]</title>
            <description>Abatacept was administered intravenously (IV) on Days 1, 15, 29 and every 28 days thereafter for a total of 14 doses. Administration was as follows: 500 mg for participants &lt; 60 kg, 750 mg for participants 60 to 100 kg and 1 gram for participants &gt; 100 kg. All participants received a stable dose of MTX (minimum 15 mg weekly).</description>
          </group>
          <group group_id="O2">
            <title>INF + MTX [DB]</title>
            <description>Infliximab was given 3 mg/kg IV (approved labeled dose) on Days 1, 15, 43, 85 and every 56 days thereafter for a total of 8 doses. All participants received a stable dose of MTX (minimum 15 mg weekly)</description>
          </group>
          <group group_id="O3">
            <title>PLA + MTX [DB]</title>
            <description>Normal saline was administered as placebo. All participants received a stable dose of MTX (minimum 15 mg weekly). After placebo treatment from Day 1-197, participants were reallocated to receive abatacept (weight based) plus a stable dose of MTX (minimum 15 mg weekly).</description>
          </group>
        </group_list>
        <measure>
          <title>OL; Percentage of Participants With Clinically Meaningful Health Assessment Questionnaire-Disability Index (HAQ-DI) Response Over Time</title>
          <description>The disability section of the full HAQ includes 20 questions to assess physical functions in 8 domains: dressing, arising, eating, walking, hygiene, reach, grip and common activities. The questions are evaluated on a 4-point scale: 0=without any difficulty, 1= with some difficulty, 2= with much difficulty, and 3= unable to do. Higher scores= greater dysfunction. A disability index was calculated by summing the worst scores in each domain and dividing by the number of domains answered. Clinically meaningful HAQ response=an improvement of at least 0.3 units from baseline in HAQ disability Index.</description>
          <population>Number of Participants Analyzed=All Treated Population, all participants who entered the open-label period and received at least one dose of abatacept at any time during this period. Treatment groups represent treatment received in the DB period.n=number of participants with data available.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="132"/>
                <count group_id="O2" value="136"/>
                <count group_id="O3" value="104"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 197 (n=131, n=134, n=103)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70.2"/>
                    <measurement group_id="O2" value="68.7"/>
                    <measurement group_id="O3" value="42.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 225 (n=132, n=133, n=101)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75.0"/>
                    <measurement group_id="O2" value="72.9"/>
                    <measurement group_id="O3" value="52.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 253 (n=130, n=135, n=102)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71.5"/>
                    <measurement group_id="O2" value="65.2"/>
                    <measurement group_id="O3" value="57.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 281 (n=131, n=135, n=102)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73.3"/>
                    <measurement group_id="O2" value="71.9"/>
                    <measurement group_id="O3" value="52.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 309 (n=131, n=134, n=102)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71.0"/>
                    <measurement group_id="O2" value="70.1"/>
                    <measurement group_id="O3" value="62.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 337 (n=130, n=136, n=101)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71.5"/>
                    <measurement group_id="O2" value="72.1"/>
                    <measurement group_id="O3" value="63.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 365 (n=130, n=136, n=103)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70.8"/>
                    <measurement group_id="O2" value="67.6"/>
                    <measurement group_id="O3" value="61.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 449 (n=129, n=133, n=101)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70.5"/>
                    <measurement group_id="O2" value="72.9"/>
                    <measurement group_id="O3" value="64.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 533 (n=128, n=127, n=103)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74.2"/>
                    <measurement group_id="O2" value="78.0"/>
                    <measurement group_id="O3" value="61.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 617 (n=123, n=127, n=103)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="78.9"/>
                    <measurement group_id="O2" value="79.5"/>
                    <measurement group_id="O3" value="64.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 729 (n=122, n=127, n=103)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74.6"/>
                    <measurement group_id="O2" value="78.0"/>
                    <measurement group_id="O3" value="63.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>OL; Adjusted Mean Change From Baseline to Day 729 in HAQ-DI</title>
        <description>The disability section of the full HAQ includes 20 questions to assess physical functions in 8 domains: dressing, arising, eating, walking, hygiene, reach, grip and common activities. The questions are evaluated on a 4-point scale: 0=without any difficulty, 1= with some difficulty, 2= with much difficulty, and 3= unable to do. Higher scores= greater dysfunction. A disability index was calculated by summing the worst scores in each domain and dividing by the number of domains answered. Clinically meaningful HAQ response=an improvement of at least 0.3 units from baseline in HAQ disability Index.</description>
        <time_frame>Day 1 (Baseline), Day 729</time_frame>
        <population>All Treated Population, all participants who entered the open-label period and received at least one dose of abatacept at any time during this period. Treatment groups represent treatment received in the DB period.</population>
        <group_list>
          <group group_id="O1">
            <title>ABA + MTX [DB]</title>
            <description>Abatacept was administered intravenously (IV) on Days 1, 15, 29 and every 28 days thereafter for a total of 14 doses. Administration was as follows: 500 mg for participants &lt; 60 kg, 750 mg for participants 60 to 100 kg and 1 gram for participants &gt; 100 kg. All participants received a stable dose of MTX (minimum 15 mg weekly).</description>
          </group>
          <group group_id="O2">
            <title>INF + MTX [DB]</title>
            <description>Infliximab was given 3 mg/kg IV (approved labeled dose) on Days 1, 15, 43, 85 and every 56 days thereafter for a total of 8 doses. All participants received a stable dose of MTX (minimum 15 mg weekly)</description>
          </group>
          <group group_id="O3">
            <title>PLA + MTX [DB]</title>
            <description>Normal saline was administered as placebo. All participants received a stable dose of MTX (minimum 15 mg weekly)</description>
          </group>
        </group_list>
        <measure>
          <title>OL; Adjusted Mean Change From Baseline to Day 729 in HAQ-DI</title>
          <description>The disability section of the full HAQ includes 20 questions to assess physical functions in 8 domains: dressing, arising, eating, walking, hygiene, reach, grip and common activities. The questions are evaluated on a 4-point scale: 0=without any difficulty, 1= with some difficulty, 2= with much difficulty, and 3= unable to do. Higher scores= greater dysfunction. A disability index was calculated by summing the worst scores in each domain and dividing by the number of domains answered. Clinically meaningful HAQ response=an improvement of at least 0.3 units from baseline in HAQ disability Index.</description>
          <population>All Treated Population, all participants who entered the open-label period and received at least one dose of abatacept at any time during this period. Treatment groups represent treatment received in the DB period.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="122"/>
                <count group_id="O2" value="127"/>
                <count group_id="O3" value="103"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>HAQ-DI</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.83" spread="0.06"/>
                    <measurement group_id="O2" value="-0.84" spread="0.06"/>
                    <measurement group_id="O3" value="-0.64" spread="0.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HAQ-DI component: dressing and grooming</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.93" spread="0.08"/>
                    <measurement group_id="O2" value="-91.0" spread="0.08"/>
                    <measurement group_id="O3" value="-0.68" spread="0.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HAQ-DI component: arising</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.8" spread="0.09"/>
                    <measurement group_id="O2" value="-0.77" spread="0.08"/>
                    <measurement group_id="O3" value="-0.72" spread="0.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HAQ-DI component: eating</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.86" spread="0.09"/>
                    <measurement group_id="O2" value="-0.99" spread="0.09"/>
                    <measurement group_id="O3" value="-0.82" spread="0.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HAQ-DI component: walking</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.78" spread="0.09"/>
                    <measurement group_id="O2" value="-0.73" spread="0.08"/>
                    <measurement group_id="O3" value="-0.54" spread="0.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HAQ-DI component: hygiene</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.65" spread="0.10"/>
                    <measurement group_id="O2" value="-0.65" spread="0.08"/>
                    <measurement group_id="O3" value="-0.5" spread="0.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HAQ-DI component: reach</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.97" spread="0.09"/>
                    <measurement group_id="O2" value="-0.94" spread="0.10"/>
                    <measurement group_id="O3" value="-0.64" spread="0.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HAQ-DI component: grip</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.88" spread="0.09"/>
                    <measurement group_id="O2" value="-0.96" spread="0.09"/>
                    <measurement group_id="O3" value="-0.61" spread="0.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HAQ-DI component: activities</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.75" spread="0.09"/>
                    <measurement group_id="O2" value="-0.73" spread="0.09"/>
                    <measurement group_id="O3" value="-0.61" spread="0.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>OL; Mean Change From Baseline to Day 729 in White Blood Cells</title>
        <description>Leukocytes: &lt;0.75 x LLN, &gt;1.25 x ULN; neutrophils+bands: &lt;1.0 x 10^3 c/uL; eosinophils: &gt;0.750 x 10^3 c/uL; basophils: &gt; 400 mm3; monocytes: &gt;2000 mm3; lymphocytes: &lt;0.750 x 10^3 c/uL, &gt;7.50 x 10^3 c/uL.</description>
        <time_frame>Baseline (Day 1), Day 729</time_frame>
        <population>Number of Participants Analyzed=All Treated Population, all participants who entered the open-label period and received at least one dose of abatacept at any time during this period. Treatment groups represent treatment received in the DB period. n=number of participants with data available.</population>
        <group_list>
          <group group_id="O1">
            <title>ABA + MTX [DB]</title>
            <description>Abatacept was administered intravenously (IV) on Days 1, 15, 29 and every 28 days thereafter for a total of 14 doses. Administration was as follows: 500 mg for participants &lt; 60 kg, 750 mg for participants 60 to 100 kg and 1 gram for participants &gt; 100 kg. All participants received a stable dose of MTX (minimum 15 mg weekly).</description>
          </group>
          <group group_id="O2">
            <title>INF + MTX [DB]</title>
            <description>Infliximab was given 3 mg/kg IV (approved labeled dose) on Days 1, 15, 43, 85 and every 56 days thereafter for a total of 8 doses. All participants received a stable dose of MTX (minimum 15 mg weekly)</description>
          </group>
          <group group_id="O3">
            <title>PLA + MTX [DB]</title>
            <description>Normal saline was administered as placebo. All participants received a stable dose of MTX (minimum 15 mg weekly)</description>
          </group>
        </group_list>
        <measure>
          <title>OL; Mean Change From Baseline to Day 729 in White Blood Cells</title>
          <description>Leukocytes: &lt;0.75 x LLN, &gt;1.25 x ULN; neutrophils+bands: &lt;1.0 x 10^3 c/uL; eosinophils: &gt;0.750 x 10^3 c/uL; basophils: &gt; 400 mm3; monocytes: &gt;2000 mm3; lymphocytes: &lt;0.750 x 10^3 c/uL, &gt;7.50 x 10^3 c/uL.</description>
          <population>Number of Participants Analyzed=All Treated Population, all participants who entered the open-label period and received at least one dose of abatacept at any time during this period. Treatment groups represent treatment received in the DB period. n=number of participants with data available.</population>
          <units>10^3 c/uL</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="124"/>
                <count group_id="O2" value="125"/>
                <count group_id="O3" value="102"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Leukocytes (n=124, n=125, n=102)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.57" spread="0.23"/>
                    <measurement group_id="O2" value="-1.23" spread="0.26"/>
                    <measurement group_id="O3" value="-1.28" spread="0.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Neutrophils + bands (n=123, n=123, n=101)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.62" spread="0.21"/>
                    <measurement group_id="O2" value="-1.35" spread="0.23"/>
                    <measurement group_id="O3" value="-1.33" spread="0.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Basophils (n=123, n=123, n=101)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.01" spread="0.00"/>
                    <measurement group_id="O2" value="0.00" spread="0.00"/>
                    <measurement group_id="O3" value="-0.01" spread="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Monocytes (n=123, n=123, n=101)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.05" spread="0.02"/>
                    <measurement group_id="O2" value="-0.02" spread="0.04"/>
                    <measurement group_id="O3" value="-0.03" spread="0.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Eosinophils (n=123, n=123, n=101)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.01" spread="0.01"/>
                    <measurement group_id="O2" value="-0.03" spread="0.02"/>
                    <measurement group_id="O3" value="-0.05" spread="0.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lymphocytes (n=123, n=123, n=101)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.13" spread="0.06"/>
                    <measurement group_id="O2" value="0.18" spread="0.06"/>
                    <measurement group_id="O3" value="0.08" spread="0.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>OL; Mean Change From Baseline to Day 729 in Erythrocytes</title>
        <description>Erythrocytes: &lt;0.75 x BL</description>
        <time_frame>Baseline (Day 1), Day 729</time_frame>
        <population>Number of Participants Analyzed=All Treated Population, all participants who entered the open-label period and received at least one dose of abatacept at any time during this period. Treatment groups represent treatment received in the DB period. n=number of participants with data available.</population>
        <group_list>
          <group group_id="O1">
            <title>ABA + MTX [DB]</title>
            <description>Abatacept was administered intravenously (IV) on Days 1, 15, 29 and every 28 days thereafter for a total of 14 doses. Administration was as follows: 500 mg for participants &lt; 60 kg, 750 mg for participants 60 to 100 kg and 1 gram for participants &gt; 100 kg. All participants received a stable dose of MTX (minimum 15 mg weekly).</description>
          </group>
          <group group_id="O2">
            <title>INF + MTX [DB]</title>
            <description>Infliximab was given 3 mg/kg IV (approved labeled dose) on Days 1, 15, 43, 85 and every 56 days thereafter for a total of 8 doses. All participants received a stable dose of MTX (minimum 15 mg weekly)</description>
          </group>
          <group group_id="O3">
            <title>PLA + MTX [DB]</title>
            <description>Normal saline was administered as placebo. All participants received a stable dose of MTX (minimum 15 mg weekly)</description>
          </group>
        </group_list>
        <measure>
          <title>OL; Mean Change From Baseline to Day 729 in Erythrocytes</title>
          <description>Erythrocytes: &lt;0.75 x BL</description>
          <population>Number of Participants Analyzed=All Treated Population, all participants who entered the open-label period and received at least one dose of abatacept at any time during this period. Treatment groups represent treatment received in the DB period. n=number of participants with data available.</population>
          <units>10^6 c/uL</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="124"/>
                <count group_id="O2" value="125"/>
                <count group_id="O3" value="102"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.07" spread="0.03"/>
                    <measurement group_id="O2" value="0.04" spread="0.03"/>
                    <measurement group_id="O3" value="0.02" spread="0.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>OL; Mean Change From Baseline to Day 729 in Electrolytes</title>
        <description>Sodium (Na): &lt;0.95 x LLN, &gt;1.05 x ULN; potassium (K): &lt;0.9 x LLN, &gt;1.1 x ULN; chloride (Cl): &lt;0.9 x LLN, &gt;1.1 x ULN</description>
        <time_frame>Baseline (Day 1), Day 729</time_frame>
        <population>Number of Participants Analyzed=All Treated Population, all participants who entered the open-label period and received at least one dose of abatacept at any time during this period. Treatment groups represent treatment received in the DB period. n=number of participants with data available.</population>
        <group_list>
          <group group_id="O1">
            <title>ABA + MTX [DB]</title>
            <description>Abatacept was administered intravenously (IV) on Days 1, 15, 29 and every 28 days thereafter for a total of 14 doses. Administration was as follows: 500 mg for participants &lt; 60 kg, 750 mg for participants 60 to 100 kg and 1 gram for participants &gt; 100 kg. All participants received a stable dose of MTX (minimum 15 mg weekly).</description>
          </group>
          <group group_id="O2">
            <title>INF + MTX [DB]</title>
            <description>Infliximab was given 3 mg/kg IV (approved labeled dose) on Days 1, 15, 43, 85 and every 56 days thereafter for a total of 8 doses. All participants received a stable dose of MTX (minimum 15 mg weekly)</description>
          </group>
          <group group_id="O3">
            <title>PLA + MTX [DB]</title>
            <description>Normal saline was administered as placebo. All participants received a stable dose of MTX (minimum 15 mg weekly)</description>
          </group>
        </group_list>
        <measure>
          <title>OL; Mean Change From Baseline to Day 729 in Electrolytes</title>
          <description>Sodium (Na): &lt;0.95 x LLN, &gt;1.05 x ULN; potassium (K): &lt;0.9 x LLN, &gt;1.1 x ULN; chloride (Cl): &lt;0.9 x LLN, &gt;1.1 x ULN</description>
          <population>Number of Participants Analyzed=All Treated Population, all participants who entered the open-label period and received at least one dose of abatacept at any time during this period. Treatment groups represent treatment received in the DB period. n=number of participants with data available.</population>
          <units>mEq/L</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="124"/>
                <count group_id="O2" value="127"/>
                <count group_id="O3" value="102"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Na</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.10" spread="0.28"/>
                    <measurement group_id="O2" value="-1.12" spread="0.29"/>
                    <measurement group_id="O3" value="-1.22" spread="0.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>K</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.03" spread="0.04"/>
                    <measurement group_id="O2" value="-0.04" spread="0.04"/>
                    <measurement group_id="O3" value="-0.02" spread="0.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cl</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.31" spread="0.26"/>
                    <measurement group_id="O2" value="-1.28" spread="0.31"/>
                    <measurement group_id="O3" value="-2.03" spread="0.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>OL; Mean Change From Baseline to Day 729 in Bilirubin, Blood Urea Nitrogen, Creatinine, Calcium, Phosphorous, Serum Glucose, Fasting Serum Glucose, and Uric Acid</title>
        <description>Bilirubin: &gt;2 x ULN; blood urea nitrogen (BUN): &gt;2 x BL; creatinine: &gt;4 x BL; calcium (Ca): &lt;0.8 x LLN, &gt;1.2 x ULN; phosphorous (P): &lt;0.75 x LLN, &gt;1.2 5 x ULN; serum glucose (Glu): &lt;65 mg/dL, &gt;220 mg/dL; fasting serum Glu: &lt;0.8 x LLN, &gt;1.5 x ULN; uric acid: &gt;1.5 x ULN;</description>
        <time_frame>Baseline (Day 1), Day 729</time_frame>
        <population>Number of Participants Analyzed=All Treated Population, all participants who entered the open-label period and received at least one dose of abatacept at any time during this period. Treatment groups represent treatment received in the DB period. n=number of participants with data available.</population>
        <group_list>
          <group group_id="O1">
            <title>ABA + MTX [DB]</title>
            <description>Abatacept was administered intravenously (IV) on Days 1, 15, 29 and every 28 days thereafter for a total of 14 doses. Administration was as follows: 500 mg for participants &lt; 60 kg, 750 mg for participants 60 to 100 kg and 1 gram for participants &gt; 100 kg. All participants received a stable dose of MTX (minimum 15 mg weekly).</description>
          </group>
          <group group_id="O2">
            <title>INF + MTX [DB]</title>
            <description>Infliximab was given 3 mg/kg IV (approved labeled dose) on Days 1, 15, 43, 85 and every 56 days thereafter for a total of 8 doses. All participants received a stable dose of MTX (minimum 15 mg weekly)</description>
          </group>
          <group group_id="O3">
            <title>PLA + MTX [DB]</title>
            <description>Normal saline was administered as placebo. All participants received a stable dose of MTX (minimum 15 mg weekly)</description>
          </group>
        </group_list>
        <measure>
          <title>OL; Mean Change From Baseline to Day 729 in Bilirubin, Blood Urea Nitrogen, Creatinine, Calcium, Phosphorous, Serum Glucose, Fasting Serum Glucose, and Uric Acid</title>
          <description>Bilirubin: &gt;2 x ULN; blood urea nitrogen (BUN): &gt;2 x BL; creatinine: &gt;4 x BL; calcium (Ca): &lt;0.8 x LLN, &gt;1.2 x ULN; phosphorous (P): &lt;0.75 x LLN, &gt;1.2 5 x ULN; serum glucose (Glu): &lt;65 mg/dL, &gt;220 mg/dL; fasting serum Glu: &lt;0.8 x LLN, &gt;1.5 x ULN; uric acid: &gt;1.5 x ULN;</description>
          <population>Number of Participants Analyzed=All Treated Population, all participants who entered the open-label period and received at least one dose of abatacept at any time during this period. Treatment groups represent treatment received in the DB period. n=number of participants with data available.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="124"/>
                <count group_id="O2" value="127"/>
                <count group_id="O3" value="102"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Creatinine (n=124, n=127, n=102)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.08" spread="0.02"/>
                    <measurement group_id="O2" value="0.08" spread="0.01"/>
                    <measurement group_id="O3" value="0.07" spread="0.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BUN (n=124, n=127, n=102)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.37" spread="0.43"/>
                    <measurement group_id="O2" value="-0.12" spread="0.44"/>
                    <measurement group_id="O3" value="0.20" spread="0.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ca (n=124, n=127, n=102)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.01" spread="0.04"/>
                    <measurement group_id="O2" value="-0.01" spread="0.05"/>
                    <measurement group_id="O3" value="0.02" spread="0.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>P (n=124, n=127, n=102)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.05" spread="0.05"/>
                    <measurement group_id="O2" value="-0.16" spread="0.06"/>
                    <measurement group_id="O3" value="-0.08" spread="0.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Uric Acid (n=124, n=127, n=102)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.22" spread="0.08"/>
                    <measurement group_id="O2" value="-0.02" spread="0.09"/>
                    <measurement group_id="O3" value="-0.10" spread="0.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total bilirubin (n=124, n=127, n=101)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.01" spread="0.02"/>
                    <measurement group_id="O2" value="0.04" spread="0.02"/>
                    <measurement group_id="O3" value="0.03" spread="0.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serum glucose (n=123, n=126, n=101)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.92" spread="3.04"/>
                    <measurement group_id="O2" value="7.52" spread="2.02"/>
                    <measurement group_id="O3" value="3.74" spread="2.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>OL; Mean Change From Baseline to Day 729 in Alanine Aminotransferase, Aspartate Aminotransferase, G-Glutamyl Transferase, and Alkaline Phosphatase</title>
        <description>alanine aminotransferase (ALT): &gt;3 x ULN; aspartate aminotransferase (AST): &gt;3 x ULN; G-Glutamyl transferase (GGT): &gt;2 x ULN; Alkaline phosphatase (ALP): &gt;2 x ULN</description>
        <time_frame>Baseline (Day 1), Day 729</time_frame>
        <population>Number of Participants Analyzed=All Treated Population, all participants who entered the open-label period and received at least one dose of abatacept at any time during this period. Treatment groups represent treatment received in the DB period. n=number of participants with data available.</population>
        <group_list>
          <group group_id="O1">
            <title>ABA + MTX [DB]</title>
            <description>Abatacept was administered intravenously (IV) on Days 1, 15, 29 and every 28 days thereafter for a total of 14 doses. Administration was as follows: 500 mg for participants &lt; 60 kg, 750 mg for participants 60 to 100 kg and 1 gram for participants &gt; 100 kg. All participants received a stable dose of MTX (minimum 15 mg weekly).</description>
          </group>
          <group group_id="O2">
            <title>INF + MTX [DB]</title>
            <description>Infliximab was given 3 mg/kg IV (approved labeled dose) on Days 1, 15, 43, 85 and every 56 days thereafter for a total of 8 doses. All participants received a stable dose of MTX (minimum 15 mg weekly)</description>
          </group>
          <group group_id="O3">
            <title>PLA + MTX [DB]</title>
            <description>Normal saline was administered as placebo. All participants received a stable dose of MTX (minimum 15 mg weekly)</description>
          </group>
        </group_list>
        <measure>
          <title>OL; Mean Change From Baseline to Day 729 in Alanine Aminotransferase, Aspartate Aminotransferase, G-Glutamyl Transferase, and Alkaline Phosphatase</title>
          <description>alanine aminotransferase (ALT): &gt;3 x ULN; aspartate aminotransferase (AST): &gt;3 x ULN; G-Glutamyl transferase (GGT): &gt;2 x ULN; Alkaline phosphatase (ALP): &gt;2 x ULN</description>
          <population>Number of Participants Analyzed=All Treated Population, all participants who entered the open-label period and received at least one dose of abatacept at any time during this period. Treatment groups represent treatment received in the DB period. n=number of participants with data available.</population>
          <units>U/L</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="124"/>
                <count group_id="O2" value="127"/>
                <count group_id="O3" value="102"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>ALT</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.73" spread="1.59"/>
                    <measurement group_id="O2" value="1.02" spread="1.83"/>
                    <measurement group_id="O3" value="-0.89" spread="1.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AST</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.03" spread="1.17"/>
                    <measurement group_id="O2" value="-0.22" spread="1.22"/>
                    <measurement group_id="O3" value="-2.45" spread="1.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GGT</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.23" spread="2.38"/>
                    <measurement group_id="O2" value="-0.41" spread="2.14"/>
                    <measurement group_id="O3" value="-1.93" spread="2.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ALP</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.55" spread="2.17"/>
                    <measurement group_id="O2" value="-2.61" spread="2.83"/>
                    <measurement group_id="O3" value="-3.91" spread="3.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>OL; Mean Change From Baseline to Day 1121 in Hemoglobin, Total Protein, and Albumin</title>
        <description>Hemoglobin (HGB): &gt;3 g/dL decrease from BL; total protein: &lt; 0.9 x LLN, &gt;1.1 x ULN; albumin:&lt;0.9 x LLN</description>
        <time_frame>Baseline (Day 1), Day 1121</time_frame>
        <population>Number of Participants Analyzed=All Treated Population, all participants who entered the open-label period and received at least one dose of abatacept at any time during this period. Treatment groups represent treatment received in the DB period. n=number of participants with data available.</population>
        <group_list>
          <group group_id="O1">
            <title>ABA + MTX [DB]</title>
            <description>Abatacept was administered intravenously (IV) on Days 1, 15, 29 and every 28 days thereafter for a total of 14 doses. Administration was as follows: 500 mg for participants &lt; 60 kg, 750 mg for participants 60 to 100 kg and 1 gram for participants &gt; 100 kg. All participants received a stable dose of MTX (minimum 15 mg weekly).</description>
          </group>
          <group group_id="O2">
            <title>INF + MTX [DB]</title>
            <description>Infliximab was given 3 mg/kg IV (approved labeled dose) on Days 1, 15, 43, 85 and every 56 days thereafter for a total of 8 doses. All participants received a stable dose of MTX (minimum 15 mg weekly)</description>
          </group>
          <group group_id="O3">
            <title>PLA + MTX [DB]</title>
            <description>Normal saline was administered as placebo. All participants received a stable dose of MTX (minimum 15 mg weekly)</description>
          </group>
        </group_list>
        <measure>
          <title>OL; Mean Change From Baseline to Day 1121 in Hemoglobin, Total Protein, and Albumin</title>
          <description>Hemoglobin (HGB): &gt;3 g/dL decrease from BL; total protein: &lt; 0.9 x LLN, &gt;1.1 x ULN; albumin:&lt;0.9 x LLN</description>
          <population>Number of Participants Analyzed=All Treated Population, all participants who entered the open-label period and received at least one dose of abatacept at any time during this period. Treatment groups represent treatment received in the DB period. n=number of participants with data available.</population>
          <units>g/dL</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="102"/>
                <count group_id="O2" value="98"/>
                <count group_id="O3" value="86"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>HGB (n=102, n=98, n=85)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.66" spread="0.13"/>
                    <measurement group_id="O2" value="0.53" spread="0.14"/>
                    <measurement group_id="O3" value="0.57" spread="0.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total protein (n=102, n=98, n=86)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.35" spread="0.05"/>
                    <measurement group_id="O2" value="-0.24" spread="0.05"/>
                    <measurement group_id="O3" value="-0.33" spread="0.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Albumin (n=102, n=98, n=86)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.04" spread="0.04"/>
                    <measurement group_id="O2" value="0.08" spread="0.04"/>
                    <measurement group_id="O3" value="-0.01" spread="0.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>OL; Mean Change From Baseline to Day 1121 in Platelets</title>
        <description>Platelets (PLT): &lt;0.67 x LLN, &gt;1.5 x ULN</description>
        <time_frame>Baseline (Day 1), Day 1121</time_frame>
        <population>Number of Participants Analyzed=All Treated Population, all participants who entered the open-label period and received at least one dose of abatacept at any time during this period. Treatment groups represent treatment received in the DB period. n=number of participants with data available.</population>
        <group_list>
          <group group_id="O1">
            <title>ABA + MTX [DB]</title>
            <description>Abatacept was administered intravenously (IV) on Days 1, 15, 29 and every 28 days thereafter for a total of 14 doses. Administration was as follows: 500 mg for participants &lt; 60 kg, 750 mg for participants 60 to 100 kg and 1 gram for participants &gt; 100 kg. All participants received a stable dose of MTX (minimum 15 mg weekly).</description>
          </group>
          <group group_id="O2">
            <title>INF + MTX [DB]</title>
            <description>Infliximab was given 3 mg/kg IV (approved labeled dose) on Days 1, 15, 43, 85 and every 56 days thereafter for a total of 8 doses. All participants received a stable dose of MTX (minimum 15 mg weekly)</description>
          </group>
          <group group_id="O3">
            <title>PLA + MTX [DB]</title>
            <description>Normal saline was administered as placebo. All participants received a stable dose of MTX (minimum 15 mg weekly)</description>
          </group>
        </group_list>
        <measure>
          <title>OL; Mean Change From Baseline to Day 1121 in Platelets</title>
          <description>Platelets (PLT): &lt;0.67 x LLN, &gt;1.5 x ULN</description>
          <population>Number of Participants Analyzed=All Treated Population, all participants who entered the open-label period and received at least one dose of abatacept at any time during this period. Treatment groups represent treatment received in the DB period. n=number of participants with data available.</population>
          <units>10^9 c/L</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="101"/>
                <count group_id="O2" value="95"/>
                <count group_id="O3" value="85"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-67.5" spread="7.49"/>
                    <measurement group_id="O2" value="-66.1" spread="8.86"/>
                    <measurement group_id="O3" value="-62.5" spread="8.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>OL; Mean Change From Baseline to Day 1121 in Hematocrit</title>
        <description>Hematocrit: &lt;0.75 x BL</description>
        <time_frame>Baseline (Day 1), Day 1121</time_frame>
        <population>Number of Participants Analyzed=All Treated Population, all participants who entered the open-label period and received at least one dose of abatacept at any time during this period. Treatment groups represent treatment received in the DB period. n=number of participants with data available.</population>
        <group_list>
          <group group_id="O1">
            <title>ABA + MTX [DB]</title>
            <description>Abatacept was administered intravenously (IV) on Days 1, 15, 29 and every 28 days thereafter for a total of 14 doses. Administration was as follows: 500 mg for participants &lt; 60 kg, 750 mg for participants 60 to 100 kg and 1 gram for participants &gt; 100 kg. All participants received a stable dose of MTX (minimum 15 mg weekly).</description>
          </group>
          <group group_id="O2">
            <title>INF + MTX [DB]</title>
            <description>Infliximab was given 3 mg/kg IV (approved labeled dose) on Days 1, 15, 43, 85 and every 56 days thereafter for a total of 8 doses. All participants received a stable dose of MTX (minimum 15 mg weekly)</description>
          </group>
          <group group_id="O3">
            <title>PLA + MTX [DB]</title>
            <description>Normal saline was administered as placebo. All participants received a stable dose of MTX (minimum 15 mg weekly)</description>
          </group>
        </group_list>
        <measure>
          <title>OL; Mean Change From Baseline to Day 1121 in Hematocrit</title>
          <description>Hematocrit: &lt;0.75 x BL</description>
          <population>Number of Participants Analyzed=All Treated Population, all participants who entered the open-label period and received at least one dose of abatacept at any time during this period. Treatment groups represent treatment received in the DB period. n=number of participants with data available.</population>
          <units>percentage of red blood cells</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="100"/>
                <count group_id="O2" value="98"/>
                <count group_id="O3" value="85"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.83" spread="0.37"/>
                    <measurement group_id="O2" value="1.50" spread="0.39"/>
                    <measurement group_id="O3" value="1.47" spread="0.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>OL; Mean Change From Baseline to Day 1121 in White Blood Cells</title>
        <description>Leukocytes: &lt;0.75 x LLN, &gt;1.25 x ULN; neutrophils+bands: &lt;1.0 x 10^3 c/uL; eosinophils: &gt;0.750 x 10^3 c/uL; basophils: &gt; 400 mm3; monocytes: &gt;2000 mm3; lymphocytes: &lt;0.750 x 10^3 c/uL, &gt;7.50 x 10^3 c/uL.</description>
        <time_frame>Baseline (Day 1), Day 1121</time_frame>
        <population>Number of Participants Analyzed=All Treated Population, all participants who entered the open-label period and received at least one dose of abatacept at any time during this period. Treatment groups represent treatment received in the DB period. n=number of participants with data available.</population>
        <group_list>
          <group group_id="O1">
            <title>ABA + MTX [DB]</title>
            <description>Abatacept was administered intravenously (IV) on Days 1, 15, 29 and every 28 days thereafter for a total of 14 doses. Administration was as follows: 500 mg for participants &lt; 60 kg, 750 mg for participants 60 to 100 kg and 1 gram for participants &gt; 100 kg. All participants received a stable dose of MTX (minimum 15 mg weekly).</description>
          </group>
          <group group_id="O2">
            <title>INF + MTX [DB]</title>
            <description>Infliximab was given 3 mg/kg IV (approved labeled dose) on Days 1, 15, 43, 85 and every 56 days thereafter for a total of 8 doses. All participants received a stable dose of MTX (minimum 15 mg weekly)</description>
          </group>
          <group group_id="O3">
            <title>PLA + MTX [DB]</title>
            <description>Normal saline was administered as placebo. All participants received a stable dose of MTX (minimum 15 mg weekly)</description>
          </group>
        </group_list>
        <measure>
          <title>OL; Mean Change From Baseline to Day 1121 in White Blood Cells</title>
          <description>Leukocytes: &lt;0.75 x LLN, &gt;1.25 x ULN; neutrophils+bands: &lt;1.0 x 10^3 c/uL; eosinophils: &gt;0.750 x 10^3 c/uL; basophils: &gt; 400 mm3; monocytes: &gt;2000 mm3; lymphocytes: &lt;0.750 x 10^3 c/uL, &gt;7.50 x 10^3 c/uL.</description>
          <population>Number of Participants Analyzed=All Treated Population, all participants who entered the open-label period and received at least one dose of abatacept at any time during this period. Treatment groups represent treatment received in the DB period. n=number of participants with data available.</population>
          <units>10^3 c/uL</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="102"/>
                <count group_id="O2" value="98"/>
                <count group_id="O3" value="85"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Leukocytes (n=102, n=98, n=85)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.07" spread="0.27"/>
                    <measurement group_id="O2" value="-1.09" spread="0.26"/>
                    <measurement group_id="O3" value="-0.99" spread="0.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Neutrophils + bands (n=99, n=96, n=84)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.17" spread="0.25"/>
                    <measurement group_id="O2" value="-1.40" spread="0.25"/>
                    <measurement group_id="O3" value="-1.28" spread="0.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Basophils (n=99, n=96, n=85)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00" spread="0.00"/>
                    <measurement group_id="O2" value="0.00" spread="0.00"/>
                    <measurement group_id="O3" value="0.00" spread="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Monocytes (n=99, n=96, n=84)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.03" spread="0.02"/>
                    <measurement group_id="O2" value="0.00" spread="0.03"/>
                    <measurement group_id="O3" value="0.01" spread="0.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Eosinophils (n=99, n=96, n=84)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00" spread="0.01"/>
                    <measurement group_id="O2" value="-0.06" spread="0.02"/>
                    <measurement group_id="O3" value="-0.04" spread="0.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lymphocytes (n=99, n=96, n=84)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.16" spread="0.08"/>
                    <measurement group_id="O2" value="0.34" spread="0.07"/>
                    <measurement group_id="O3" value="0.32" spread="0.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>OL; Mean Change From Baseline to Day 1121 in Erythrocytes</title>
        <description>Erythrocytes: &lt;0.75 x BL</description>
        <time_frame>Baseline (Day 1), Day 1121</time_frame>
        <population>Number of Participants Analyzed=All Treated Population, all participants who entered the open-label period and received at least one dose of abatacept at any time during this period. Treatment groups represent treatment received in the DB period. n=number of participants with data available.</population>
        <group_list>
          <group group_id="O1">
            <title>ABA + MTX [DB]</title>
            <description>Abatacept was administered intravenously (IV) on Days 1, 15, 29 and every 28 days thereafter for a total of 14 doses. Administration was as follows: 500 mg for participants &lt; 60 kg, 750 mg for participants 60 to 100 kg and 1 gram for participants &gt; 100 kg. All participants received a stable dose of MTX (minimum 15 mg weekly).</description>
          </group>
          <group group_id="O2">
            <title>INF + MTX [DB]</title>
            <description>Infliximab was given 3 mg/kg IV (approved labeled dose) on Days 1, 15, 43, 85 and every 56 days thereafter for a total of 8 doses. All participants received a stable dose of MTX (minimum 15 mg weekly)</description>
          </group>
          <group group_id="O3">
            <title>PLA + MTX [DB]</title>
            <description>Normal saline was administered as placebo. All participants received a stable dose of MTX (minimum 15 mg weekly)</description>
          </group>
        </group_list>
        <measure>
          <title>OL; Mean Change From Baseline to Day 1121 in Erythrocytes</title>
          <description>Erythrocytes: &lt;0.75 x BL</description>
          <population>Number of Participants Analyzed=All Treated Population, all participants who entered the open-label period and received at least one dose of abatacept at any time during this period. Treatment groups represent treatment received in the DB period. n=number of participants with data available.</population>
          <units>10^6 c/uL</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="102"/>
                <count group_id="O2" value="98"/>
                <count group_id="O3" value="85"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.11" spread="0.03"/>
                    <measurement group_id="O2" value="0.11" spread="0.04"/>
                    <measurement group_id="O3" value="0.12" spread="0.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>OL; Mean Change From Baseline to Day 1121 in Electrolytes</title>
        <description>Sodium (Na): &lt;0.95 x LLN, &gt;1.05 x ULN; potassium (K): &lt;0.9 x LLN, &gt;1.1 x ULN; chloride (Cl): &lt;0.9 x LLN, &gt;1.1 x ULN</description>
        <time_frame>Baseline (Day 1), Day 1121</time_frame>
        <population>Number of Participants Analyzed=All Treated Population, all participants who entered the open-label period and received at least one dose of abatacept at any time during this period. Treatment groups represent treatment received in the DB period. n=number of participants with data available.</population>
        <group_list>
          <group group_id="O1">
            <title>ABA + MTX [DB]</title>
            <description>Abatacept was administered intravenously (IV) on Days 1, 15, 29 and every 28 days thereafter for a total of 14 doses. Administration was as follows: 500 mg for participants &lt; 60 kg, 750 mg for participants 60 to 100 kg and 1 gram for participants &gt; 100 kg. All participants received a stable dose of MTX (minimum 15 mg weekly).</description>
          </group>
          <group group_id="O2">
            <title>INF + MTX [DB]</title>
            <description>Infliximab was given 3 mg/kg IV (approved labeled dose) on Days 1, 15, 43, 85 and every 56 days thereafter for a total of 8 doses. All participants received a stable dose of MTX (minimum 15 mg weekly)</description>
          </group>
          <group group_id="O3">
            <title>PLA + MTX [DB]</title>
            <description>Normal saline was administered as placebo. All participants received a stable dose of MTX (minimum 15 mg weekly)</description>
          </group>
        </group_list>
        <measure>
          <title>OL; Mean Change From Baseline to Day 1121 in Electrolytes</title>
          <description>Sodium (Na): &lt;0.95 x LLN, &gt;1.05 x ULN; potassium (K): &lt;0.9 x LLN, &gt;1.1 x ULN; chloride (Cl): &lt;0.9 x LLN, &gt;1.1 x ULN</description>
          <population>Number of Participants Analyzed=All Treated Population, all participants who entered the open-label period and received at least one dose of abatacept at any time during this period. Treatment groups represent treatment received in the DB period. n=number of participants with data available.</population>
          <units>mEq/L</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="102"/>
                <count group_id="O2" value="98"/>
                <count group_id="O3" value="86"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Na (n=102, n=98, n=86)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.80" spread="0.33"/>
                    <measurement group_id="O2" value="-1.38" spread="0.38"/>
                    <measurement group_id="O3" value="-1.34" spread="0.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>K (n=102, n=98, n=85)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.01" spread="0.04"/>
                    <measurement group_id="O2" value="0.08" spread="0.05"/>
                    <measurement group_id="O3" value="0.01" spread="0.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cl (n=102, n=98, n=86)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.88" spread="0.35"/>
                    <measurement group_id="O2" value="-0.94" spread="0.38"/>
                    <measurement group_id="O3" value="-1.42" spread="0.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>OL; Mean Change From Baseline to Day 1121 in Bilirubin, Blood Urea Nitrogen, Creatinine, Calcium, Phosphorous, Serum Glucose, Fasting Serum Glucose, and Uric Acid</title>
        <description>Bilirubin: &gt;2 x ULN; blood urea nitrogen (BUN): &gt;2 x BL; creatinine: &gt;4 x BL; calcium (Ca): &lt;0.8 x LLN, &gt;1.2 x ULN; phosphorous (P): &lt;0.75 x LLN, &gt;1.2 5 x ULN; serum glucose (Glu): &lt;65 mg/dL, &gt;220 mg/dL; fasting serum Glu: &lt;0.8 x LLN, &gt;1.5 x ULN; uric acid: &gt;1.5 x ULN;</description>
        <time_frame>Baseline (Day 1), Day 1121</time_frame>
        <population>Number of Participants Analyzed=All Treated Population, all participants who entered the open-label period and received at least one dose of abatacept at any time during this period. Treatment groups represent treatment received in the DB period. n=number of participants with data available.</population>
        <group_list>
          <group group_id="O1">
            <title>ABA + MTX [DB]</title>
            <description>Abatacept was administered intravenously (IV) on Days 1, 15, 29 and every 28 days thereafter for a total of 14 doses. Administration was as follows: 500 mg for participants &lt; 60 kg, 750 mg for participants 60 to 100 kg and 1 gram for participants &gt; 100 kg. All participants received a stable dose of MTX (minimum 15 mg weekly).</description>
          </group>
          <group group_id="O2">
            <title>INF + MTX [DB]</title>
            <description>Infliximab was given 3 mg/kg IV (approved labeled dose) on Days 1, 15, 43, 85 and every 56 days thereafter for a total of 8 doses. All participants received a stable dose of MTX (minimum 15 mg weekly)</description>
          </group>
          <group group_id="O3">
            <title>PLA + MTX [DB]</title>
            <description>Normal saline was administered as placebo. All participants received a stable dose of MTX (minimum 15 mg weekly)</description>
          </group>
        </group_list>
        <measure>
          <title>OL; Mean Change From Baseline to Day 1121 in Bilirubin, Blood Urea Nitrogen, Creatinine, Calcium, Phosphorous, Serum Glucose, Fasting Serum Glucose, and Uric Acid</title>
          <description>Bilirubin: &gt;2 x ULN; blood urea nitrogen (BUN): &gt;2 x BL; creatinine: &gt;4 x BL; calcium (Ca): &lt;0.8 x LLN, &gt;1.2 x ULN; phosphorous (P): &lt;0.75 x LLN, &gt;1.2 5 x ULN; serum glucose (Glu): &lt;65 mg/dL, &gt;220 mg/dL; fasting serum Glu: &lt;0.8 x LLN, &gt;1.5 x ULN; uric acid: &gt;1.5 x ULN;</description>
          <population>Number of Participants Analyzed=All Treated Population, all participants who entered the open-label period and received at least one dose of abatacept at any time during this period. Treatment groups represent treatment received in the DB period. n=number of participants with data available.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="102"/>
                <count group_id="O2" value="98"/>
                <count group_id="O3" value="86"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Creatinine (n=102, n=98, n=86)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.06" spread="0.02"/>
                    <measurement group_id="O2" value="0.07" spread="0.03"/>
                    <measurement group_id="O3" value="0.08" spread="0.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BUN (n=102, n=98, n=86)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.04" spread="0.49"/>
                    <measurement group_id="O2" value="0.34" spread="0.73"/>
                    <measurement group_id="O3" value="0.20" spread="0.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ca (n=102, n=98, n=86)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.01" spread="0.05"/>
                    <measurement group_id="O2" value="-0.03" spread="0.06"/>
                    <measurement group_id="O3" value="0.04" spread="0.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>P (n=102, n=98, n=85)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.18" spread="0.07"/>
                    <measurement group_id="O2" value="-0.19" spread="0.07"/>
                    <measurement group_id="O3" value="-0.11" spread="0.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Uric Acid (n=102, n=98, n=86)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.05" spread="0.11"/>
                    <measurement group_id="O2" value="0.13" spread="0.10"/>
                    <measurement group_id="O3" value="0.20" spread="0.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total bilirubin (n=102, n=98, n=86)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.02" spread="0.02"/>
                    <measurement group_id="O2" value="0.03" spread="0.02"/>
                    <measurement group_id="O3" value="0.03" spread="0.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serum glucose (n=101, n=98, n=85)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.99" spread="3.31"/>
                    <measurement group_id="O2" value="6.91" spread="2.10"/>
                    <measurement group_id="O3" value="9.07" spread="3.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>OL; Mean Change From Baseline to Day 1121 in Alanine Aminotransferase, Aspartate Aminotransferase, G-Glutamyl Transferase, and Alkaline Phosphatase</title>
        <description>alanine aminotransferase (ALT): &gt;3 x ULN; aspartate aminotransferase (AST): &gt;3 x ULN; G-Glutamyl transferase (GGT): &gt;2 x ULN; Alkaline phosphatase (ALP): &gt;2 x ULN</description>
        <time_frame>Baseline (Day 1), Day 1121</time_frame>
        <population>Number of Participants Analyzed=All Treated Population, all participants who entered the open-label period and received at least one dose of abatacept at any time during this period. Treatment groups represent treatment received in the DB period. n=number of participants with data available.</population>
        <group_list>
          <group group_id="O1">
            <title>ABA + MTX [DB]</title>
            <description>Abatacept was administered intravenously (IV) on Days 1, 15, 29 and every 28 days thereafter for a total of 14 doses. Administration was as follows: 500 mg for participants &lt; 60 kg, 750 mg for participants 60 to 100 kg and 1 gram for participants &gt; 100 kg. All participants received a stable dose of MTX (minimum 15 mg weekly).</description>
          </group>
          <group group_id="O2">
            <title>INF + MTX [DB]</title>
            <description>Infliximab was given 3 mg/kg IV (approved labeled dose) on Days 1, 15, 43, 85 and every 56 days thereafter for a total of 8 doses. All participants received a stable dose of MTX (minimum 15 mg weekly)</description>
          </group>
          <group group_id="O3">
            <title>PLA + MTX [DB]</title>
            <description>Normal saline was administered as placebo. All participants received a stable dose of MTX (minimum 15 mg weekly)</description>
          </group>
        </group_list>
        <measure>
          <title>OL; Mean Change From Baseline to Day 1121 in Alanine Aminotransferase, Aspartate Aminotransferase, G-Glutamyl Transferase, and Alkaline Phosphatase</title>
          <description>alanine aminotransferase (ALT): &gt;3 x ULN; aspartate aminotransferase (AST): &gt;3 x ULN; G-Glutamyl transferase (GGT): &gt;2 x ULN; Alkaline phosphatase (ALP): &gt;2 x ULN</description>
          <population>Number of Participants Analyzed=All Treated Population, all participants who entered the open-label period and received at least one dose of abatacept at any time during this period. Treatment groups represent treatment received in the DB period. n=number of participants with data available.</population>
          <units>U/L</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="102"/>
                <count group_id="O2" value="98"/>
                <count group_id="O3" value="86"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>ALT (n=102, n=98, n=86)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.74" spread="1.95"/>
                    <measurement group_id="O2" value="4.66" spread="2.88"/>
                    <measurement group_id="O3" value="-0.35" spread="2.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AST (n=102, n=98, n=86)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.79" spread="1.60"/>
                    <measurement group_id="O2" value="4.49" spread="2.13"/>
                    <measurement group_id="O3" value="0.38" spread="1.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GGT (n=102, n=98, n=86)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.60" spread="2.79"/>
                    <measurement group_id="O2" value="-2.88" spread="2.16"/>
                    <measurement group_id="O3" value="-0.14" spread="3.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ALP (n=88, n=79, n=69)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.25" spread="2.62"/>
                    <measurement group_id="O2" value="-4.03" spread="3.79"/>
                    <measurement group_id="O3" value="-7.35" spread="3.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>OL; Mean Change From Baseline to Day 1513 in Hemoglobin, Total Protein, and Albumin</title>
        <description>Hemoglobin (HGB): &gt;3 g/dL decrease from BL; total protein: &lt; 0.9 x LLN, &gt;1.1 x ULN; albumin:&lt;0.9 x LLN</description>
        <time_frame>Baseline (Day 1), Day 1513</time_frame>
        <population>Number of Participants Analyzed=All Treated Population, all participants who entered the open-label period and received at least one dose of abatacept at any time during this period. Treatment groups represent treatment received in the DB period. n=number of participants with data available.</population>
        <group_list>
          <group group_id="O1">
            <title>ABA + MTX [DB]</title>
            <description>Abatacept was administered intravenously (IV) on Days 1, 15, 29 and every 28 days thereafter for a total of 14 doses. Administration was as follows: 500 mg for participants &lt; 60 kg, 750 mg for participants 60 to 100 kg and 1 gram for participants &gt; 100 kg. All participants received a stable dose of MTX (minimum 15 mg weekly).</description>
          </group>
          <group group_id="O2">
            <title>INF + MTX [DB]</title>
            <description>Infliximab was given 3 mg/kg IV (approved labeled dose) on Days 1, 15, 43, 85 and every 56 days thereafter for a total of 8 doses. All participants received a stable dose of MTX (minimum 15 mg weekly)</description>
          </group>
          <group group_id="O3">
            <title>PLA + MTX [DB]</title>
            <description>Normal saline was administered as placebo. All participants received a stable dose of MTX (minimum 15 mg weekly)</description>
          </group>
        </group_list>
        <measure>
          <title>OL; Mean Change From Baseline to Day 1513 in Hemoglobin, Total Protein, and Albumin</title>
          <description>Hemoglobin (HGB): &gt;3 g/dL decrease from BL; total protein: &lt; 0.9 x LLN, &gt;1.1 x ULN; albumin:&lt;0.9 x LLN</description>
          <population>Number of Participants Analyzed=All Treated Population, all participants who entered the open-label period and received at least one dose of abatacept at any time during this period. Treatment groups represent treatment received in the DB period. n=number of participants with data available.</population>
          <units>g/dL</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>HGB</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.25" spread="0.33"/>
                    <measurement group_id="O2" value="0.44" spread="0.31"/>
                    <measurement group_id="O3" value="0.56" spread="0.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total protein</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.73" spread="0.09"/>
                    <measurement group_id="O2" value="-0.33" spread="0.11"/>
                    <measurement group_id="O3" value="-0.34" spread="0.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Albumin</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.06" spread="0.07"/>
                    <measurement group_id="O2" value="0.10" spread="0.07"/>
                    <measurement group_id="O3" value="0.00" spread="0.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>OL; Mean Change From Baseline to Day 1513 in Platelets</title>
        <description>Platelets (PLT): &lt;0.67 x LLN, &gt;1.5 x ULN</description>
        <time_frame>Baseline (Day 1), Day 1513</time_frame>
        <population>Number of Participants Analyzed=All Treated Population, all participants who entered the open-label period and received at least one dose of abatacept at any time during this period. Treatment groups represent treatment received in the DB period. n=number of participants with data available.</population>
        <group_list>
          <group group_id="O1">
            <title>ABA + MTX [DB]</title>
            <description>Abatacept was administered intravenously (IV) on Days 1, 15, 29 and every 28 days thereafter for a total of 14 doses. Administration was as follows: 500 mg for participants &lt; 60 kg, 750 mg for participants 60 to 100 kg and 1 gram for participants &gt; 100 kg. All participants received a stable dose of MTX (minimum 15 mg weekly).</description>
          </group>
          <group group_id="O2">
            <title>INF + MTX [DB]</title>
            <description>Infliximab was given 3 mg/kg IV (approved labeled dose) on Days 1, 15, 43, 85 and every 56 days thereafter for a total of 8 doses. All participants received a stable dose of MTX (minimum 15 mg weekly)</description>
          </group>
          <group group_id="O3">
            <title>PLA + MTX [DB]</title>
            <description>Normal saline was administered as placebo. All participants received a stable dose of MTX (minimum 15 mg weekly)</description>
          </group>
        </group_list>
        <measure>
          <title>OL; Mean Change From Baseline to Day 1513 in Platelets</title>
          <description>Platelets (PLT): &lt;0.67 x LLN, &gt;1.5 x ULN</description>
          <population>Number of Participants Analyzed=All Treated Population, all participants who entered the open-label period and received at least one dose of abatacept at any time during this period. Treatment groups represent treatment received in the DB period. n=number of participants with data available.</population>
          <units>10^9 c/L</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="19"/>
                <count group_id="O3" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-78.0" spread="17.20"/>
                    <measurement group_id="O2" value="-74.0" spread="16.18"/>
                    <measurement group_id="O3" value="-99.2" spread="19.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>OL; Mean Change From Baseline to Day 1513 in Hematocrit</title>
        <description>Hematocrit: &lt;0.75 x BL</description>
        <time_frame>Baseline (Day 1), Day 1513</time_frame>
        <population>Number of Participants Analyzed=All Treated Population, all participants who entered the open-label period and received at least one dose of abatacept at any time during this period. Treatment groups represent treatment received in the DB period. n=number of participants with data available.</population>
        <group_list>
          <group group_id="O1">
            <title>ABA + MTX [DB]</title>
            <description>Abatacept was administered intravenously (IV) on Days 1, 15, 29 and every 28 days thereafter for a total of 14 doses. Administration was as follows: 500 mg for participants &lt; 60 kg, 750 mg for participants 60 to 100 kg and 1 gram for participants &gt; 100 kg. All participants received a stable dose of MTX (minimum 15 mg weekly).</description>
          </group>
          <group group_id="O2">
            <title>INF + MTX [DB]</title>
            <description>Infliximab was given 3 mg/kg IV (approved labeled dose) on Days 1, 15, 43, 85 and every 56 days thereafter for a total of 8 doses. All participants received a stable dose of MTX (minimum 15 mg weekly)</description>
          </group>
          <group group_id="O3">
            <title>PLA + MTX [DB]</title>
            <description>Normal saline was administered as placebo. All participants received a stable dose of MTX (minimum 15 mg weekly)</description>
          </group>
        </group_list>
        <measure>
          <title>OL; Mean Change From Baseline to Day 1513 in Hematocrit</title>
          <description>Hematocrit: &lt;0.75 x BL</description>
          <population>Number of Participants Analyzed=All Treated Population, all participants who entered the open-label period and received at least one dose of abatacept at any time during this period. Treatment groups represent treatment received in the DB period. n=number of participants with data available.</population>
          <units>percentage of red blood cells</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="19"/>
                <count group_id="O3" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.92" spread="1.00"/>
                    <measurement group_id="O2" value="1.28" spread="0.92"/>
                    <measurement group_id="O3" value="1.18" spread="1.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>OL; Mean Change From Baseline to Day 1513 in White Blood Cells</title>
        <description>Leukocytes: &lt;0.75 x LLN, &gt;1.25 x ULN; neutrophils+bands: &lt;1.0 x 10^3 c/uL; eosinophils: &gt;0.750 x 10^3 c/uL; basophils: &gt; 400 mm3; monocytes: &gt;2000 mm3; lymphocytes: &lt;0.750 x 10^3 c/uL, &gt;7.50 x 10^3 c/uL.</description>
        <time_frame>Baseline (Day 1), Day 1513</time_frame>
        <population>Number of Participants Analyzed=All Treated Population, all participants who entered the open-label period and received at least one dose of abatacept at any time during this period. Treatment groups represent treatment received in the DB period. n=number of participants with data available.</population>
        <group_list>
          <group group_id="O1">
            <title>ABA + MTX [DB]</title>
            <description>Abatacept was administered intravenously (IV) on Days 1, 15, 29 and every 28 days thereafter for a total of 14 doses. Administration was as follows: 500 mg for participants &lt; 60 kg, 750 mg for participants 60 to 100 kg and 1 gram for participants &gt; 100 kg. All participants received a stable dose of MTX (minimum 15 mg weekly).</description>
          </group>
          <group group_id="O2">
            <title>INF + MTX [DB]</title>
            <description>Infliximab was given 3 mg/kg IV (approved labeled dose) on Days 1, 15, 43, 85 and every 56 days thereafter for a total of 8 doses. All participants received a stable dose of MTX (minimum 15 mg weekly)</description>
          </group>
          <group group_id="O3">
            <title>PLA + MTX [DB]</title>
            <description>Normal saline was administered as placebo. All participants received a stable dose of MTX (minimum 15 mg weekly)</description>
          </group>
        </group_list>
        <measure>
          <title>OL; Mean Change From Baseline to Day 1513 in White Blood Cells</title>
          <description>Leukocytes: &lt;0.75 x LLN, &gt;1.25 x ULN; neutrophils+bands: &lt;1.0 x 10^3 c/uL; eosinophils: &gt;0.750 x 10^3 c/uL; basophils: &gt; 400 mm3; monocytes: &gt;2000 mm3; lymphocytes: &lt;0.750 x 10^3 c/uL, &gt;7.50 x 10^3 c/uL.</description>
          <population>Number of Participants Analyzed=All Treated Population, all participants who entered the open-label period and received at least one dose of abatacept at any time during this period. Treatment groups represent treatment received in the DB period. n=number of participants with data available.</population>
          <units>10^3 c/uL</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Leukocytes (n=23, n=20, n=16)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.34" spread="0.45"/>
                    <measurement group_id="O2" value="-1.08" spread="0.63"/>
                    <measurement group_id="O3" value="-2.13" spread="0.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Neutrophils + bands (n=22, n=17, n=16)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.37" spread="0.33"/>
                    <measurement group_id="O2" value="-1.03" spread="0.68"/>
                    <measurement group_id="O3" value="-1.93" spread="0.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Basophils (n=22, n=17, n=16)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00" spread="0.01"/>
                    <measurement group_id="O2" value="-0.01" spread="0.01"/>
                    <measurement group_id="O3" value="-0.01" spread="0.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Monocytes (n=22, n=17, n=16)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.01" spread="0.03"/>
                    <measurement group_id="O2" value="-0.10" spread="0.09"/>
                    <measurement group_id="O3" value="-0.05" spread="0.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Eosinophils (n=22, n=17, n=16)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.04" spread="0.06"/>
                    <measurement group_id="O2" value="-0.11" spread="0.16"/>
                    <measurement group_id="O3" value="-0.23" spread="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lymphocytes (n=22, n=17, n=16)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.20" spread="0.14"/>
                    <measurement group_id="O2" value="0.16" spread="0.16"/>
                    <measurement group_id="O3" value="-0.15" spread="0.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>OL; Mean Change From Baseline to Day 1513 in Erythrocytes</title>
        <description>Erythrocytes: &lt;0.75 x BL</description>
        <time_frame>Baseline (Day 1), Day 1513</time_frame>
        <population>Number of Participants Analyzed=All Treated Population, all participants who entered the open-label period and received at least one dose of abatacept at any time during this period. Treatment groups represent treatment received in the DB period. n=number of participants with data available.</population>
        <group_list>
          <group group_id="O1">
            <title>ABA + MTX [DB]</title>
            <description>Abatacept was administered intravenously (IV) on Days 1, 15, 29 and every 28 days thereafter for a total of 14 doses. Administration was as follows: 500 mg for participants &lt; 60 kg, 750 mg for participants 60 to 100 kg and 1 gram for participants &gt; 100 kg. All participants received a stable dose of MTX (minimum 15 mg weekly).</description>
          </group>
          <group group_id="O2">
            <title>INF + MTX [DB]</title>
            <description>Infliximab was given 3 mg/kg IV (approved labeled dose) on Days 1, 15, 43, 85 and every 56 days thereafter for a total of 8 doses. All participants received a stable dose of MTX (minimum 15 mg weekly)</description>
          </group>
          <group group_id="O3">
            <title>PLA + MTX [DB]</title>
            <description>Normal saline was administered as placebo. All participants received a stable dose of MTX (minimum 15 mg weekly)</description>
          </group>
        </group_list>
        <measure>
          <title>OL; Mean Change From Baseline to Day 1513 in Erythrocytes</title>
          <description>Erythrocytes: &lt;0.75 x BL</description>
          <population>Number of Participants Analyzed=All Treated Population, all participants who entered the open-label period and received at least one dose of abatacept at any time during this period. Treatment groups represent treatment received in the DB period. n=number of participants with data available.</population>
          <units>10^6 c/uL</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="19"/>
                <count group_id="O3" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.10" spread="0.09"/>
                    <measurement group_id="O2" value="0.00" spread="0.09"/>
                    <measurement group_id="O3" value="-0.09" spread="0.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>OL; Mean Change From Baseline to Day 1513 in Electrolytes</title>
        <description>Sodium (Na): &lt;0.95 x LLN, &gt;1.05 x ULN; potassium (K): &lt;0.9 x LLN, &gt;1.1 x ULN; chloride (Cl): &lt;0.9 x LLN, &gt;1.1 x ULN</description>
        <time_frame>Baseline (Day 1), Day 1513</time_frame>
        <population>Number of Participants Analyzed=All Treated Population, all participants who entered the open-label period and received at least one dose of abatacept at any time during this period. Treatment groups represent treatment received in the DB period. n=number of participants with data available.</population>
        <group_list>
          <group group_id="O1">
            <title>ABA + MTX [DB]</title>
            <description>Abatacept was administered intravenously (IV) on Days 1, 15, 29 and every 28 days thereafter for a total of 14 doses. Administration was as follows: 500 mg for participants &lt; 60 kg, 750 mg for participants 60 to 100 kg and 1 gram for participants &gt; 100 kg. All participants received a stable dose of MTX (minimum 15 mg weekly).</description>
          </group>
          <group group_id="O2">
            <title>INF + MTX [DB]</title>
            <description>Infliximab was given 3 mg/kg IV (approved labeled dose) on Days 1, 15, 43, 85 and every 56 days thereafter for a total of 8 doses. All participants received a stable dose of MTX (minimum 15 mg weekly)</description>
          </group>
          <group group_id="O3">
            <title>PLA + MTX [DB]</title>
            <description>Normal saline was administered as placebo. All participants received a stable dose of MTX (minimum 15 mg weekly)</description>
          </group>
        </group_list>
        <measure>
          <title>OL; Mean Change From Baseline to Day 1513 in Electrolytes</title>
          <description>Sodium (Na): &lt;0.95 x LLN, &gt;1.05 x ULN; potassium (K): &lt;0.9 x LLN, &gt;1.1 x ULN; chloride (Cl): &lt;0.9 x LLN, &gt;1.1 x ULN</description>
          <population>Number of Participants Analyzed=All Treated Population, all participants who entered the open-label period and received at least one dose of abatacept at any time during this period. Treatment groups represent treatment received in the DB period. n=number of participants with data available.</population>
          <units>mEq/L</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Na (n=22, n=20, n=16)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.36" spread="0.73"/>
                    <measurement group_id="O2" value="-3.80" spread="0.99"/>
                    <measurement group_id="O3" value="-4.50" spread="0.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>K (n=23, n=20, n=16)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.16" spread="0.10"/>
                    <measurement group_id="O2" value="-0.32" spread="0.08"/>
                    <measurement group_id="O3" value="-0.46" spread="0.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cl (n=23, n=20, n=16)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.48" spread="0.71"/>
                    <measurement group_id="O2" value="-2.60" spread="0.84"/>
                    <measurement group_id="O3" value="-4.13" spread="0.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>OL; Mean Change From Baseline to Day 1513 in Bilirubin, Blood Urea Nitrogen, Creatinine, Calcium, Phosphorous, Serum Glucose, Fasting Serum Glucose, and Uric Acid</title>
        <description>Bilirubin: &gt;2 x ULN; blood urea nitrogen (BUN): &gt;2 x BL; creatinine: &gt;4 x BL; calcium (Ca): &lt;0.8 x LLN, &gt;1.2 x ULN; phosphorous (P): &lt;0.75 x LLN, &gt;1.2 5 x ULN; serum glucose (Glu): &lt;65 mg/dL, &gt;220 mg/dL; fasting serum Glu: &lt;0.8 x LLN, &gt;1.5 x ULN; uric acid: &gt;1.5 x ULN;</description>
        <time_frame>Baseline (Day 1), Day 1513</time_frame>
        <population>Number of Participants Analyzed=All Treated Population, all participants who entered the open-label period and received at least one dose of abatacept at any time during this period. Treatment groups represent treatment received in the DB period. n=number of participants with data available.</population>
        <group_list>
          <group group_id="O1">
            <title>ABA + MTX [DB]</title>
            <description>Abatacept was administered intravenously (IV) on Days 1, 15, 29 and every 28 days thereafter for a total of 14 doses. Administration was as follows: 500 mg for participants &lt; 60 kg, 750 mg for participants 60 to 100 kg and 1 gram for participants &gt; 100 kg. All participants received a stable dose of MTX (minimum 15 mg weekly).</description>
          </group>
          <group group_id="O2">
            <title>INF + MTX [DB]</title>
            <description>Infliximab was given 3 mg/kg IV (approved labeled dose) on Days 1, 15, 43, 85 and every 56 days thereafter for a total of 8 doses. All participants received a stable dose of MTX (minimum 15 mg weekly)</description>
          </group>
          <group group_id="O3">
            <title>PLA + MTX [DB]</title>
            <description>Normal saline was administered as placebo. All participants received a stable dose of MTX (minimum 15 mg weekly)</description>
          </group>
        </group_list>
        <measure>
          <title>OL; Mean Change From Baseline to Day 1513 in Bilirubin, Blood Urea Nitrogen, Creatinine, Calcium, Phosphorous, Serum Glucose, Fasting Serum Glucose, and Uric Acid</title>
          <description>Bilirubin: &gt;2 x ULN; blood urea nitrogen (BUN): &gt;2 x BL; creatinine: &gt;4 x BL; calcium (Ca): &lt;0.8 x LLN, &gt;1.2 x ULN; phosphorous (P): &lt;0.75 x LLN, &gt;1.2 5 x ULN; serum glucose (Glu): &lt;65 mg/dL, &gt;220 mg/dL; fasting serum Glu: &lt;0.8 x LLN, &gt;1.5 x ULN; uric acid: &gt;1.5 x ULN;</description>
          <population>Number of Participants Analyzed=All Treated Population, all participants who entered the open-label period and received at least one dose of abatacept at any time during this period. Treatment groups represent treatment received in the DB period. n=number of participants with data available.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Creatinine</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.10" spread="0.02"/>
                    <measurement group_id="O2" value="0.05" spread="0.04"/>
                    <measurement group_id="O3" value="0.08" spread="0.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BUN</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.87" spread="0.90"/>
                    <measurement group_id="O2" value="-0.40" spread="1.13"/>
                    <measurement group_id="O3" value="0.63" spread="1.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ca</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.27" spread="0.07"/>
                    <measurement group_id="O2" value="0.38" spread="0.09"/>
                    <measurement group_id="O3" value="0.35" spread="0.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>P</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.09" spread="0.11"/>
                    <measurement group_id="O2" value="-0.51" spread="0.16"/>
                    <measurement group_id="O3" value="-0.17" spread="0.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Uric Acid</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.03" spread="0.18"/>
                    <measurement group_id="O2" value="0.06" spread="0.21"/>
                    <measurement group_id="O3" value="0.33" spread="0.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total bilirubin</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.08" spread="0.10"/>
                    <measurement group_id="O2" value="0.09" spread="0.03"/>
                    <measurement group_id="O3" value="0.23" spread="0.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serum glucose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.87" spread="3.19"/>
                    <measurement group_id="O2" value="9.00" spread="1.88"/>
                    <measurement group_id="O3" value="8.44" spread="4.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>OL; Mean Change From Baseline to Day 1513 in Alanine Aminotransferase, Aspartate Aminotransferase, G-Glutamyl Transferase, and Alkaline Phosphatase</title>
        <description>alanine aminotransferase (ALT): &gt;3 x ULN; aspartate aminotransferase (AST): &gt;3 x ULN; G-Glutamyl transferase (GGT): &gt;2 x ULN; Alkaline phosphatase (ALP): &gt;2 x ULN</description>
        <time_frame>Baseline (Day 1), Day 1513</time_frame>
        <population>Number of Participants Analyzed=All Treated Population, all participants who entered the open-label period and received at least one dose of abatacept at any time during this period. Treatment groups represent treatment received in the DB period. n=number of participants with data available.</population>
        <group_list>
          <group group_id="O1">
            <title>ABA + MTX [DB]</title>
            <description>Abatacept was administered intravenously (IV) on Days 1, 15, 29 and every 28 days thereafter for a total of 14 doses. Administration was as follows: 500 mg for participants &lt; 60 kg, 750 mg for participants 60 to 100 kg and 1 gram for participants &gt; 100 kg. All participants received a stable dose of MTX (minimum 15 mg weekly).</description>
          </group>
          <group group_id="O2">
            <title>INF + MTX [DB]</title>
            <description>Infliximab was given 3 mg/kg IV (approved labeled dose) on Days 1, 15, 43, 85 and every 56 days thereafter for a total of 8 doses. All participants received a stable dose of MTX (minimum 15 mg weekly)</description>
          </group>
          <group group_id="O3">
            <title>PLA + MTX [DB]</title>
            <description>Normal saline was administered as placebo. All participants received a stable dose of MTX (minimum 15 mg weekly)</description>
          </group>
        </group_list>
        <measure>
          <title>OL; Mean Change From Baseline to Day 1513 in Alanine Aminotransferase, Aspartate Aminotransferase, G-Glutamyl Transferase, and Alkaline Phosphatase</title>
          <description>alanine aminotransferase (ALT): &gt;3 x ULN; aspartate aminotransferase (AST): &gt;3 x ULN; G-Glutamyl transferase (GGT): &gt;2 x ULN; Alkaline phosphatase (ALP): &gt;2 x ULN</description>
          <population>Number of Participants Analyzed=All Treated Population, all participants who entered the open-label period and received at least one dose of abatacept at any time during this period. Treatment groups represent treatment received in the DB period. n=number of participants with data available.</population>
          <units>U/L</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>ALT</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.87" spread="2.73"/>
                    <measurement group_id="O2" value="-9.20" spread="3.75"/>
                    <measurement group_id="O3" value="2.44" spread="8.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AST</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.35" spread="1.72"/>
                    <measurement group_id="O2" value="-2.85" spread="2.55"/>
                    <measurement group_id="O3" value="0.38" spread="7.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GGT</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.00" spread="2.99"/>
                    <measurement group_id="O2" value="-10.9" spread="5.79"/>
                    <measurement group_id="O3" value="-3.06" spread="10.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ALP</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-15.8" spread="5.23"/>
                    <measurement group_id="O2" value="-18.7" spread="7.12"/>
                    <measurement group_id="O3" value="-11.30" spread="7.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>OL; Mean Systolic (SBP) and Diastolic (DBP) Blood Pressure During Open Label Period</title>
        <description>Seated Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP), units=mm mercury (Hg)</description>
        <time_frame>Days 365, 729, 1121, and 1513</time_frame>
        <population>Number of Participants Analyzed=All Treated Population, all participants who entered the open-label period and received at least one dose of abatacept at any time during this period.n=number of participants with data available.</population>
        <group_list>
          <group group_id="O1">
            <title>ABA + MTX [OL]</title>
            <description>All participants received ABA at a weight-tiered dose of 10 mg/kg plus a stable dose of MTX (minimum 15 mg weekly).</description>
          </group>
        </group_list>
        <measure>
          <title>OL; Mean Systolic (SBP) and Diastolic (DBP) Blood Pressure During Open Label Period</title>
          <description>Seated Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP), units=mm mercury (Hg)</description>
          <population>Number of Participants Analyzed=All Treated Population, all participants who entered the open-label period and received at least one dose of abatacept at any time during this period.n=number of participants with data available.</population>
          <units>mm mercury (Hg)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="372"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 365 SBP pre-dose (n=343)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="119.0" spread="15.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 365 SBP post-dose (n=341)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="118.8" spread="15.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 729 SBP pre-dose (n=321)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="120.4" spread="15.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 729 SBP post-dose (n=323)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="119.5" spread="15.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1121 SBP pre-dose (n=265)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="121.1" spread="15.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1121 SBP post-dose (n=265)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="119.2" spread="13.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1513 SBP pre-dose (n=52)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="114.6" spread="13.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1513 SBP post-dose (n=52)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="114.2" spread="12.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 365 DBP pre-dose (n=343)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74.5" spread="9.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 365 DBP post-dose (n=341)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74.0" spread="10.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 729 DBP pre-dose (n=321)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74.9" spread="9.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 729 DBP post-dose (n=323)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74.6" spread="9.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1121 DBP pre-dose (n=265)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74.9" spread="9.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1121 DBP post-dose (n=265)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73.6" spread="9.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1513 DBP pre-dose (n=52)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71.7" spread="9.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1513 DBP post-dose (n=52)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72.1" spread="9.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>OL; Mean Heart Rate (HR) During Open Label Period</title>
        <description>Heart Rate (HR), units=beats per minute (bpm)</description>
        <time_frame>Days 365, 729, 1121, and 1513</time_frame>
        <population>Number of Participants Analyzed=All Treated Population, all participants who entered the open-label period and received at least one dose of abatacept at any time during this period.n=number of participants with data available.</population>
        <group_list>
          <group group_id="O1">
            <title>ABA + MTX [OL]</title>
            <description>All participants received ABA at a weight-tiered dose of 10 mg/kg plus a stable dose of MTX (minimum 15 mg weekly).</description>
          </group>
        </group_list>
        <measure>
          <title>OL; Mean Heart Rate (HR) During Open Label Period</title>
          <description>Heart Rate (HR), units=beats per minute (bpm)</description>
          <population>Number of Participants Analyzed=All Treated Population, all participants who entered the open-label period and received at least one dose of abatacept at any time during this period.n=number of participants with data available.</population>
          <units>beats per minute (bpm)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="372"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 365 HR pre-dose (n=343)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74.2" spread="9.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 365 HR post-dose (n=341)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74.1" spread="8.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 729 HR pre-dose (n=322)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74.2" spread="9.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 729 HR post-dose (n=324)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73.4" spread="8.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1121 HR pre-dose (n=265)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73.9" spread="9.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1121 HR post-dose (n=265)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73.8" spread="9.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1513 HR pre-dose (n=52)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73.0" spread="8.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1513 HR post-dose (n=52)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73.8" spread="7.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>OL; Mean Temperature (T) During Open Label Period</title>
        <description>Temperature (T), units=degrees Celcius</description>
        <time_frame>Days 365, 729, 1121, and 1513</time_frame>
        <population>Number of Participants Analyzed=All Treated Population, all participants who entered the open-label period and received at least one dose of abatacept at any time during this period.n=number of participants with data available.</population>
        <group_list>
          <group group_id="O1">
            <title>ABA + MTX [OL]</title>
            <description>All participants received ABA at a weight-tiered dose of 10 mg/kg plus a stable dose of MTX (minimum 15 mg weekly).</description>
          </group>
        </group_list>
        <measure>
          <title>OL; Mean Temperature (T) During Open Label Period</title>
          <description>Temperature (T), units=degrees Celcius</description>
          <population>Number of Participants Analyzed=All Treated Population, all participants who entered the open-label period and received at least one dose of abatacept at any time during this period.n=number of participants with data available.</population>
          <units>degrees Celsius</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="372"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 365 T pre-dose (n=339)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.3" spread="0.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 365 T post-dose (n=339)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.3" spread="0.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 729 T pre-dose (n=320)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.3" spread="0.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 729 T post-dose (n=323)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.3" spread="0.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1121 T pre-dose (n=263)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.2" spread="0.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1121 T post-dose (n=264)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.2" spread="0.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1513 T pre-dose (n=52)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.1" spread="0.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1513 T post-dose (n=52)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.1" spread="0.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>ABA (DB)</title>
          <description>Abatacept was administered intravenously (IV) on Days 1, 15, 29 and every 28 days thereafter for a total of 14 doses. Administration was as follows: 500 mg for participants &lt; 60 kg, 750 mg for participants 60 to 100 kg and 1 gram for participants &gt; 100 kg. All participants received a stable dose of MTX (minimum 15 mg weekly).</description>
        </group>
        <group group_id="E2">
          <title>ABA + MTX [OL]</title>
          <description>All participants received ABA at a weight-tiered dose of 10 mg/kg plus a stable dose of MTX (minimum 15 mg weekly).</description>
        </group>
        <group group_id="E3">
          <title>INF + MTX [DB]</title>
          <description>Infliximab was given 3 mg/kg IV (approved labeled dose) on Days 1, 15, 43, 85 and every 56 days thereafter for a total of 8 doses. All participants received a stable dose of MTX (minimum 15 mg weekly).</description>
        </group>
        <group group_id="E4">
          <title>PLA + MTX [DB]</title>
          <description>Normal saline was administered as placebo. All participants received a stable dose of MTX (minimum 15 mg weekly). After placebo treatment from Day 1-197, 104 participants were reallocated to receive abatacept (weight based) plus a stable dose of MTX (minimum 15 mg weekly).</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 12.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="156"/>
                <counts group_id="E2" subjects_affected="90" subjects_at_risk="372"/>
                <counts group_id="E3" subjects_affected="30" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="21" subjects_at_risk="110"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>ANAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="372"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>THROMBOCYTOPENIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="156"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="372"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="110"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>ARRHYTHMIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="372"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>PERICARDITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="372"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>ANGINA PECTORIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="156"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="372"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>ANGINA UNSTABLE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="156"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="372"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>CARDIAC FAILURE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="372"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>ATRIAL TACHYCARDIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="372"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>MYOCARDIAL INFARCTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="372"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>CORONARY ARTERY DISEASE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="372"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>CORONARY ARTERY OCCLUSION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="156"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="372"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>ACUTE MYOCARDIAL INFARCTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="372"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="110"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>VERTIGO</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="372"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="110"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>ADRENAL INSUFFICIENCY</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="372"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="110"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>CATARACT</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="372"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>CORNEAL PERFORATION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="372"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="110"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>DIARRHOEA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="372"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>GASTRITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="372"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>ANAL FISSURE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="372"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>ABDOMINAL PAIN</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="372"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>ANAL SKIN TAGS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="372"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>INGUINAL HERNIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="372"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>UMBILICAL HERNIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="372"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>PANCREATITIS ACUTE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="372"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>HYPERTROPHIC ANAL PAPILLA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="372"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>UPPER GASTROINTESTINAL HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="372"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="110"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>PYREXIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="156"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="372"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>HYPERTHERMIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="372"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="110"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>BILIARY COLIC</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="372"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>CHOLELITHIASIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="156"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="372"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="110"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>ANAPHYLACTIC SHOCK</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="372"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="110"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>SEPSIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="372"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>ABSCESS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="372"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>PNEUMONIA</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="156"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="372"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>SINUSITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="156"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="372"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>BRONCHITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="372"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>CELLULITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="372"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>ERYSIPELAS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="372"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>APPENDICITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="372"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>SEPTIC SHOCK</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="372"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>HERPES ZOSTER</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="372"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>OSTEOMYELITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="372"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>GASTROENTERITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="372"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>LOBAR PNEUMONIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="372"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>WOUND INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="372"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>BURSITIS INFECTIVE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="372"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>ABSCESS SOFT TISSUE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="372"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>ENCEPHALITIS HERPES</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="372"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>INFECTED SKIN ULCER</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="156"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="372"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>SUBCUTANEOUS ABSCESS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="372"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>NECROTISING FASCIITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="372"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>PULMONARY TUBERCULOSIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="372"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>APPENDICITIS PERFORATED</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="372"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>PERITONEAL TUBERCULOSIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="372"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>URINARY TRACT INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="372"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>LUNG INFECTION PSEUDOMONAL</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="372"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>POSTOPERATIVE WOUND INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="372"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>PNEUMOCYSTIS JIROVECI PNEUMONIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="372"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="110"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>FALL</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="372"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>ACCIDENT</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="372"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>HIP FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="156"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="372"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>ANKLE FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="372"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>ILIUM FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="372"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>TENDON RUPTURE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="372"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>TIBIA FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="156"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="372"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>CARTILAGE INJURY</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="372"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>MULTIPLE INJURIES</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="372"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>FAILURE OF IMPLANT</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="372"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>SUBDURAL HAEMATOMA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="372"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>ACCIDENTAL OVERDOSE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="372"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>LOWER LIMB FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="372"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>PUBIC RAMI FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="372"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>UPPER LIMB FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="372"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>COMPLICATED FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="372"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>ROAD TRAFFIC ACCIDENT</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="156"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="372"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>LUMBAR VERTEBRAL FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="372"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>POST PROCEDURAL HAEMATOMA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="156"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="372"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>CERVICAL VERTEBRAL FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="156"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="372"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>POST PROCEDURAL COMPLICATION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="372"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>DISLOCATION OF JOINT PROSTHESIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="372"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="110"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>HORMONE LEVEL ABNORMAL</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="372"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>ALANINE AMINOTRANSFERASE INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="372"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>ASPARTATE AMINOTRANSFERASE INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="372"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="110"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>DEHYDRATION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="372"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>HYPOGLYCAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="156"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="372"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>DIABETES MELLITUS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="372"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="110"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>FISTULA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="372"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>ARTHRITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="372"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>ARTHRALGIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="372"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>OSTEONECROSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="156"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="372"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>FOOT DEFORMITY</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="372"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>JOINT SWELLING</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="372"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>OSTEOARTHRITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="156"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="372"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>RHEUMATOID ARTHRITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="156"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="372"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>SPINAL OSTEOARTHRITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="156"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="372"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>LUMBAR SPINAL STENOSIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="372"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>MUSCULOSKELETAL CHEST PAIN</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="372"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>INTERVERTEBRAL DISC PROTRUSION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="372"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="110"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>LEIOMYOMA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="372"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>FIBROSARCOMA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="372"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>BLADDER CANCER</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="156"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="372"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>UTERINE LEIOMYOMA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="156"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="372"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>BASAL CELL CARCINOMA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="372"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>BENIGN LUNG NEOPLASM</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="372"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>PITUITARY TUMOUR BENIGN</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="372"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>SQUAMOUS CELL CARCINOMA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="372"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>MALIGNANT ANORECTAL NEOPLASM</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="372"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>BENIGN NEOPLASM OF THYROID GLAND</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="372"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="110"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>SCIATICA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="372"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>CEREBROVASCULAR ACCIDENT</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="156"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="372"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="110"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>DEPRESSION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="372"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="110"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>RENAL FAILURE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="372"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>BLADDER PROLAPSE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="372"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>RENAL IMPAIRMENT</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="372"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>STRESS URINARY INCONTINENCE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="372"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="110"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>OVARIAN CYST</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="372"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>DYSMENORRHOEA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="372"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>UTERINE POLYP</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="372"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>OVARIAN TORSION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="372"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>UTERINE PROLAPSE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="372"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="110"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>HAEMOTHORAX</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="372"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>LARYNGEAL OEDEMA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="372"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>LARYNGEAL GRANULOMA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="372"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>RESPIRATORY FAILURE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="372"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>SLEEP APNOEA SYNDROME</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="372"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>ACUTE RESPIRATORY FAILURE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="372"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>OBSTRUCTIVE AIRWAYS DISORDER</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="372"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="110"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>PSORIASIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="372"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>URTICARIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="372"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="110"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>ARTERITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="372"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>HAEMATOMA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="372"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>VASCULITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="156"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="372"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>HYPERTENSION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="372"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>AORTIC STENOSIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="372"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>HYPERTENSIVE CRISIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="156"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="372"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="110"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 12.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="105" subjects_at_risk="156"/>
                <counts group_id="E2" subjects_affected="285" subjects_at_risk="372"/>
                <counts group_id="E3" subjects_affected="130" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="82" subjects_at_risk="110"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>NAUSEA</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="156"/>
                <counts group_id="E2" subjects_affected="26" subjects_at_risk="372"/>
                <counts group_id="E3" subjects_affected="21" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>VOMITING</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="156"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="372"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>DIARRHOEA</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="156"/>
                <counts group_id="E2" subjects_affected="56" subjects_at_risk="372"/>
                <counts group_id="E3" subjects_affected="21" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>DYSPEPSIA</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="156"/>
                <counts group_id="E2" subjects_affected="41" subjects_at_risk="372"/>
                <counts group_id="E3" subjects_affected="17" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>GASTRITIS</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="156"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="372"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>ABDOMINAL PAIN UPPER</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="156"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="372"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="110"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>OEDEMA PERIPHERAL</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="156"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="372"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="110"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>INFLUENZA</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="156"/>
                <counts group_id="E2" subjects_affected="49" subjects_at_risk="372"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>SINUSITIS</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="156"/>
                <counts group_id="E2" subjects_affected="29" subjects_at_risk="372"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>BRONCHITIS</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="156"/>
                <counts group_id="E2" subjects_affected="41" subjects_at_risk="372"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="11" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>PHARYNGITIS</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="156"/>
                <counts group_id="E2" subjects_affected="43" subjects_at_risk="372"/>
                <counts group_id="E3" subjects_affected="17" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>GASTROENTERITIS</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="156"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="372"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>NASOPHARYNGITIS</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="156"/>
                <counts group_id="E2" subjects_affected="69" subjects_at_risk="372"/>
                <counts group_id="E3" subjects_affected="26" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="15" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>URINARY TRACT INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="156"/>
                <counts group_id="E2" subjects_affected="67" subjects_at_risk="372"/>
                <counts group_id="E3" subjects_affected="18" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="13" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>UPPER RESPIRATORY TRACT INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="156"/>
                <counts group_id="E2" subjects_affected="50" subjects_at_risk="372"/>
                <counts group_id="E3" subjects_affected="19" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="16" subjects_at_risk="110"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>ALANINE AMINOTRANSFERASE INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="156"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="372"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="110"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>BACK PAIN</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="156"/>
                <counts group_id="E2" subjects_affected="41" subjects_at_risk="372"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="110"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>HEADACHE</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="156"/>
                <counts group_id="E2" subjects_affected="54" subjects_at_risk="372"/>
                <counts group_id="E3" subjects_affected="34" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="24" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>DIZZINESS</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="156"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="372"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="110"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>ANXIETY</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="156"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="372"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>INSOMNIA</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="156"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="372"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>DEPRESSION</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="156"/>
                <counts group_id="E2" subjects_affected="26" subjects_at_risk="372"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="110"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>COUGH</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="156"/>
                <counts group_id="E2" subjects_affected="28" subjects_at_risk="372"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="110"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>RASH</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="156"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="372"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>PRURITUS</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="156"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="372"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>URTICARIA</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="156"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="372"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="110"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>HYPERTENSION</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="156"/>
                <counts group_id="E2" subjects_affected="42" subjects_at_risk="372"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="165"/>
                <counts group_id="E4" subjects_affected="13" subjects_at_risk="110"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period 60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>BMS Study Director</name_or_title>
      <organization>Bristol-Myers Squibb</organization>
      <email>Clinical.Trials@bms.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

